Skip to Late-Breaking Abstracts »
All accepted abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC).
Abstract Titles
Poster Presentation Dates
All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.
Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.
| # | Type | Title | Authors | Category | Keywords |
|---|---|---|---|---|---|
| 1 | Poster Presentation | Tumour associated macrophages in HPV-related carcinoma with adenoid cystic like features of the sinonasal tract; a review of three cases | Kasimu U. Adoke, MBBS, FMCPath; Jonathan Madukwe; Faruk Mohammed, Msc; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Monocyte/Macrophage; Tumor microenvironment; Tumor stroma |
| 2 | Poster Presentation | The Multi-physics Automated Reconfigurable Separation (MARS®) System Provides High Purity, High Recovery and High Throughput Enrichment of Immune Cells for Immunotherapy | Liping Yu, MD Ph.D.; Gregory Schneider, Ph.D.; Alice Wang, Ph.D.; | Biomarkers, Immune Monitoring and Novel Technologies | CAR T cells; Immune monitoring; Inflammation; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 9 | Poster Presentation | Mesenchymal Features of a Novel 27-Gene Algorithm Associate with Canonical Tumor Promoting Signaling Pathways which may Identify Therapeutic Options for Immunotherapy Resistant Patients | Tyler J. Nielsen, MS; Rob S. Seitz; Douglas T. Ross, MD, PhD; David R. Hout, PhD; Brock L. Schweitzer, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Angiogenesis; Biomarkers; Checkpoint blockade; Immune contexture; Immune monitoring; Solid tumors; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 13 | Poster Presentation | Use of anti-viral T cells to model HLA-restricted anti-tumor cytotoxic lymphocyte responses | Michael Overstreet, PhD; Vanessa M. Muniz-Medina; Ruoyan Chen; James Kurasawa; Stacy R. Kentner; Deepali Malhotra, PhD; Jane Osbourn; Jill Walker; Gordon Moody; Michael Overstreet, PhD; Michael Overstreet, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Adoptive immunotherapy; Checkpoint blockade; Solid tumors; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs) |
| 18 | Poster Presentation | New method of assessing tumor heterogeneity utilizing both circulating tumor DNA and tissue DNA to predict the response to immunotherapy | Jaeyoun Choi, M.D.; Myungwoo Nam, MD; Stanislav Fridland; Jinyoung Hwang; Chan Mi Jung; Christmann Low; Young Kwang Chae, MD, MPH, MBA; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade |
| 21 | Oral Presentation | Plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients | Michal Harel, PhD; Coren Lahav, MSc; Eyal Jacob, PhD; Eran Issler, MSc; Haim Bar, PhD; Adam P. Dicker, MD, PhD; Ofer Sharon, MD; Antonietta Bacchiocchi, MSc; Ruth Halaban, PhD; Mario Sznol, MD; Yuval Shaked, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Checkpoint blockade; Clinical trial; Immune suppression; Proteomics; Solid tumors; Systems biology |
| 25 | Poster Presentation | Line of therapy adjustment in a patient with advanced triple-negative breast cancer (TNBC) by using personalized ctDNA test for treatment response monitoring | Georges Azzi, MD; Shifra Krinshpun, MS, LCGC; Antony Tin, PhD; Allyson K. Malashevich, PhD; Meenakshi Malhotra; Paul Billings, MD, PhD; Angel Rodriguez, MD; Alexey Aleshin, MD, MBA; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Chemotherapy; Immune adjuvant |
| 26 | Poster Presentation | ctDNA clearance and radiographic resolution of lymph node metastasis in a patient with metastatic microsatellite stable colorectal cancer on immunotherapy | Charles J. Schneider, MD, FACP; Michael Krainock, MD; Meenakshi Malhotra; Paul Billings, MD, PhD; Alexey Aleshin, MD, MBA; | Biomarkers, Immune Monitoring and Novel Technologies | Bioinformatics; Biomarkers; Chemotherapy; Immune adjuvant; Solid tumors |
| 35 | Poster Presentation | Targeted non-viral integration of large cargo in primary human T cells by CRISPR/Cas9 guided homology mediated end joining | Beau R. Webber, PhD; Matthew J. Johnson, PhD; Nicholas J. Slipek; Walker S. Lahr; Xiaohong Qiu; Blaine Rathmann; Miechaleen D. Diers; Bryce Wick; R. Scott McIvor, PhD; Branden S. Moriarity, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; CAR T cells; T cell |
| 42 | Poster Presentation | Intravital multiphoton microscopy of infiltrating T cell and tumor cell metabolism in a murine melanoma model | Alexa R. Heaton, PhD; Tiffany M. Heaster, PhD; Anna Hoefges, MS; Alexander L. Rakhmilevich, MD, PhD; Amy K. Erbe, PhD; Paul M. Sondel, MD, PhD; Melissa C. Skala, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Adoptive immunotherapy; Checkpoint blockade; Cytokine; Metabolism; Radiotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 47 | Poster Presentation | Pathologists enhance interpretation of automated multiplex immunohistochemistry assays in cancer immunotherapy trials | Emmanuel Pacia; Ju Young Kim, PhD; Evelyn Diaz; Beiru Chen, MD; Nathan Roscoe; Jason Hughes; Thai Tran, PhD; Jennifer M. Bordeaux, PhD; Bashar Dabbas, MD; Shabnam Tangri, PhD; Margaret McLaughlin, MD; Alexander Savchenko, MD, PhD; Naveen Dakappagari, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Clinical study |
| 54 | Poster Presentation | Patient Stratification using Clinical Proteomics – Validated multiplexed MRM assays to quantify HER2 and other biomarkers in clinical FFPE tissues | Maxim Isabelle, PhD; Maxim Isabelle, PhD; Maxim Isabelle, PhD; Michael Schirm; Gwenaël Pottiez; Rudolf Guilbaud; Lorella Di Donato; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Clinical study; Proteomics |
| 55 | Poster Presentation | Thousands of antigens are recognized in mice via endogenous antibodies after being cured of a B78 melanoma via immunotherapy | Anna Hoefges, MS; Amy K. Erbe, PhD; Sean J. Mcilwain, PhD; Trang Q. Le; Angie Xu; Nicholas Mathers; Eric Zhang; Andrew S. Melby; Claire Baniel; Alexander L. Rakhmilevich, MD, PhD; Jacquelyn A. Hank, PhD; Richard Pinapati, PhD; Brad Garcia, PhD; Jigar Patel, PhD; Zachary S. Morris, MD, PhD; Irene M. Ong, PhD; Paul M. Sondel, MD, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; Antigen presenting cells; B cell; Bioinformatics; Biomarkers; Neoantigens; Proteomics; Radiotherapy; Solid tumors; Tumor antigens |
| 65 | Poster Presentation | PD-L1 by RNA next generation sequencing: Comparison with PD-L1 IHC 22C3 and association with survival benefit from pembrolizumab with or without chemotherapy in non-small cell lung cancer. | Yong Hee Lee; Grace K. Dy; Paul DePietro, PhD; Jeffrey Conroy, BS; Sarabjot Pabla, PhD; Mary K. Nesline, MS | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Chemotherapy; Gene expression; RNA; Solid tumors; Tumor microenvironment |
| 77 | Poster Presentation | Association Between Programmed Death-Ligand 1 (PD-L1) Expression and Gene Signatures of Response or Resistance to Tislelizumab Monotherapy in Hepatocellular Carcinoma (HCC) | Ming-Mo Hou; Kun-Ming Rau; Yoon-Koo Kang; Jong-Seok Lee; Hongming Pan; Ying Yuan; Cunjing Yu; Yun Zhang; Xiaopeng Ma; Xikun Wu; Xin Li; Katie Wood; Chia-Jui Yen, MD, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical trial; Tumor microenvironment |
| 78 | Poster Presentation | T-Cell, MHC I, and Tumor Intrinsic Gene Signatures Predict Clinical Benefit and Resistance to Tislelizumab Monotherapy in Pretreated PD-L1+ Urothelial Carcinoma | Dingwei Ye; Aiping Zhou; Qing Zou; Hanzhong Li; Cheng Fu; Hailong Hu; Jian Huang; Wei Shen; Yun Zhang; Xiaopeng Ma; Pei Zhang; Ruiqi Huang; Xiusong Qiu; Lilin Zhang; Feng Bi; | Biomarkers, Immune Monitoring and Novel Technologies | Angiogenesis; Antigen presenting cells; Biomarkers; Checkpoint blockade; Clinical trial; Immune contexture; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 81 | Poster Presentation | Inclusion of PD-L1-expressing tumor cells in the Combined Positive Score algorithm yields superior identification of positive specimens around diagnostic cut-offs across multiple indications | Jay Milo, MAS; Christopher LaPlaca; Julia Hand; Stephanie Hund; Angeliki Apostolaki; Lindsay Guerrero; Kenneth Emancipator, MD; Jonathan Juco, MD; Bryce Portier; Siena Tabuena-Frolli; Karina Kulangara; | Biomarkers, Immune Monitoring and Novel Technologies | Antibody; Antigen presenting cells; Bioinformatics; Biomarkers; Chemotherapy; Solid tumors; T cell |
| 82 | Poster Presentation | SQ3370 is a novel approach that decreases adverse drug exposure and achieves robust injected and non-injected anti-tumor responses | Sangeetha Srinivasan, PhD; Nathan A. Yee, PhD; Kui Wu, PhD; Amir Mahmoodi, MS; Michael Zakharian, MS; Maksim Royzen, PhD; Jose M. Mejia Oneto, MD, PhD; | Biomarkers, Immune Monitoring and Novel Technologies | Chemotherapy; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 89 | Poster Presentation | First-in-human CAR T targets cleaved MUC1, the growth factor receptor form | Benoit J. Smagghe, PhD; Andrew K. Stewart, PhD; Pengyu Huang, PhD; Tyler E. Swanson; Danica M. Page; Mark G. Carter; Trevor J. Grant, PhD; Jennifer Specht, MD; Cynthia C. Bamdad, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; Stem cell/cancer-initiating cell; T cell; Targeted therapy |
| 91 | Poster Presentation | Directly Link T Cell Phenotype and Function to Genotype with the Opto™ Cell Therapy Development 1.0 Workflow | Yelena Bronevetsky, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Cytokine; T cell |
| 92 | Poster Presentation | Adoptive transfer of immature myeloid cells lacking NF-κB p50 (p50-IMC) slows high-risk neuroblastoma tumor growth | Cheng Cui, Ph.D.; Theresa Barberi, PhD; Rahul Suresh, Ph.D.; Ludovic Zimmerlin, Ph.D.; Elias Zambidis, M.D., Ph.D.; Alan D. Friedman, MD; | Cellular Therapies | Adoptive immunotherapy; Monocyte/Macrophage; Myeloid cells; Pediatric tumors |
| 94 | Poster Presentation | The T cell Antigen Coupler (TAC) redirects T cell oncolysis while limiting tonic signaling to create a safer engineered T cell product with a higher threshold for activation | Duane Moogk, PhD; Vivian W. Lau; Arya Afsahi, MSc; Anna Dvorkin-Gheva, PhD; Ksenia Bezverbnaya; Joanne A. Hammill, PhD; Jonathan L. Bramson, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Immune toxicity |
| 95 | Poster Presentation | Inhibition of AKT signaling during expansion of TCR-engineered T-cells from patient leukocyte material generates SPEAR T-cells with enhanced functional potential in vitro | Katerina Mardilovich; Lilli Wang; Rachel Kenneil; Gareth Betts, PhD; Natalie Bath, MSc; Will Spinner; Vanessa De Mello; Seint Lwin; Joseph P. Sanderson, PhD; Jonathan D. Silk, PhD; Alex J. Tipping, PhD; Andrew B. Gerry, PhD; Phil Bassett; Karen Miller, PhD; Mark Dudley; Emily Schmidt | Cellular Therapies | Adoptive immunotherapy; T cell; Targeted therapy |
| 96 | Poster Presentation | Decitabine gene modulation sensitizes human non–small cell lung cancer (NSCLC) to NY-ESO-1 TCR immunotherapy (letetresgene autoleucel; GSK3377794) in vivo | Dmitry Pankov; Ioanna S. Eleftheriadou; Anna Domogala; Sara J. Brett, PhD; Lea Patasic; Magdalena A. Kijewska; Gary Thripp; Jack Euesden; Jan Klapwijk; Katrina Soor; Miriam Damm; Mark D. W. Hill; Mirella Georgouli; Aiman Shalabi; Cedrik Britten; | Cellular Therapies | Adoptive immunotherapy; Cytokine; Epigenetics; Gene expression; Solid tumors; T cell; Tumor antigens |
| 98 | Poster Presentation | ATA3271: An Armored, Next-Generation Off-The-Shelf, Allogeneic, Mesothelin-CAR T Cell Therapy for Solid Tumors | Jiangyue Liu, MS; Xianhui Chen, PhD; Jason Karlen; Alfonso Brito, MS; Tiffany Jheng, MS; Philippe Foubert, PhD; Janani Krishnamurthy, PhD; Yannick Bulliard, PhD; Blake T. Aftab, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Immune suppression; Targeted therapy; Tumor antigens; Tumor microenvironment |
| 100 | Poster Presentation | Drug-regulatable engineered T cells eliminate CD33+ and CD33ΔE2+ AML | Jacob S. Appelbaum, MD, PhD; Wai-Hang Leung; Unja Martin; Kaori Oda; Giacomo Tampella, PhD; Dong Xia; Joy Zhang; Anne-Rachael Krostag; Rachael Logan; Claudya Evandy; Quennie Vong; Kyle S. Jones; John C. Timmer, PhD; Brendan P. Eckelman, PhD; Jim Rottman; Danielle Montt; Bryan Peguero; Mark Pogson; Alexander Astrakhan; Jordan Jarjour, PhD; Joshua Gustafson, PhD; Michael C. Jensen, MD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; Myeloid cells |
| 101 | Poster Presentation | Engineering gamma/delta T cells with the T-Cell Antigen Coupler receptor effectively induces antigen-specific tumor cytotoxicity in vitro and in vivo | Sarah E. Asbury, BSc; Seung Mi Yoo, PhD; Jonathan L. Bramson, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell |
| 102 | Poster Presentation | Cord-blood derived NK cells, and CAR-T cells, an attractive improved immunotherapy treatment to be considered for hematological malignancies | Mireia Bachiller García, Pharm; Lorena Pérez-Amill; Anthony M. Battram, PhD; Alvaro Urbano-Ispizua; Beatriz Martín-Antonio; Mireia Bachiller García, Pharm; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Myeloid cells; NK/NK T cell; Targeted therapy |
| 103 | Poster Presentation | Inclusion of a Dap10 costimulatory domain enhances anti-tumor efficacy of chimeric PD1-expressing T cells in multiple types of solid tumors | Amorette Barber, Ph.D.; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Solid tumors |
| 104 | Poster Presentation | BCMA-targeting CAR-T cells expanded in IL-15 have an improved phenotype for therapeutic use compared to those grown in IL-2 or IL-15/IL-7 | Anthony M. Battram, PhD; Mireia Bachiller, Pharm; Álvaro Urbano-Ispizua; Beatriz Martin-Antonio, Jr.; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Cytokine; T cell |
| 105 | Poster Presentation | A third-generation human GUCY2C-targeted CAR-T cell for colorectal cancer immunotherapy | Trevor R. Baybutt, BA; Adam E. Snook, PhD; Scott A. Waldman, MD, PhD; Jonathan M. Stem, MD; Ellen Caparosa, MD; Alicja Zalewski, MD; Trevor R. Baybutt, BA; | Cellular Therapies | CAR T cells; Solid tumors; T cell |
| 106 | Poster Presentation | Increasing AMPK activity in human T cells enhances memory subset formation without sacrificing in vitro expansion | Erica Braverman, MD; Andrea Dobbs, MSc; Darlene A. Monlish, PhD; Craig Byersdorfer, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Metabolism; T cell lineages |
| 109 | Poster Presentation | Dominant-negative TGFβ receptor 2 enhances GPC3-targeting CAR-T cell efficacy against hepatocellular carcinoma | Nina J. Chu, PhD; Michael Overstreet, PhD; Ryan Gilbreth; Lori Clarke; Christina Gesse; Eric Tu; Letizia Giardino; Gordon Moody; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Immune suppression; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 111 | Poster Presentation | Highly efficient multiplexed base editing enables development of universal CD7-targeting CAR-T Cells to treat T-ALL | Jason Gehrke, PhD; Aaron Edwards; Ryan Murray; Angelica Messana; Lindsey Coholan; Henry Poulin; Melissa Le; Alden Ladd; Mark Naniong; Faith Musenge; Adam Camblin; Yeh-Chuin Poh; Sarah Smith; Giuseppe Ciaramella; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; T cell |
| 112 | Poster Presentation | Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy | Letizia Giardino; Ryan Gilbreth; Cui Chen; Erin Sult; Noel Monks; Ravinder Tammali; Jon Chesebrough; Kevin Schifferli; Nina Chu; Jessica Tong; Lori Clarke,; Christina Gesse; Xiao-Tao Yao; Karma DaCosta; Kapil Vashisht; Gordon Moody; Letizia Giardino; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; T cell; Targeted therapy |
| 113 | Poster Presentation | Development of T cell-based immunotherapies to target dormant disseminated breast cancer cells | Erica T. Goddard, PhD; Shivani Srivastava, PhD; Stanley R. Riddell, MD; Cyrus Ghajar, PhD; Erica T. Goddard, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; T cell; Tumor microenvironment |
| 114 | Poster Presentation | Preclinical development of a novel iPSC-derived CAR-MICA/B NK cell immunotherapy to overcome solid tumor escape from NKG2D-mediated mechanisms of recognition and killing | John Goulding, PhD; John Goulding, PhD; Mochtar Pribadi, PhD; Robert Blum, MS; Wen-I Yeh, PhD; Yijia Pan, PhD; Svetlana Gaidarova, MS; Chia-Wei Chang, PhD; Hui-Yi Chu, PhD; Ellen Liu, MS; Shohreh Sikaroodi, PhD; Lucas Ferrari de Andrade, PhD; Lauren Fong, PhD; Janel Huffman, MS; Tom T. Lee, PhD; Ryan Bjordahl, PhD; Kai W. Wucherpfennig, MD, PhD; Bahram Valamehr, PhD; | Cellular Therapies | Adoptive immunotherapy; NK/NK T cell; Solid tumors; Targeted therapy; Tumor antigens; Tumor evasion |
| 115 | Poster Presentation | Engineered T cells directed at tumors with defined allelic loss | Agi Hamburger, PhD; Breanna DiAndreth; Jiajia Cui; Mark Daris, PhD; Melanie Munguia; Kiran Deshmukh; Jee-Young Mock; Grace Asuelime; Emily Lim; Michelle Kreke; Talar Tokatlian; Alexander Kamb, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell |
| 116 | Poster Presentation | Multi-antigen targeting of heterogenous solid tumors using CAR T cells secreting bi-specific T-cell engagers | Martin Hosking, PhD; Bishwas Shrestha; Megan M. Boyett; Soheila Shirinbak; Angela Gentile; Eric Sung; Yijia Pan, PhD; Tom T. Lee, PhD; Jason ORourke; Dan Shoemaker, PhD; Cokey Nguyen; Bahram Valamehr, PhD; | Cellular Therapies | Adoptive immunotherapy; Bispecifics; CAR T cells; Solid tumors; Tumor evasion |
| 117 | Poster Presentation | Rapid point-of-care subcutaneous CAR-T from blood draw to injection in 4 hours with modified LV encoding CARs and synthetic driver elements enables efficient CAR-T expansion and tumor regression | Frederic Vigant, PhD; Qun He, PhD; Wei Zhang, PhD; Hongliang Zong, MD, PhD; Anirban Kundu; Ewa Jaruga-Killeen, PhD; Gregory Schreiber, PhD; Michelle Andraza; Alissa Kerner, PhD; Gregory I. Frost, PhD | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; T cell; Targeted therapy |
| 119 | Poster Presentation | IL-6 is critical for memory responses elicited by Th17 cells to tumors | Hannah M. Knochelmann, BS; Connor J. Dwyer, PhD; Aubrey S. Smith, BS; Megan Wyatt, MS; Guillermo O. Rangel RIvera, B.S.; Gregory B. Lesinski, PhD; Zihai Li, MD, PhD; Mark P. Rubinstein, PhD; Chrystal M. Paulos, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Cytokine; Immune toxicity; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| 120 | Poster Presentation | P-MUC1C-ALLO1: An Allogeneic CAR-T for Multiple Solid Tumor Indications | Anna K. Kozlowska, PhD; Yan Zhang, PhD; Jacqueline Fritz, BS; Steven Wang, PhD; Rebecca A. Codde, BS; Elvira Argus, PhD; Samad A. Ibitokou, PhD; Vanitra Richardson, MS; Sumiti Jain, PhD; Maximilian Richter, PhD; Deepak Patil, PhD; Yening Tan, MS; Min Tong, MS; Lu Yao, PhD; Majid Ghoddusi, PhD; Eric M. Ostertag, MD, PhD; Julia Coronella, PhD; Devon J. Shedlock, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; T cell |
| 122 | Oral Presentation | Guanylyl cyclase C as a target for CAR-T cell therapy in a metastatic gastric cancer model | Amanda N. Lisby, MS; Trevor R. Baybutt, BA; Megan Weindorfer, BS; Robert Carlson, BS; Alicja Zalewski, MD; Scott A. Waldman, MD, PhD; Adam E. Snook, PhD; | Cellular Therapies | Adoptive immunotherapy; Antibody; Biomarkers; CAR T cells; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| 123 | Poster Presentation | Natural killer cells engineered with an inducible, responsive genetic construct targeting TIGIT and CD73 to relieve immunosuppression within the GBM microenvironment | Kyle B. Lupo, BS; Sandro Matosevic, PhD; | Cellular Therapies | Adoptive immunotherapy; NK/NKT cell; Solid tumors; Targeted therapy; Tumor microenvironment |
| 124 | Poster Presentation | Optimizing the Generation from Umbilical Cord Blood of “Off-the-Shelf” CD19-Chimeric Antigen Receptor (CAR) expressing T cells | Cristina Maccalli, PhD; Asma Al Sulaiti, Bachelor; Moza Al Khulaifi; Shilpa Ravindran, MSc; Mohammed El-Anbari; Mohammed Toufiq; Rebecca Mathew; Chiara Bonini; Monica Casucci, PhD; Chiara Cugno, MD; Suruchi Mohan; Sara Deola; Damien Chaussabel; Sara Tomei, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Cytokine; Gene expression; Leukemia/Lymphoma; T cell; T cell lineages |
| 125 | Poster Presentation | Reexamination of MAGE-A3 as a T-cell Therapeutic Target | Aaron D. Martin, M.A.; Xueyin Wang, PhD; Han Xu, PhD; Alexander S. Kamb; Mark Sandberg, PhD; Kathleen Negri; Ming Wu; Dora Toledo Warshaviak, PhD; Grant Gabrelow; Michele Mcelvain; Mark Daris, PhD; Bella Lee; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell; Targeted therapy |
| 127 | Poster Presentation | Preclinical evaluation of NKX019, a CD19-targeting CAR NK Cell | Nadege Morisot; Sarah Wadsworth; Tina Davis; Nicole Dailey; Kyle Hansen; Denise Gonzalez; Nafees Rahman; Alex Aronov; Y Fan; Chao Guo; Luxuan Buren; Anmol Vohra, MS; Kate Jamboretz; H Leman; Sasha Lazetic, BA; Ivan Chan, PhD; James T. Trager, PhD; Joanne BT. Tan; | Cellular Therapies | Adoptive immunotherapy; Leukemia/Lymphoma; NK/NK T cell |
| 128 | Poster Presentation | Development of an M1-polarized, non-viral chimeric antigen receptor macrophage (CAR-M) platform for cancer immunotherapy | Yumi Ohtani, PhD; Kayleigh Ross; Aditya Dandekar; Rashid Gabbasov, PhD; Michael Klichinsky, PharmD, PhD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Gene expression; Monocyte/Macrophage; Myeloid cells; Solid tumors; TLR; Tumor microenvironment |
| 129 | Poster Presentation | A novel CAR conducting antigen-specific JAK-STAT signals demonstrates superior antitumor effects with minimal undesired non-specific activation | Sachiko Okamoto, PhD; Sachiko Okamoto, PhD; Yasunori Amaishi; Mitsuki Shigeta, PhD; Yu Okubo, PhD; Yota Ohashi; Naoto Hirano, MD, PhD; Junichi Mineno, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Costimulation; Leukemia/Lymphoma; Solid tumors; T cell; Tumor antigens |
| 130 | Poster Presentation | Immunogenic potential of chimeric antigen receptor (CAR)-engineered T cells expressing inducible nuclease-deactivated SpCas9 (dCas9) | Dharmeshkumar Patel, PhD, MS; Angshumala Goswami; Vitaly Balan; Zhifen Yang, Dr.; Lingyu Li, PhD; Sowndharya Rajavel, Sr.; Alper Kearney, PhD; Rona Harari-Steinfeld; Maggie Bobbin; Bing C. Wang, PhD; Alessandra Cesano, MD, PhD; Stanley L. Qi, Ph.D.; Francesco M. Marincola, MD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; CAR T cells; Immune monitoring; Immune toxicity; Solid tumors; T cell; Targeted therapy |
| 131 | Poster Presentation | CoupledCAR® Technology Strengthens Adoptive T Cell Therapy by Promoting Rapid Expansion | Zhiyuan Cao; Chengfei Pu; Xianyang Jiang; Xiaogang Shen; Ruihong Zhu; Yuzhe Peng; Xi Huang; Zhao Wu; Lei Xiao, Ph.D.; | Cellular Therapies | Adoptive immunotherapy; Biomarkers; CAR T cells; Clinical study; Gene expression; Inflammation; Solid tumors; T cell; Tumor antigens |
| 133 | Poster Presentation | Development of novel cellular therapeutics for metastatic and primary CNS malignancies | Paul D. Rennert, PhD; Alyssa Birt; Lihe Su, PhD; Lan Wu, PhD; Fay J. Dufort, PhD; Roy R. Lobb, PhD; Christine Ambrose, PhD; | Cellular Therapies | Adoptive immunotherapy; Antibody; Bispecifics; CAR T cells; Pediatric tumors; Solid tumors; Tumor antigens |
| 134 | Poster Presentation | Tumor-responsive, multi-functional genetically-engineered natural killer cells for immunotherapy of glioblastoma | Jiao Wang, PhD; Yeonhee I. Yun; Karen E Pollok; Anthony L. Sinn; Randy R Brutkiewicz; Michael C Veronesi; Sandro Matosevic, PhD; Jiao Wang, PhD; | Cellular Therapies | Adoptive immunotherapy; Chemokine; Immune suppression; Metabolism; NK/NKT cell; Solid tumors; Tumor antigens; Tumor evasion; Tumor microenvironment; Tumor stroma |
| 136 | Poster Presentation | Targeting MET with Chimeric Antigen Receptor T cells in Hepatocellular Carcinoma | Yuan Qin; Anna Qin; Anna Musket; Joseph Lee; Zhi Q. Yao; Giedre Krenciute, PhD; Qian Xie; Qian Xie | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; Targeted therapy |
| 138 | Poster Presentation | In vivo localization of genetically engineered natural killer cells against glioblastoma using PET imaging | Yeonhee I. Yun; Jiao Wang, PhD; Karen Pollok; Tony Sinn; Randy Brutkiewicz; Sandro Matosevic, PhD; Michael Veronesi; | Cellular Therapies | Chemokine; Immune suppression; Metabolism; NK/NKT cell; Radiotherapy; Solid tumors; Tumor antigens; Tumor evasion |
| 139 | Poster Presentation | Establishment of canine CAR T cells treatment model for solid tumor immunotherapy development | Shihong Zhang, Ph.D; Karan Kohli, Ph.D; R. Graeme Black; Brian J. Hayes, Ph.D; Cassandra Miller, DVM; Mari Maeda-Whitaker, PhD; Brett A. Schroeder, MD; Kraig Abrams; Bernard Seguin, DVM; Stephen Gottschalk, MD; Peter F. Moore, DVM, Ph.D.; Beverly J. Torok-Storb, Ph.D; Seth M. Pollack, MD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; Tumor antigens |
| 140 | Poster Presentation | Adoptive transfer of T cells surface-tethered with IL-12 promote antigen spreading for enhanced anti-tumor efficacy | Ditte E. Jaehger, PhD; Kate L. Stokes, PhD; Hólmfridur R. Halldórsdóttir, MSc; Alvin Pratama, PhD; Gulzar Ahmad, PhD; Jonathan D. Nardozzi, PhD.; Katharine Sackton, PhD; Douglas Jones, PhD; Thomas L. Andresen, PhD; | Cellular Therapies | Adoptive immunotherapy; Dendritic cell; Immune adjuvant; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 141 | Poster Presentation | PBMC-based cancer vaccines generated with microfluidics squeezing demonstrate synergistic and durable tumor reduction in combination with PD1 checkpoint and FAP targeted IL-2 variants | Matthew G. Booty, PhD; Adam Stockmann; Olivia Pryor; Melissa Myint, PhD; Christine Trumpfheller, PhD; Valeria G. Nicolini; Christian Klein, Dr rer nat; Laura Codarri, Dr.; Pablo Umana, PhD; Armon Sharei, PhD; Howard Bernstein, MD, PhD; Katherine Seidl, PhD; Scott M. Loughhead, PhD; | Cellular Therapies | Adoptive immunotherapy; Antibody; Bispecifics; Checkpoint blockade; Cytokine; Tumor microenvironment; Vaccine |
| 142 | Poster Presentation | Contextual reprogramming of CAR T cells for the treatment of HER2-expressing cancers | Zhifen Yang, Dr.; Lingyu Li, PhD; Ahu Turkoz, Ph.D.; Pohan Chen, MS; Hana Choi, MS; Damla Inel, MS; Stanley L. Qi, Ph.D.; Francesco M. Marincola, MD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Costimulation; Immune contexture; Solid tumors; T cell lineages; Tumor microenvironment |
| 146 | Poster Presentation | Alloantigen-specific Tr1 cells designed to prevent GvHD have a distinct molecular identity and suppress through CTLA-4 and PD-1 | Alma-Martina Cepika; Pauline P. Chen; Molly J. Uyeda; Brandon Cieniewicz; Mansi Narula; Laura Amaya; David M. Louis; Liwen Xu; Xuhuai Ji; Alice Bertaina; Rajni Agarwal-Hashmi; Mark M. Davis; Everett Meyer; Rosa Bacchetta; Maria Grazia Roncarolo | Cellular Therapies | Adoptive immunotherapy; Immune suppression; Immune tolerance; Leukemia/Lymphoma; Regulatory T cell (Treg cell); T cell |
| 147 | Poster Presentation | CD155 blockade boosts alloreactive natural killer cell antitumor effects against osteosarcoma | Monica M. Cho, BSE; Monica M. Cho, BSE; Madison F. Phillips; Longzhen Song, Ph.D.; Amy K. Erbe, PhD; Christian M. Capitini, MD; | Cellular Therapies | Adoptive immunotherapy; NK/NKT cell; Pediatric tumors; Solid tumors |
| 148 | Poster Presentation | Identification of prostate-restricted epithelial antigens for transgenic T cell adoptive therapy against prostate cancer | Diana DeLucia, PhD; Tiffany Pariva; Roland Strong; Owen Witte; John Lee; | Cellular Therapies | Adoptive immunotherapy; Solid tumors; T cell; Tumor antigens |
| 149 | Poster Presentation | GEN-011: An ATLASTM-guided peripheral-blood derived neoantigen-specific T cell therapy designed to improve on TIL approaches | Pranay D. Khare, PhD; Harshal Zope; James Perry; Victoria L. DeVault, PhD; Mercay R. Reuter; Adrienne Li, PhD; Daniel B. DeOliveira, PhD; Hubert Lam, PhD; Manish Jain, PhD; Jessica B. Flechtner, PhD; Pranay D. Khare, PhD; | Cellular Therapies | Adoptive immunotherapy; Neoantigens; Solid tumors; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs) |
| 150 | Poster Presentation | GAIA-102: a new class off-the-shelf allogeneic NK-like cells that can eliminate solid tumors | Yui Harada, PhD; Yoshikazu Yonemitsu, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; NK/NK T cell; Solid tumors |
| 152 | Oral Presentation | Adoptive T cell therapy targeting somatic p53 mutations | Peter Kim, PhD; Parisa Malekzadeh, MD; Nolan Vale; Elizabeth Hedges; Nikolaos Zacharakis, PhD, MS; Steven A. Rosenberg, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; Neoantigens; T cell; Tumor infiltrating lymphocytes (TILs) |
| 153 | Poster Presentation | NEO-PTC-01 (BNT-221), an autologous neoantigen-specific T-cell product for adoptive cell therapy of metastatic melanoma | Divya R. Lenkala, MS; Jessica Kohler, PhD; Brian McCarthy; Michael Nelson; Jonathan McGee; Daniel Kallin; Janani Sridar; Paul Turcott; Dewi Harjanto; Cynthia Nijenhuis; Joost H. Van Den Berg, PharmD; Richard B. Gaynor, MD; Marit M. Van Buuren, PhD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Bioinformatics; Dendritic cell; Neoantigens; T cell |
| 154 | Poster Presentation | Marrow-infiltrating Lymphocytes (MILs): A Novel Adoptive Immunotherapy for Hematological and Solid Tumors | Eric R. Lutz, PhD; Lakshmi Rudraraju, MS; Elizabeth DeOliveira; Amanda L. Seiz; Monil Shah, PharmD; Celine Colmenares; Beverly Dan Fu; Daniela Bota, MD, PhD; Collin Brummel; Chad Brenner, PhD; Paul Swiecicki, MD; Nicole E. Fredrich; David B. Page, MD; Eleni Efstatihiou, MD, PhD; Ivan M. Borrello, MD; Kimberly A. Noonan, PhD, MPH; | Cellular Therapies | Adoptive immunotherapy; Solid tumors; T cell |
| 155 | Poster Presentation | iPSC-derived NK cells mediate robust anti-tumor activity against glioblastoma | Jeff S. Miller, MD; Frank S. Cichocki, PhD; Jianfang Ning; Ryan Bjordahl, PhD; Zachary B. Davis, PhD; Katie Tuininga; Hongbo Wang; Paul Rogers; Moyar Ge; Tom T. Lee; Bob Valamehr, PhD; Clark C. Chen; | Cellular Therapies | Adoptive immunotherapy; NK/NK T cell; Solid tumors |
| 156 | Poster Presentation | Discovery of TSC-100: A Natural HA-1-specific TCR to Treat Leukemia Following Hematopoietic Stem Cell Transplant Therapy | Ribhu Nayar, Ph.D.; Sonal Jangalwe; Mollie M. Jurewicz; Antoine J. Boudot; Andrew S. Basinski; Robert Prenovitz; Elizabeth A. Olesin; Daniel C. Pollacksmith; Qikai Xu; Yifan Wang; Amy Virbasius; Jeffery Li; Holly Whitton; Garrett S. Dunlap; Alexander Cristofaro; Nancy Nabilsi; Ruan Zhang; Candace Perullo; Sida Liao; Kenneth L. Jahan; Kenneth Olivier; Gavin MacBeath, Ph.D.; | Cellular Therapies | Adoptive immunotherapy; Genetic polymorphism; Inflammation; Leukemia/Lymphoma; T cell; Targeted therapy; Tumor antigens |
| 157 | Poster Presentation | A critical role of CD40 and CD70 signaling in cDC1s in expansion and antitumor efficacy of adoptively transferred tumor-specific T cells | Takaaki Oba, MD,PhD; Toshifumi Hoki, MD,PhD; Takayoshi Yamauchi; Tibor Keler, PhD; Henry C. Marsh; Xuefang Cao; Fumito Ito; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Costimulation; Dendritic cell |
| 158 | Poster Presentation | Inhibition of PI3Kδ improves tumor specific T cell immunity and metabolic fitness | Guillermo O. Rangel RIvera, B.S.; Guillermo O. Rangel RIvera, B.S.; Connor J. Dwyer, PhD; Dimitrios C. Arhontoulis; Hannah M. Knochelmann, BS; Aubrey S. Smith, BS; Megan M. Wyatt, MS; Amalia M. Rivera Reyes, BS; Chrystal M. Paulos, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Metabolism; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs) |
| 159 | Poster Presentation | Adoptively transferred CD8+ T cells that target neoantigen persist and regress melanomas to a greater extent than those that target self/tumor-antigen | Amalia M. Rivera Reyes, BS; Megan M. Wyatt, MS; Connor J. Dwyer, PhD; Hannah M. Knochelmann, BS; Aubrey S. Smith, BS; Guillermo O. Rangel RIvera, B.S.; Chrystal M. Paulos, PhD; | Cellular Therapies | Adoptive immunotherapy; Neoantigens; Solid tumors |
| 160 | Poster Presentation | TLR9-activated B cells imprint adoptively transferred CD8+ T cells with potent tumor immunity and persistence in vivo | Aubrey S. Smith, BS; Hannah M. Knochelmann, BS; Connor J. Dwyer, PhD; Megan M. Wyatt, MS; Guillermo O. Rangel RIvera, B.S.; Amalia M. Rivera Reyes, BS; Jessica E. Thaxton, PhD, MS; Eric C. Bartee, PhD; Mark P. Rubinstein, PhD; Bei Liu, MD MPH; Chrystal M. Paulos, PhD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; B cell; Proteomics; T cell; TLR; Tumor infiltrating lymphocytes (TILs) |
| 161 | Poster Presentation | Development of a CD8 co-receptor independent T cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T cell-based immunotherapy | Kathrin Davari, PHD; Tristan Holland; Laura Prassmayer; Giulia Longinotti; Kenneth Ganley; Lisa J. Pechilis; Iulia Diaconu; Prashant R. Nambiar; Mike S. Magee; Dolores J. Schendel, PhD; Daniel Sommermeyer, PhD; Christian Ellinger, Dr. Rer. Nat.; | Cellular Therapies | Adoptive immunotherapy; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| 163 | Poster Presentation | NICE: Neoantigen-Cytokine-Chemokine Multifunctional Engager for NK cell immunotherapy of solid tumors | Xue Yao, MS; Sandro Matosevic, PhD; | Cellular Therapies | Adoptive immunotherapy; Bispecifics; Chemokine; Cytokine; Neoantigens; NK/NK T cell; Solid tumors; Tumor antigens; Tumor microenvironment |
| 164 | Poster Presentation | AgenT-797, a novel allogenic and “off-the shelf” iNKT cell therapy promotes effective tumor killing | Burcu Yigit, PhD; Xavier Michelet, PhD; Shalu S. Kharkwal; Eleni Chantzoura, PhD; Jan Bergmann; Alvaro Sebastian Yague, Ph.D; Simon Yue; Darrian Moskowitz; Benjamin Wolf, PhD; Mark A. Exley, PhD; Dhan Chand, PhD; Marc A. Van Dijk, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; NK/NK T cell |
| 165 | Poster Presentation | Activating antigen carriers generated with microfluidics cell squeezing drive effective anti-tumor responses | Katarina Blagovic, PhD; Katarina Blagovic, PhD; Katarina Blagovic, PhD; Amritha K. Ramakrishnan, PhD; Armon Sharei, PhD; Howard Bernstein, MD, PhD; Katherine J. Seidl, PhD; Defne Yarar, PhD; | Cellular Therapies | Adoptive immunotherapy; Immune adjuvant; Solid tumors; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Vaccine |
| 166 | Poster Presentation | Mucosal-associated invariant T-cells (MAIT) in pancreatic cancer | Jéssica O. Kamiki, Master's student; Patrícia A. António; Pedro Noronha; Carolina Condeço; Georgia Paraschoudi, M.Sc. in Cell and Molecular Biology, Sweden; Eric De Sousa; Andreia Maia, PhD student; Mireia Castillo-Martin, MD, PhD; Antonio Beltran; Carlos Carvalho, MD; Joana Lérias, DVM; Markus J. Maeurer, MD, PhD, FRCP(London); | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Microbiome; T cell; T cell lineages; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| 167 | Poster Presentation | B-cell-based vaccination elicit potent immunity against glioblastoma | Catalina Lee-Chang, PhD; Jason Miska, PhD; David Hou; Aida Rashidi, MD; Peng Zhang, PhD; Rachel A. Burga, PhD; Crag M. Horbinski, MD, PhD; Roger Stupp, MD; Maciej S. Lesniak, MD; | Cellular Therapies | Adoptive immunotherapy; Antibody; Antigen presenting cells; B cell; Checkpoint blockade; Costimulation; Solid tumors; Tumor microenvironment; Vaccine |
| 169 | Poster Presentation | Microfluidics cell squeezing enables human PBMCs as drivers of antigen-specific CD8 T responses across broad range of antigens for diverse clinical applications | Michael F. Maloney, PhD; Scott M. Loughhead, PhD; Amritha K. Ramakrishnan, PhD; Carolyne Smith, PhD; Anita Venkitaraman; Christian Yee; Miye Jacques, MSc; Defne Yarar, PhD; Armon Sharei, PhD; Howard Bernstein, MD, PhD; Kelan A. Hlavaty, PhD; Melissa Myint, PhD; Katherine J. Seidl, PhD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Cytokine; T cell; Targeted therapy; Tumor antigens; Vaccine |
| 170 | Poster Presentation | Microfluidics Cell Squeezing Enables Potent Cellular Vaccines in Murine Models Through Direct Cytosolic Loading and Direct CD8 T Cell Priming | Emrah I. Ozay, PhD; Matthew G. Booty; Katarina Blagovic, PhD; David Soto; Olivia Pryor; Adam Stockmann; Disha Subramanya; Kelly Volk; Armon Sharei, PhD; Howard Bernstein, MD, PhD; Defne Yarar, PhD; Katherine J. Seidl, PhD; Scott M. Loughhead, PhD; | Cellular Therapies | Antigen presenting cells; Chemotherapy; Immune adjuvant; Inflammation; Solid tumors; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| 173 | Poster Presentation | An In Vivo CRISPR/Cas9 Screening Platform to Identify T Cell Enhancing Edits in Distinct Solid Tumor Microenvironments | Amy Becker, PhD; Troy Luster; Ishina Balwani; Nachiket Shevale; Jingwei Sun, PhD; Erica Del Aguila; Jeff Jones; Srijani Sridhar; Nishit Patel; Daniel O'Connell; Reynald Lescarbeau; Birgit C. Schultes; | Cellular Therapies | Adoptive immunotherapy; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 174 | Poster Presentation | An ex vivo tumoroid model of fresh patient tumors (3D-ACT) to assess efficacy of cellular therapy in immuno-oncology | Stephen Iwanowycz, PhD; Jared C. Ehrhart, PhD; Mibel Pabon, PhD; Tina Pastoor; Jenny Kreahling, PhD; Soner Altiok, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; Antibody; CAR T cells; Cytokine; Gene expression; Immune monitoring; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 175 | Poster Presentation | A Fas-4-1BB immunomodulatory fusion protein converts a pro-death to a pro-survival signal, enhancing T cell function and efficacy of adoptive cell therapy in murine models of AML and pancreatic cancer | Shannon K. Oda, PhD; Shannon K. Oda, PhD; Kristin G. Anderson, PhD; Philip D. Greenberg, MD; Nicolas Garcia, BS; Pranali Ravikumar; Patrick Bonson; Cody Jenkins; Summer Zhuang; Andrew W. Daman; Shannon K. Oda, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Costimulation; Immune suppression; Leukemia/Lymphoma; Metabolism; Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
| 179 | Poster Presentation | Immunotherapy trials lack a biomarker for inclusion: implications for drug development | Jacob J. Adashek, DO; Alexey Goloubev; Shumei Kato, MD; Razelle Kurzrock, MD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Clinical study |
| 180 | Poster Presentation | The effect of packed red blood cell transfusions on the clinical efficacy of immunotherapy | Christopher D'Avella, MD; Karthik Devarajan, PhD; Martin Edelman, MD; Daniel M. Geynisman, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Solid tumors |
| 183 | Poster Presentation | Overcoming immunotherapy resistance in T cell-inflamed lung cancer | Brendan L. Horton, PhD; Duncan Morgan; Noor Momin; Vidit Bhandarkar; Dane Wittrup, PhD; Chris Love, PhD; Stefani Spranger, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Cytokine; Immune contexture; Immune suppression; Immune tolerance; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| 185 | Poster Presentation | Camrelizumab monotherapy or combination therapy in patients with recurrent or metastatic cervical and endometrial carcinoma：a retrospective study | Hong Liu, MD; Hong Liu, MD; Shuhuai Niu; Zhaohui Fang; Xi Chen; Qianying Zhang; | Checkpoint Blockade Therapy | Antibody; Biomarkers; Checkpoint blockade; Chemotherapy; Clinical study; Cytokine; Immune toxicity; Radiotherapy; Solid tumors; T cell |
| 192 | Poster Presentation | 'Immune-Brain': A case series of cognitive dysfunction/decline in cancer patients on immunotherapy | Sarah R. Gillett, MD, PhD; Ximena Jordan-Bruno, MD; Hibba Rehman, MD; Alissa Thomas, MD; Sarah R. Gillett, MD, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune toxicity; Solid tumors |
| 197 | Poster Presentation | Survival outcomes and toxicity among patients treated with concomitant radiotherapy and immunotherapy for advanced melanoma: two faces of the abscopal effect? | Nikolaos Andreatos, MD; Joanna Roopkumar, MBBS, MPH; Alok A. Khorana, MD; Neil M. Woody, MD, MS; Brian R. Gastman, MD; Pauline Funchain, MD; | Checkpoint Blockade Therapy | Autoimmunity; Checkpoint blockade; Immune toxicity; Radiotherapy; Solid tumors; Tumor antigens |
| 198 | Poster Presentation | Combination intratumoral treatment with INTASYL™ self-delivering RNAi targeting TIGIT and PD-1/PD-L1 improves tumor control compared to monotherapy in a CT26 model of murine colorectal cancer | Benjamin Cuiffo, PhD; Melissa Maxwell, MS; Dingxue Yan; Andrej Jedinak, PhD; James Cardia, PhD; Simon P. Fricker, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Coinhibition; Gene expression; RNA; T cell; Targeted therapy; Tumor microenvironment |
| 201 | Poster Presentation | Carboplatin, paclitaxel and pembrolizumab for the first line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma | Angelica Valadez; Madeleine Welsh; Christine Kim; Angela Johns; Alain P. Algazi, MD; Hyunseok Kang, MD, MPH; Hyunseok Kang, MD, MPH; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemotherapy; Clinical study; Solid tumors |
| 202 | Poster Presentation | In vitro and in vivo combination therapy of Low Molecular Weight Heparins, chemotherapy and immunotherapy, induce antitumor activity in Pancreatic Cancer | Michalis Karamouzis; Panagiotis Sarantis, MD, PhD; Evangelos Koustas; Adriana Papadimitropoulou; Pavlos Papakotoulas; Alexandros Bokas; Dimitrios Schizas; Alexandros Papalampros; Evangelos Felekouras; Theodoros Liakakos; Athanasios Papavassiliou; | Checkpoint Blockade Therapy | Checkpoint blockade; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 212 | Poster Presentation | CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and synergizing with tumor-targeted antibodies. | Vanessa Gauttier; Marion Drouin; Sabrina Pengam; Javier Saenz; Bérangère Evrard; Caroline Mary; Géraldine Teppaz; Ariane Desselle; Virginie Thépénier; Emmanuelle Wilhelm; Elise Chiffoleau; Nicolas Poirier, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Dendritic cell; Myeloid cells; Tumor microenvironment |
| 213 | Poster Presentation | Use of A novel peptide ligand targeting multiple immune checkpoints: A novel approach to immunotherapy against Central Nervous System Tumors | Christopher Moertel; Zhengming Xiong; Michael Olin, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Solid tumors |
| 221 | Poster Presentation | Poor performance status negatively affects survival benefit of immunotherapy in non-small cell lung cancer | Hameem I. Kawsar, MD, PhD; Pramod I. Gaudel, MD; Nahid Suleiman, MD, PharmaD; Mohammed Al-Jumayli, MD; Chao Huang, MD; Prakash Neupane, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune toxicity; Solid tumors |
| 224 | Poster Presentation | Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis | Tamara A. Sussman, MD; Wei Wei, MS; Pauline Funchain, MD; Brian R. Gastman, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Solid tumors; T cell |
| 227 | Poster Presentation | Using 3D spheroid cultures towards personalized ex vivo profiling of immune checkpoint inhibitor efficacy in melanoma and non-small cell lung cancer | Kathryn Appleton, PhD; Katy A. Lassahn, MS; Ashley K. Elrod; Tessa DesRochers, PhD; | Checkpoint Blockade Therapy | Antibody; Biomarkers; Checkpoint blockade; Chemokine; Chemotherapy; T cell; T cell lineages; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 228 | Poster Presentation | Radiological dynamics and resistance types in patients with advanced melanoma treated with anti-PD-1 monotherapy | Xue Bai, MD; Michelle Kim; Gyulnara Kasumova; Lu Si; Bixia Tang; Chuanliang Cui; Xiaoling Yang; Xiaoting Wei; Justine V. Cohen, DO; Donald P. Lawrence, MD; Christine Freedman, RN; Riley Fadden, NP; Krista M. Rubin, NP, MS; Tatyana Sharova; Dennie Frederick; Keith Flaherty, MD; Ryan J. Sullivan, MD; Jun Guo; Genevieve M. Boland, MD, PhD; | Checkpoint Blockade Therapy | Clinical study |
| 229 | Poster Presentation | Discovery of ganglioside GM2 activator as a novel proteomic biomarker associated with response to treatment in first-line melanoma subjects treated with PD-1 immunotherapy | Kristina Beeler, Dr.; Jakob Vowinckel, PhD; Martin Soste; Domenico Mallardo, MD; Mariaelena Capone, MD; Madonna Gabriele, MD; Antonio Sorrentino, MD; Vito Vanella, MD; Kamil Sklodowski, PhD; Daniel Heinzmann, MSc; Paolo A. Ascierto, MD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Immune monitoring; Immune suppression; Metabolism; Proteomics; Tumor microenvironment |
| 230 | Poster Presentation | Single cell PIK3 gene expression patterns support duvelisib (PI3K-delta, gamma inhibitor) treatment of melanoma and other tumors after checkpoint inhibitor therapy | Samantha Hidy; David Weaver, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Gene expression; Targeted therapy |
| 238 | Poster Presentation | Molecular dissection of tumor-immune microenvironment factors associated with response to checkpoint inhibitor therapy in non-small cell lung cancer patients using Nanostring Digital Spatial Profiling | Omar J. Jabado, PhD; Suzana Couto, PhD, DVM pathologist; Jordan Blum, PhD; Patrick Franken; Patricia Coutinho de Souza, PhD; Maria N. Jure-Kunkel, PhD, DVM; Nora Pencheva, PhD; Brandon W. Higgs, PhD; Kate Sasser, PhD; Mark Fereshteh, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemotherapy; Gene expression; Immune contexture; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 239 | Poster Presentation | Decr2 loss promotes resistance of tumor cells to immunotherapy by affecting CD8+ T cell-regulated tumor ferroptosis | Thomas F. Gajewski, MD, PhD; Emily Higgs, BA; Shuyin Li, PhD; Shuyin Li, PhD; Blake Flood, BS; Ken Hatogai; | Checkpoint Blockade Therapy | Checkpoint blockade; Metabolism |
| 241 | Poster Presentation | Clinical Outcomes of Metastatic Melanoma Patients with Liver Metastases Treated with Anti-PD-1 Monotherapy Versus Combination Ipilimumab/Nivolumab | Vincent T. Ma, MD; Kent A. Griffith, MPH, MS; Jessica J. Waninger, BS; Stephanie Daignault-Newton, MS; Leslie A. Fecher, MD; Ajjai S. Alva, MBBS; Christopher D. Lao, MD, MPH; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Clinical study; Immune tolerance; Solid tumors |
| 245 | Poster Presentation | Human TLR8 knock-in mice potentiate immunotherapy responses of MC38 syngeneic tumors | Shanshan Qi, PhD; Hongjuan Zhang, PhD; Ruilin Sun; Annie X. An; Henry Q. Li; Davy X. Ouyang, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Dendritic cell; T cell; TLR |
| 247 | Poster Presentation | Assessment of sensitivity to a PD-1 check point inhibitor and cisplatin in bladder cancer patient-derived xenografts with various levels of PD-L1 expression in HuCD34NCG mice | Simon Tarpinian, BS; Jenny Rowe, PhD; Ruziboy Husanov, MS; Uma Saha, MS; Prabal Banerjee, PhD; Rukiye Eraslan, PhD; Beverly Jones, PhD; Stephen Festin, PhD; Vladimir Khazak, PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Chemotherapy; Solid tumors; Stem cell/cancer-initiating cell |
| 248 | Oral Presentation | Immunotherapy persister cells uncovered by dynamic single-cell RNA-sequencing | Kartik Sehgal, MD; Andrew Portell; Elena Ivanova; Patrick Lizotte, PhD; Navin R. Mahadevan; Jonathan R. Greene; Amir Vadji; Carino Gurjao; Tyler Teceno; Luke J. Taus; Tran C. Thai; Shunsuke Kitajima; Derek Liu; Tetsuo Tani; Moataz Noureddine; Christie J. Lau; Paul T. Kirschmeier, PhD; David Liu, MD, MPH, MS; Marios Giannakis, MD, PhD; Russell W. Jenkins; Prafulla C. Gokhale, PhD; Silvia Goldoni; Maria Pinzon-Ortiz, BS; William D. Hastings; Peter Hammerman; Juan Miret; Cloud P. Paweletz, Ph.D.; David A. Barbie, MD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Gene expression; Stem cell/cancer-initiating cell; Targeted therapy; Tumor evasion |
| 259 | Poster Presentation | Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + selicrelumab (seli) + gemcitabine+nab-paclitaxel (gem+nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC | Gulam A. Manji, MD PhD; Nathan Bahary, MD PhD; Vincent Chung, MD; Florence Dalenc; Michel Ducreux; Carlos A. Gomez-Roca, MD; Seock-Ah Im; Jeremy Kortmansky; Jill Lacy, MD; Neil H. Segal, MD; Olivier Tredan; Olivera Cirovic, MD, PhD; Kelly DuPree; Christelle Lenain; Danny Lu; Lidia Robert; Jeffrey Xu; Xiaosong Zhang, MD PhD; Sung-Bae Kim; | Completed Clinical Trials | Checkpoint blockade; Chemotherapy; Clinical trial |
| 260 | Poster Presentation | T Cell Infiltrating Repertoire Diversity is Associated with Enhanced Survival Following Neoadjuvant Therapy in Patients with Resectable Pancreatic Cancer | Pranav Murthy, BS; Pragosh Saini; Kira L. Russell, BS; Wenjing Pan, PhD; Daniel Weber, BS; Miranda L. Byrne-Steele, PhD; Jian Han, MD PhD; Viginia Espina, PhD; Lance Liotta, MD, PhD; Herbert J. Zeh III, MD; Nathan Bahary, MD PhD; Aatur D. Singhi, MD PhD; Tullia C. Bruno, PhD; Amer H. Zureikat, MD; Michael T. Lotze, MD; | Completed Clinical Trials | B cell; Bioinformatics; Biomarkers; Chemotherapy; Immune contexture; Inflammation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 267 | Poster Presentation | Pseudoprogression patterns: Analysis from 2 independent phase-2 studies with immunotherapy for recurrent cervical cancer | David M. O'Malley, MD; Waldo Ortuzar Feliu, MD; Isabelle Ray-Coquard, MDPhD; Michael O'Neal; Jerome Alexandre, MD; Julie Cole, MD; Robert Ludwig, MD; Madhavi Nallewar; Jennifer S. Buell, PhD; Remigiusz Kaleta, MD; Anna Wijatyk, MD; Victoria Borisovskaya; | Completed Clinical Trials | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Immune toxicity; Solid tumors |
| 271 | Poster Presentation | Consistent high-quality dendritic cell vaccines produced post-chemotherapy in patients with acute myeloid leukemia for use in a Phase I/II trial | Frauke Schnorfeil; Christiane Geiger, PhD; Iris Bigalke; Dag Josefsen; Yngvar Floisand; Gunnar Kvalheim, MD, PhD; Dolores J. Schendel, PhD; Anna Tafuri; Kai Pinkernell; | Completed Clinical Trials | Antigen presenting cells; Dendritic cell; Leukemia/Lymphoma; Targeted therapy; Tumor antigens; Vaccine |
| 272 | Poster Presentation | Use of LioCyx-M, Autologous Hepatitis B Virus (HBV)-Specific T cell receptor (TCR) T-cells, in Advanced HBV-related Hepatocellular Carcinoma (HCC) | Fu-Sheng Wang, MD, PhD; Fanping Meng, MD, PhD; Jiehua Jin, PhD; Yuanyuan Li, MD, PhD; Regina Wanju Wong, PhD; Anthony Tanoto Tan, PhD; Tingting Wang, MD, PhD; Antonio Bertoletti, MD; | Completed Clinical Trials | Adoptive immunotherapy; Clinical trial; T cell |
| 273 | Poster Presentation | Phase I Study of LioCyx-M, Autologous Hepatitis B Virus (HBV)-Specific T cell receptor (TCR) T-cells, in Recurrent HBV-Related Hepatocellular Carcinoma (HCC) Post-Liver Transplantation | Wenjie Chen, MD, PhD; Jintao Cheng, MD; Xiaofang Zheng, BSc; Fan Yang, MD, PhD; Royce Fam, BSc; Sarene Koh, PhD; Lu-En Wai, PhD; Tingting Wang, MD, PhD; Antonio Bertoletti, MD; Qi Zhang, MD, PhD; | Completed Clinical Trials | Adoptive immunotherapy; Clinical trial; T cell |
| 276 | Poster Presentation | Prognostic value of tumor size varies by treatment in a meta-analysis of 15 randomized clinical trials in advanced non-small cell lung cancer across immunotherapy, TKI, and chemotherapy regimens | Jacqueline Buros, BA; Krzysztof Sakrejda, PhD; Daniel Lee, MS; Eric Novik, MS; Jacqueline Buros, BA; Philip Jewsbury, PhD; | Completed Clinical Trials | Biomarkers; Checkpoint blockade; Clinical trial |
| 277 | Oral Presentation | Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy | Boris Sepesi, MD; Erin M. Corsini; Annikka Weissferdt; Apar Pataer; Mehmet Altan, MD; Mara B. Antonoff, MD; George R. Blumenschein, Jr., MD; Yasir Y. Elamin; Frank Fossella; Bonnie S. Glisson, MD; Wayne Hofstetter; Jonathan Kurie; Xiuning Le, MD, PhD; Cheuk Hong Leung, MS; Heather Lin, MS, PhD; Charles Lu; Reza Mehran; Frank Mott; David Rice; Jack Roth; Ferdinandos Skoulidis; Stephen G. Swisher, MD; Anne Tsao, MD; Ara A. Vaporciyan, MD; Garret Walsh; Jianjun Zhang, MD, PhD; Don L. Gibbons, MD, PhD; John V. Heymach, MD, PhD; Tina Cascone, MD, PhD; | Completed Clinical Trials | Checkpoint blockade; Chemotherapy; Clinical trial; Solid tumors; Surgery; Targeted therapy |
| 278 | Poster Presentation | Phase I clinical trial evaluating the safety of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ advanced non-small cell lung cancer | George R. Blumenschein, Jr., MD; Siddhartha Devarakonda, MD; Melissa L. Johnson, MD; Victor Moreno, PhD, MD; Justin F. Gainor, MD; Martin Edelman, MD; John V. Heymach, MD, PhD; Ramaswamy Govindan, MD; Carlos Bachier, MD; Bernard Doger de Spéville; Matthew J. Frigault, MD, MSc; Anthony J. Olszanski, MD, RPh; Vincent K. Lam; Natalie Hyland; Jean-Marc Navenot, PhD; Svetlana Fayngerts, PhD; Jane Bai; Elliot Norry, MD; Paula M. Fracasso, MD, PhD | Completed Clinical Trials | Adoptive immunotherapy; Targeted therapy |
| 279 | Poster Presentation | Durvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC impacts local-regional control and overall survival | MD; Lukas Kaesmann, MD; Julian Taugner; Chukwuka Eze; Claus Belka; Farkhad Manapov; | Completed Clinical Trials | Checkpoint blockade; Clinical trial; Radiotherapy; Solid tumors |
| 280 | Poster Presentation | Both tumor intrinsic and extrinsic factors contribute to TIL resistance in lung cancer patients | Chao Wang, PhD; Jamie Teer; Jiqiang Yao, PhD; Carmen Anadon; David Noyes; Ana Landin; Xiaoqing Yu; Dongliang Du; Zachary Thompson; Bin Fang, PhD; John M. Koomen, PhD; Sungjune Kim, MD PhD; Shari A. Pilon-Thomas, PhD; Dung-Tsa Chen; Jose R. Conejo-Garcia, MD, PhD; Scott J. Antonia, MD PhD; Eric Haura, MD; Ben C. Creelan, MD, MS; | Completed Clinical Trials | Adoptive immunotherapy; Neoantigens; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| 282 | Poster Presentation | Pan-tumor analysis of the association between PD-L1 combined positive score and response to pembrolizumab monotherapy | Lingkang Huang; Jared Lunceford, PhD; Junshui Ma; Kenneth Emancipator, MD; | Completed Clinical Trials | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| 283 | Poster Presentation | Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs) | Shubham Pant, MD; Amishi Shah; Pavlos Msaouel, MD, PhD; Matthew T. Campbell, MD; Shi-Ming Tu; Jianjun Gao, MD PhD; George R. Blumenschein, Jr., MD; Frank Mott; Xiuning Le, MD, PhD; Mehmet Altan, MD; Funda Meric-Bernstam, MD; Timothy A. Yap, MD, PhD; Vivek Subbiah, MD; Jordi Rodon; Axel Glasmacher; Imke Mulder; Michael J. Chisamore, PhD; Alexander Stevenson, PhD; Nizar M. Tannir, MD, FACP; | Completed Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Microbiome; Solid tumors; TLR |
| 285 | Poster Presentation | Phase I clinical trial evaluating the safety of ADP-A2M10 in patients with MAGE-A10+ head and neck, melanoma, or urothelial tumors | David S. Hong, MD; Marcus O. Butler, MD; Russell Pachynski, MD; Ryan J. Sullivan, MD; Partow Kebriaei; Sarah Boross-Harmer; Matthew J. Frigault, MD, MSc; Ecaterina I. Dumbrava, MD; Amy Sauer; Francine Brophy; Jean-Marc Navenot, PhD; Svetlana Fayngerts, PhD; Jane Bai; Elliot Norry, MD; Paula G. Fracasso | Completed Clinical Trials | Adoptive immunotherapy; Targeted therapy |
| 290 | Poster Presentation | Cytokine and immune subset signatures in patients with various solid and hematological malignancies treated with oncolytic vaccinia virus delivered by autologous stromal vascular fraction cells | Dobrin Draganov, PhD; Antonio F. Santidrian; Ivelina Minev, MSc; Duong H. Nguyen, PhD; Dmitriy Zamarin, MD, PhD; Francesco M. Marincola, MD; Boris Minev, MD; | Completed Clinical Trials | Adoptive immunotherapy; Antigen presenting cells; Clinical study; Immune monitoring; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; Stem cell/cancer-initiating cell; T cell; T cell lineages |
| 293 | Poster Presentation | Results of the first-in-human clinical trial with personalized multi-target adoptive cell therapy (ACTolog IMA101) | Apostolia M. Tsimberidou, MD, PhD; Apostolia M. Tsimberidou, MD, PhD; Apostolia M. Tsimberidou, MD, PhD; Kerstin Guenther; Amir Alpert; Borje Andersson, MD, PhD; Zoe Coughlin; Jens Fritsche, PhD; Norbert Hilf; Patrick M. Hwu, MD; Mamta Kalra, PhD; Sabrina Kuttruff-Coqui, PhD; Dominik Maurer, PhD; Regina Mendrzyk; Ali Mohamed; Becky Norris; Anna Nowak; Rita Ort; Carsten Reinhardt, MD, PhD; Fabian Richter; Arun Satelli; Oliver Schoor, PhD; Kerry A. Sieger; Harpreet Singh, PhD; David Vining, MD; Claudia Wagner; Toni Weinschenk, PhD; Cassian Yee, MD; Steffen Walter, PhD; | Completed Clinical Trials | Adoptive immunotherapy; Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| 297 | Poster Presentation | Modeling the efficacy of NY-ESO-1 TCR T cells (letetresgene autoleucel; GSK3377794) in patients with synovial sarcoma: correlations of response with transduced cell kinetics and biomarkers | Alexandra Gyurdieva; Stefan Zajic; Ya-Fang Chang; E. Andres Houseman; Shan Zhong; Jaegil Kim; David C. Turner; Laura A. Johnson; Ioanna S. Eleftheriadou; Jenna Tress; Aisha N. Hasan, MBBS MD; Victoria L. Chiou; Naimish Pandya; John Glod, MD; Dejka Araujo, MD; Warren Chow; Mihaela Druta; George D. Demetri; Brian A. Van Tine, MD, PhD; Sandra P. D’Angelo; | Completed Clinical Trials | Adoptive immunotherapy; Biomarkers; Chemokine; Cytokine; Gene expression; Immune monitoring; Pediatric tumors; Solid tumors; T cell; Targeted therapy |
| 298 | Poster Presentation | Final analysis of the Phase 1 trial of NY-ESO-1–specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS) | Sandra P. D'Angelo, MD; George D. Demetri; Brian A. Van Tine, MD, PhD; Mihaela Druta; John Glod, MD; Warren Chow; Naimish Pandya; Aisha N. Hasan, MBBS MD; Victoria L. Chiou; Jenna Tress; Julie Edwards; Tim Young; Mary Woessner; Alexandra Gyuerdieva; Stefan Zajic; Sophia Goodison; Dejka Araujo, MD; | Completed Clinical Trials | Adoptive immunotherapy; Clinical trial; Solid tumors; T cell; Tumor antigens |
| 306 | Poster Presentation | Predictors of immunotherapy benefit in Merkel cell carcinoma | Alec J. Kacew, BA; Harita Dharaneeswaran; Gabriel J. Starrett; Manisha Thakuria; Nicole R. LeBoeuf, MD, MPH; Ann W. Silk, MD, MS; James A. DeCaprio; Glenn J. Hanna, MD; | Completed Clinical Trials | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| 312 | Poster Presentation | Female sex independently predicts adjuvant immunotherapeutic benefit from CTLA4 immune checkpoint inhibition | Ahmad A. Tarhini, MD, PhD, MS; Ni Kang; Sandra Lee; F. Stephen Hodi, Jr., MD; Gary I. Cohen; Omid Hamid, MD; Laura F. Hutchins; Jeffrey A. Sosman, MD; Harriett M. Kluger; Zeynep Eroglu, MD; Henry Koon, MD; Donald P. Lawrence, MD; Kari L. Kendra; David R. Minor, MD; Carrie Lee, RN, MSN, OCN; Mark R. Albertini, MD; Lawrence E. Flaherty, MD; Teresa Petrella; Howard Striecher; Vernon K. Sondak, MD; John M. Kirkwood, MD; | Completed Clinical Trials | Biomarkers; Checkpoint blockade; Clinical trial; Immune tolerance; Solid tumors |
| 315 | Poster Presentation | W0180 novel anti-VISTA antibody: Rationale for target patient population and first-in-human trial design in monotherapy and in combination with anti-PD1 antibody | Ignacio J. Melero, Dr., MD, PhD; Carlos A. Gomez-Roca, MD; Pierre Ferre, VetMD, PhD; Pierre Ferre, VetMD, PhD; Eric Chetaille; Aurelie Petain; Celine Thuilliez; Isabelle Vandenberghe; Francisco Cruzalegui, PhD; Asmaa Boudribila; Mariya Pavlyuk; Aurelien Marabelle, MD, PhD; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical trial; Immune contexture; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor microenvironment |
| 319 | Poster Presentation | Phase II trial of immunotherapy in primary glioblastoma: antigens from self-renewing autologous tumor cells presented by autologous dendritic cell vaccine | Daniela Bota, MD, MD., PhD; David E. Piccioni, MD, PhD; Christopher M. Duma, MD; Renato V. LaRocca, MD; Santosh Kesari, MD, PhD; Jose A. Carrillo, MD; Robert O’Donnell; Robert Aiken, MD; Frank Hsu; Xiao-Tang Kong; Thomas H. Taylor, PhD; Gabriel I. Nistor, MD; Robert O. Dillman, MD; Daniela Bota, MD, MD., PhD; | In-Progress Clinical Trials | Clinical trial; Dendritic cell; Immune monitoring; Neoantigens; Stem cell/cancer-initiating cell |
| 321 | Poster Presentation | Phase I clinical trial assessing the combination of systemic chemokine modulatory regimen targeting TLR3 with neoadjuvant chemotherapy in triple negative breast cancer | Shipra Gandhi, MD; Mateusz Opyrchal, MD, PhD; Cayla Ford; Victoria Fitzpatrick; Melissa Grimm, PhD; Per H. Basse, MD, PhD; Marie Quinn, MD; Agnieszka Witkiewicz, MD; Kristopher Attwood, PhD; Marc S. Ernstoff, MD; Tracey L. O'Connor, MD; Amy P. Early, MD; Ellis G. Levine, MD; Pawel Kalinski, MD, PhD; | In-Progress Clinical Trials | Chemokine; Chemotherapy; Clinical trial; Immune adjuvant; TLR; Tumor infiltrating lymphocytes (TILs) |
| 324 | Poster Presentation | BDB001, a Toll-Like Receptor 7 and 8 (TLR7/8) Agonist, can be safely administered intravenously and shows clinical responses in advanced solid tumors. | Manish Patel, MD; Drew Rasco, MD; Melissa L. Johnson, MD; Anthony W. Tolcher, MD; Lixin Li, PhD; Adam Zong, PhD; Alexander Chung, PhD; Robert H. Andtbacka, MD, CM; | In-Progress Clinical Trials | COVID and Immunotherapy; Adoptive immunotherapy; Clinical study; Clinical trial; Cytokine; Dendritic cell; Monocyte/Macrophage; Solid tumors; TLR |
| 325 | Poster Presentation | Immunotherapy with B cell activating antibody CPI-006 in patients (pts) with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells and memory T effector cells | Gerard J. Criner, MD; Mehrdad Mobasher, MD, MPH; Craig M. Hill, PhD; Shenshen Hu, PhD; Suresh Mahabhashyam, MD, MPH; Joshua Brody, MD; Thomas U. Marron, MD, PhD; Stephen Willingham, PhD; Richard A. Miller, MD; | In-Progress Clinical Trials | COVID and Immunotherapy; Antibody; B cell; Clinical study; Clinical trial; Immune adjuvant; Vaccine |
| 326 | Poster Presentation | SARS-CoV-2 specific T-cells in TIL from patients with epithelial cancer | Pedro Noronha; Georgia Paraschoudi, M.Sc. in Cell and Molecular Biology, Sweden; Eric D. Sousa; Jéssica O. Kamiki; Patrícia A. António; Carolina Condenço; Inês Silva; Andreia Maia, PhD student; Mireia Castillo-Martin; António Beltran; Carlos Carvalho, MD; Joana R. Lerias, PhD; Alimuddin Zumla; Markus J. Maeurer, MD, PhD, FRCP(London); | In-Progress Clinical Trials | COVID and Immunotherapy; Clinical study; Tumor infiltrating lymphocytes (TILs) |
| 327 | Poster Presentation | Study of anti-PD-1 antibody multimodal combination as first-line treatment on time window of advanced solid tumor | Jian Shi, MD; Baoen Shan; Junyan Wang; Jiayin Liu; Rongfeng Liu; Yujie Shan; | In-Progress Clinical Trials | COVID and Immunotherapy; Angiogenesis; Biomarkers; Checkpoint blockade; Chemotherapy; Clinical trial; Gene expression; Immune toxicity; Solid tumors; Targeted therapy |
| 328 | Poster Presentation | Phase 3 study of olaparib ± bevacizumab versus bevacizumab + fluorouracil in patients with unresectable or metastatic colorectal cancer not progressing on first-line FOLFOX + bevacizumab (LYNK-003) | Carlos A. Mayo, MD; Ellen B. Gurary; Patricia Marinello; | In-Progress Clinical Trials | Angiogenesis; Chemotherapy; Clinical study; Targeted therapy |
| 331 | Poster Presentation | Immunotherapy with Y90-radioembolization for metastatic colorectal cancer (iRE-C) | Pashtoon M. Kasi, MD, MS; Beau M. Toskich, MD; Sandeep T. Laroia, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Inflammation; Neoantigens; Radiotherapy; Solid tumors; Tumor antigens; Tumor microenvironment; Tumor stroma |
| 333 | Poster Presentation | Targeting the apical intracellular checkpoint CISH unleashes T cell neoantigen reactivity and effector program | Douglas C. Palmer, PhD; Beau R. Webber; Yogin Patel, PhD; Matthew J. Johnson, PhD; Christine M. Kariya; Walker S. Lahr; Maria r. Parkhurst; Jared Gartner, MS; Todd D. Prickett; Frank J. Lowery; Rigel J. Kishton; Devikala Gurusamy; Zulmarie Franco; Suman Vodnala; Miechaleen D. Diers; Natalie K. Wolf; Nicholas J. Slipek; David H. McKenna, Jr., MD; Darin Sumstad; Lydia Viney; Tom Henley; Tilmann Bürckstümmer; Oliver Baker; Ying Hu; Chunhua Yan; Daoud Meerzaman; Kartik Padhan; Winnie Lo; Parisa Malekzadeh; Li Jia; Drew C. Deniger; Shashank J. Patel; Paul F. Robbins; R. Scott McIvor, PhD; Modassir Choudhry; Steven A. Rosenberg; Branden S. Moriarity, PhD; Nicholas P. Restifo; | In-Progress Clinical Trials | Adoptive immunotherapy; Checkpoint blockade; Clinical study; Clinical trial; Neoantigens; Tumor antigens; Tumor infiltrating lymphocytes (TILs) |
| 335 | Poster Presentation | Novel CoupledCARTM Technology for Treating Colorectal Cancer | Song Li; Chengfei Pu; Zhiyuan Cao; Ning Li; Xinyi Yang; Youli Luo; Haiyan Zhao; Hang Yang; Xi Huang; Xiaogang Shen; Xiuwen Wang; Yongping Song; Junjie Mao; Pengfei Pang; Qun Hu; Zhao Wu; Lei Xiao, Ph.D.; | In-Progress Clinical Trials | Adoptive immunotherapy; Biomarkers; CAR T cells; Clinical study; Gene expression; Inflammation; Solid tumors; T cell; Tumor antigens |
| 338 | Poster Presentation | Emerging insights on the association of tumor molecular phenotype with clinical benefit in metastatic colorectal cancer (mCRC) subjects treated with AB928 + Modified FOLFOX-6 (mFOLFOX-6) | Akshata R. Udyavar, Ph.D; Michael Cecchini; Daniel DiRenzo, PhD; Sean Cho, PhD; Lisa Seitz, MS; Kristen Zhang, BS; Stephen W. Young, PhD; Amy E. Anderson, PhD; Kimberline Y. Gerrick; Matthew J. Walters, PhD; Houston N. Gilbert, PhD; Olivia S. Gardner; Cheng Quah, MD; Juan C. Jaen, PhD; William Grossman, MD; | In-Progress Clinical Trials | Bioinformatics; Biomarkers; Chemotherapy; Clinical trial; Gene expression; Immune suppression; Metabolism; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 345 | Poster Presentation | Phase 3 Study of Combination Pembrolizumab + Olaparib Therapy Versus Enzalutamide/Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Progression on Chemotherapy (KEYLYNK-010) | Evan Y. Yu, MD; Se Hoon Park; Yi-Hsiu Huang; Mostefa Bennamoun; Lu Xu; Jeri Kim, MD; Emmanuel S. Antonarakis, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial |
| 348 | Poster Presentation | A phase 2 umbrella study of retifanlimab (INCMGA00012) alone or in combination with other therapies in patients with advanced or metastatic endometrial cancer (POD1UM-204, GOG 3038, ENGOT-en12/NOGGO) | Brian M. Slomovitz, MD; Bradley J. Monk; Katherine Moxley; Nadeem Ghali; Justyna Fronczek Sokol; Chuan Tian, PhD; Nawel Bourayou, MD; Jalid Sehouli; | In-Progress Clinical Trials | Antibody; Checkpoint blockade; Clinical trial; Coinhibition; Targeted therapy |
| 351 | Poster Presentation | Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009 | Kevin Harrington, PhD, FRCP, FRCR; Ezra EW. Cohen, MD; Lilian L. Siu, MD; Danny Rischin, MBBS, MD; Lisa Licitra, MD; Jan Vermorken; Quynh-Thu Le, MD, FACR, FASTRO; Makoto Tahara; Jean-Pascal Machiels, MD, PhD; Natalyn Hawk; Joy Ge; Behzad Bidadi, MD, MS; Ramona F. Swaby, MD; Barbara A. Burtness, MD; | In-Progress Clinical Trials | Angiogenesis; Checkpoint blockade; Clinical trial; Targeted therapy |
| 353 | Poster Presentation | Safety and efficacy of tumor infiltrating lymphocytes (TIL, LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC | Antonio Jimeno, MD, PhD; Sophie Papa, PhD, MBBS, MRCP; Missak Haigentz, MD; Juan F. Rodríguez-Moreno,, MD; Julian Schardt; Maria Fardis, PhD; Friedrich Graf Finckenstein, MD; Rana Fiaz; Guang Chen; Alex Cacovean; Zelanna Goldberg; Ammar Sukari, MD; | In-Progress Clinical Trials | Adoptive immunotherapy; Checkpoint blockade; Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| 360 | Poster Presentation | A Phase 1 Study of an Off-the-Shelf, Multi-Neoantigen Vector (ADXS-503) Alone and in Combination with Pembrolizumab in Subjects with Metastatic Non-Small Cell Lung Cancer (NSCLC) | Jonathan W. Goldman, MD; Thomas Stinchcombe, MD; Gregory J. Gerstner, MD; Missak Haigentz Jr., MD; Surya Vangala; Megan Parsi; Victor Kabala; Dinesh Simkhada; Andres A. Gutierrez, MD PhD; Suresh S. Ramalingam, MD; | In-Progress Clinical Trials | Adoptive immunotherapy; Antigen presenting cells; Biomarkers; Checkpoint blockade; Clinical study; Immune tolerance; Neoantigens; Solid tumors; T cell; Tumor antigens |
| 364 | Poster Presentation | A personal neoantigen vaccine NEO-PV-01 in combination with chemotherapy and pembrolizumab induces broad de novo immune responses in first line, non-squamous NSCLC | Mark Awad, MD, PhD; David R. Spigel, MD; Edward B. Garon, MD; Saiama Waqar, MD; Aaron Lisberg, MD; Melissa A. Moles; Jennifer Tepper; April Lamb; Amy Wanamaker; Zakaria Khondker; John Srouji; Jesse Z. Dong; Asaf Poran; Kristen N. Balogh; Meghan Bushway; Mark DeMario, MD; Lakshmi Srinivasan, PhD; Richard B. Gaynor; Ramaswamy Govindan, MD; | In-Progress Clinical Trials | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Neoantigens; T cell; Tumor antigens; Tumor microenvironment; Vaccine |
| 365 | Poster Presentation | Tumor Treating Fields (TTFields, 150 kHz) concurrent with standard of care treatment for stage 4 non-small cell lung cancer (NSCLC) in Phase 3 LUNAR Study | Ticiana A. Leal, MD; Raphael Bueno; Libor Havel; Jeffrey Ward, MD, PhD; Ticiana A. Leal, MD; | In-Progress Clinical Trials | Checkpoint blockade; Chemotherapy; Clinical trial; Targeted therapy |
| 366 | Poster Presentation | A randomized double-blind placebo-controlled phase III study evaluating perioperative toripalimab combined with platinum-based doublet chemotherapy in resectable stage III NSCLC | Wenxiang Wang; Lin Wu, MD; Wei Zhang; Shun Lu; Haohui Fang; Guohua Yu, MD; Ming Zhou; Wenqun Xing; Qixun Chen; Xingya Li; Nong Yang; Minhua Ye; Wentao Fang; Yunchao Huang; Jichun Liu; Lijie Tan; Xiaosheng Hang; Wengang Zhang; Liwei Zhang; Jun Chen; Xun Zhang; Yu Zhang; Jie Jiang; Aihong Zhong; Shanqing Li; Yunpeng Liu; Guowu Wu; Xiaoyan Kang; Ying Tian; Tao Xu; | In-Progress Clinical Trials | Biomarkers; Checkpoint blockade; Chemotherapy; Clinical trial; Immune adjuvant; Solid tumors; Surgery |
| 373 | Poster Presentation | Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2 | John D. Powderly, II, MD; Bradley C. Carthon, MD Ph.D; Marc S. Ernstoff, MD; Anthony J. Olszanski, MD, RPh; John M. Wrangle, MD; Anthony F. Shields, MD PhD; Sarina A. Piha-Paul, MD; Kelly K. Curtis, MD; Ilda Bidollari; Yangchun Du, PhD; Lei Sun, PhD; Emily L. Putiri, PhD; Yan Wang, PhD; Heather C. Losey, PhD; Bruce Dezube, MD; Bruce Dezube, MD; Ulka N. Vaishampayan, MD; | In-Progress Clinical Trials | Clinical study; Clinical trial; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell |
| 376 | Poster Presentation | A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors | Shubham Pant, MD; Amishi Shah; Pavlos Msaouel, MD, PhD; Matthew T. Campbell, MD; Shi-Ming Tu; Jianjun Gao, MD PhD; George R. Blumenschein, Jr., MD; Frank Mott; Xiuning Le, MD, PhD; Mehmet Altan, MD; Funda Meric-Bernstam, MD; Timothy A. Yap, MD, PhD; Vivek Subbiah, MD; Jordi Rodon; Axel Glasmacher; Imke Mulder; Michael J. Chisamore, PhD; Alexander Stevenson, PhD; Nizar M. Tannir, MD, FACP; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Microbiome; Solid tumors; TLR |
| 379 | Poster Presentation | Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor | David S. Hong, MD; David S. Hong, MD; David S. Hong, MD; Jeffrey M. Clarke, MD; Tanner Johanns; Partow Kebriaei; John V. Heymach, MD, PhD; Ahmed Galal; Samuel Saibil; Adrian Sacher, MD, MSc; Francine Brophy; Gareth Betts, PhD; Natalie Bath, MSc; Spinner William; Alex J. Tipping, PhD; Jessica Tucci; Raymond Luke; Trupti Trivedi, MS; Quan Lin; Jean-Marc Navenot, PhD; Paula M. Fracasso, MD, PhD; Karen Miller, PhD; Elliot Norry, MD; Mark Dudley; Marcus O. Butler, MD; | In-Progress Clinical Trials | Adoptive immunotherapy; Targeted therapy |
| 380 | Poster Presentation | Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors | David Hong, MD; Sandip P. Patel, MD; Manish R. Patel, D.O.; Kimberly Musni, BSHA; Marlisa Anderson, MPH; Sarah Cooley, PhD, MS; Bahram Valamehr, PhD; Wayne Chu, MD; | In-Progress Clinical Trials | Adoptive immunotherapy; Checkpoint blockade; Clinical trial; Leukemia/Lymphoma; NK/NK T cell; Solid tumors |
| 381 | Poster Presentation | Role of CT Scans of Abdomen and Pelvis in Management of Patients with Immunotherapy-induced Colitis | Juan J. Ibarra Rovira, MD; Raghunandan Vikram, MD; Selvi Thirumurthi, MD; Bulent Yilmaz, MD; Heather Lin, MS, PhD; Fechukwu O. Akhmedzhanov, MD, MPH; David S. Hong, MD; Abdulrazzak Zarifa; Melissa Tagart, MD; Funda Meric-Bernstam, MD; Aung Naing, MD, FACP; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Immune toxicity; Inflammation; Targeted therapy |
| 385 | Poster Presentation | A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results | Jordan Berlin, MD; Wael A. Harb, MD; Alex A. Adjei, MD PhD; Yan Xing, MD, PhD; Paul Swiecicki, MD; Mahesh Seetharam, MD; Lakshminarayanan Nandagopal, MD; Ajay Gopal, MD; Cong Xu, MD, PhD; Cong Xu, MD, PhD; Yuan Meng, MD; Linda Lee, PharmD; Yonggang Zhao, PhD; Zhengyi Wang, PhD; Joan Huaqiong Shen, MD, PhD; | In-Progress Clinical Trials | Antibody; Clinical study; Clinical trial; Monocyte/Macrophage; Solid tumors |
| 388 | Poster Presentation | Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors | Johanna C. Bendell, MD; Wells Messersmith, MD; Drew Rasco, MD; Andrea Wang-Gillam, MD, PhD; Wungki Park, MD; Lei Zhou, MD, MS; Laura L. Carter, PhD; Jean-Marie Bruey, PhD; Jack Li, PhD; Beatrice Ferguson, MS; Jakob Dupont, MD; Marya F. Chaney, PhD; Johann S. De Bono, MD; | In-Progress Clinical Trials | Clinical trial; Gene expression; Immune contexture; Immune monitoring; Inflammation; MDSC; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 391 | Poster Presentation | A first-in-human study of intratumoral SAR441000, an mRNA mixture encoding IL-12sc, interferon alpha2b, GM-CSF and IL-15sushi as monotherapy and in combination with cemiplimab in advanced solid tumors | Oliver Bechter, MD; Jochen Utikal, MD; Jean-Francois Baurain, MD; Christophe Massard, MD; Ugur Sahin, MD; Evelyna Derhovanessian; Marie-Laure Ozoux, Phd; Rahul Marpadga, MD; Esteban-Rodrigo Imedio, MD; Nicolas P. Acquavella, MD; Carmen Loquai, MD; | In-Progress Clinical Trials | B cell; Checkpoint blockade; Clinical trial; Costimulation; Cytokine; Immune toxicity; RNA; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| 396 | Poster Presentation | Overcoming resistance to anti-PD-1 with tumor agnostic NBTXR3: from bench to bed side | James W. Welsh, MD; Colette Shen; Jessica Frakes, MD; Jiaxin Niu, MD, PhD; Jared Weiss, MD; Jimmy Caudell, MD; Hu Yun, PhD; Hampartsoum Barsoumian, PhD; Juliette Thariat, MD, PhD; Sylvie Bonvalot, MD; Zsusanna Papaï; Maria Angelica Cortez, PhD; Ping Zhang, PhD; Katherine L. Jameson, PhD; Patricia Said; Sébastien Paris; Tanguy Seiwert, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Radiotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 397 | Poster Presentation | Intra-Tumor Immunotherapy Injections utilizing Image guidance in Interventional Radiology: Clinical Trial Experience at a Tertiary care Cancer Center | Ravi Murthy; Rahul A. Sheth, MD; Alda Tam; Sanjay Gupta; Vivek Subbiah, MD; Filip Janku, MD, PhD; Timothy A. Yap, MD, PhD; Adi Diab, MD; Aung Naing, MD, FACP; Sapna Patel, MD; Funda Meric-Bernstam, MD; | In-Progress Clinical Trials | Clinical trial; Solid tumors; Vaccine |
| 400 | Poster Presentation | CoupledCARTM Technology for Treating Thyroid Cancer | Xingchen Liu; Keshu Zhou; Yong Huang; Chengfei Pu; Zhiyuan Cao; Ruihong Zhu; Haiyang Tang; Zhipeng Huang; Hang Yang; Xi Huang; Yongping Song; Renbin Liu; Zhao Wu; Lei Xiao, Ph.D.; | In-Progress Clinical Trials | Adoptive immunotherapy; Biomarkers; CAR T cells; Clinical study; Gene expression; Inflammation; Solid tumors; T cell; Tumor antigens |
| 404 | Poster Presentation | ALX148, a CD47 blocker, in combination with standard chemotherapy and antibody regimens in patients with gastric/gastroesophageal junction (GC) cancer and head and neck squamous cell carcinoma (HNSCC) | Keun-Wook Lee, MD, PhD; Hyun C. Chung, MD, PhD; Won Seog Kim, MD; Laura Q. Chow, MD; Nehal Lakhani, MD, PhD; Wells Messersmith, MD; Yung-Jue Bang, MD PhD; Patricia LoRusso, DO; Philip S. Fanning, PhD; Pierre Squifflet, MSc; Feng Jin, PhD; Alison Forgie, PhD; Hong I. Wan, PhD; Jaume Pons, PhD; Sophia S. Randolph, MD, PhD; Justin F. Gainor, MD; | In-Progress Clinical Trials | Antibody; Antigen presenting cells; Checkpoint blockade; Chemotherapy; Clinical trial; Costimulation; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor microenvironment |
| 410 | Poster Presentation | Phase I study of intratumoral NBTXR3 in combination with anti-PD-1 in patients with advanced cancers | Colette Shen; Jessica Frakes, MD; Jiaxin Niu, MD; Jared Weiss, MD; Jimmy Caudell, MD; Katherine L. Jameson, PhD; Patricia Said; Tanguy Seiwert, MD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical study; Clinical trial; Radiotherapy; T cell; Tumor infiltrating lymphocytes (TILs) |
| 411 | Poster Presentation | Novel intratumoral agent, INT230-6 induces cancer cell death, increases tumor infiltrates and results in durable benefit alone or in combination with pembrolizumab in refractory patients | Anthony El-Khoueiry, MD; Jacob Thomas, MD; Anthony J. Olszanski, MD, RPh; Nilofer Azad, MD; Lewis H. Bender, MS, MA, MBA; Ian B. Walters, MD, MBA; Ian B. Walters, MD, MBA; Giles F. Whalen, MD; Diana Hanna, MD; Matthew Ingham, MD; Lilian L. Siu, MD; | In-Progress Clinical Trials | Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Neoantigens; Solid tumors; Tumor antigens; Tumor infiltrating lymphocytes (TILs) |
| 414 | Poster Presentation | Enhancing T cell therapy for patients with relapsed/refractory Wilms Tumor | Amy Hont, MD; Conrad R. Cruz; Maja Stanojevic; Robert Ulrey; Madeline Terpilowski; Emily Reynolds; Fahmida Hoq; Maria F. Fortiz; Haili Lang; Jeffrey S. Dome; Patrick J. Hanley; Catherine Bollard, MD; Holly J. Meany; | In-Progress Clinical Trials | Adoptive immunotherapy; Clinical trial; Immune monitoring; Pediatric tumors; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| 415 | Poster Presentation | Toripalimab plus nab-paclitaxel and carboplatin as neoadjuvant therapy for patients with esophageal squamous cell carcinoma at clinical stage T2-T4/N0-N2/M0: a single-arm, single-center clinical study | Kunkun Li, MD; Xiao Yang; Wei Luo; Qiang Ma; Yingjian Wang; Yanli Xiong; Xiaolong Zhao; Xianfeng Lu; Tao Bao; Wei Guo; Mengxia Li; | In-Progress Clinical Trials | Checkpoint blockade; Chemotherapy; Clinical study; Surgery |
| 416 | Poster Presentation | SQ3370-001 is a multi-center open-label phase I dose-escalation study to test a novel intratumoral and systemic approach to treat advanced solid tumors | Vivek Bhadri, MD; Nam Bui, MD; Alexander Guminski, MD; Jose M. Mejia Oneto, MD, PhD; Ravi Murthy, MD; Kamalesh Sankhala, MD; M. Wayne Saville, MD; M. Wayne Saville, MD; M. Wayne Saville, MD; Sangeetha Srinivasan, PhD; Robert Steffner, MD; Vivek Subbiah, MD; Ding Wang, MD; Nathan A. Yee, PhD; | In-Progress Clinical Trials | Chemotherapy; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 418 | Poster Presentation | A Phase 1, Dose Escalation and Dose Expansion Study of SQZ PBMC HPV as Monotherapy and in Combination with Atezolizumab in HLA-A*02+ Patients with HPV16+ Recurrent, or Metastatic Solid Tumors. | Cathy Eng, MD; Joaquina C. Baranda, MD; Matthew H. Taylor; Michael S. Gordon; Ursula A. Matulonis, MD; Filip Janku, MD, PhD; Martin Kornacker, MD; Asha Kamat, PhD; Oliver Rosen; Antonio Jimeno, MD, PhD; Cathy Eng, MD; | In-Progress Clinical Trials | Adoptive immunotherapy; Antigen presenting cells; Biomarkers; Clinical study; T cell; Tumor infiltrating lymphocytes (TILs); Vaccine |
| 426 | Poster Presentation | MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma | Reinhard Dummer, MD; Georgina V. Long, BSc, PhD, MB, BS, FRACP; Anna Pavlick, DO; Michael Postow, MD; Antoni Ribas, MD, PhD; Caroline Robert, MD, PhD; Richard A. Scolyer, BMedSci, MBBS, MD, FRCPA, FRCPath; Janis M. Taube, MD; Michael Tetzlaff, MD, PhD; Jason Liao, PhD; Sama Ahsan, MD; Scott J. Diede, MD, PhD; Hussein A. Tawbi, MD, PhD; | In-Progress Clinical Trials | Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| 436 | Poster Presentation | Rational Sequencing of Immune-Oncology Therapies Achieves Durable Response and Immunologic Memory | Robert Saddawi-Konefka, MD PhD; Aoife E. O'Farrell; Andrew Sharabi, MD, PhD, FACS; Joseph Califano; J. Silvio Gutkind; | Combination Immunotherapies | Checkpoint blockade; Immune adjuvant; Radiotherapy; Solid tumors; Surgery; T cell; Targeted therapy |
| 437 | Poster Presentation | Adenovirus IL-12 and Docetaxel in Combination with Anti-PD1 as an Effective Treatment Strategy for TNBC | Ann C. Anselme, BS; Wei Qian, BS; Roberto R. Rosato, PhD; Jianying Zhou; Jenny C. Chang, MD; Ann C. Anselme, BS; | Combination Immunotherapies | Checkpoint blockade; Chemotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 438 | Poster Presentation | Synergy Between SEA-CD40 and Chemotherapeutics Drives Curative Antitumor Activity in Preclinical Models | Weiping Zeng; Haley Neff-LaFord; Sahar Ansari; Celine Jacquemont, PhD; Michael Schmitt, MD, PhD; Shyra J. Gardai, PhD; | Combination Immunotherapies | Antibody; Antigen presenting cells; Chemotherapy; Costimulation; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; Tumor microenvironment |
| 439 | Poster Presentation | Dual modes of action for anti-TIM-3 antibody MBG453 in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): preclinical evidence for immune-mediated and anti-leukemic activity | Catherine A. Sabatos-Peyton, PhD; Tyler A. Longmire; Lisa Baker; Nidhi Patel; Anne-Sophie Wavreille; Melanie Verneret; Pushpa Jayaraman, PhD; Xiaomo Jiang; Stephanie Schwartz; Viviana Cremasco; Hongbo Lu; Shumei Qiu; Fiona A. Sharp, PhD; Mikael Rinne; Glenn Dranoff, MD; | Combination Immunotherapies | Antibody; Leukemia/Lymphoma; Monocyte/Macrophage; Myeloid cells; Tumor microenvironment |
| 440 | Poster Presentation | Activity and safety of camrelizumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced non-small-cell lung cancer | Guo Gui Sun; Jing Hao Jia; Peng Gao; Xue Min Yao; Ming Da Chen; Wei Nan Yao; Lu Sun; Wei Wang; | Combination Immunotherapies | COVID and Immunotherapy; Checkpoint blockade; Chemotherapy; Clinical study; Immune monitoring; Immune suppression; Solid tumors; T cell; Tumor evasion; Tumor microenvironment |
| 441 | Poster Presentation | Outcomes of patients with metastatic renal cell carcinoma with intermediate- or poor-risk symptomatic disease who received their first cycle of nivolumab and ipilimumab while being hospitalized | Omar Alhalabi, MD; Elshad Hasanov; John Araujo; Jianbo Wang; Matthew T. Campbell, MD; Sangeeta Goswami, MD, PhD; Amishi Shah; Jianjun Gao, MD PhD; Pavlos Msaouel, MD, PhD; Nizar M. Tannir, MD, FACP; | Combination Immunotherapies | Checkpoint blockade; Clinical study; Solid tumors |
| 442 | Poster Presentation | ICT01, an anti-BTN3A mAb that activates Vg9Vd2 T cells, plus interleukin-2: a potent and promising combination for cancer immunotherapy | Aude de Gassart, PhD; Patrick Brune; Suong LE; Sophie Agaugué; Emmanuel Valentin, PhD; Jennifer Sims; Daniel OLIVE, M.D., Ph.D.,; Paul Frohna, MD, PharmD, PhD; Rene HOET; | Combination Immunotherapies | Antibody; T cell; T cell lineages |
| 443 | Poster Presentation | An Immunotherapy Trio in advanced HNSCC for coordinated B and T cell antigen response | Bernard A. Fox, PhD; Tarsem L. Moudgil, MS; Traci L. Hilton, PhD; Noriko NI. Iwamoto, PhD; Christopher C. Paustian, PhD; Adi Mehta, PhD; Fridtjof Lund-Johansen, MD, PhD; Rachel E. Sanborn, MD; Bryan R. Bell, MD, DDS, FACS; Madeleine Laws, BS; Glenna McDonnell, MS; Yoshinobu Koguchi, MD, PhD; Carlo B. Bifulco, MD; Brian D. Piening, PhD; Carmen Ballesteros Merino, PhD; Shawn M. Jensen, PhD; Takashi Shimada, PhD; Hong-Ming Hu, PhD; Walter J. Urba, MD, PhD; Rom S. Leidner, MD; Marcus A. Couey, MD, DDS; | Combination Immunotherapies | Antibody; Clinical study; Clinical trial; Costimulation; Neoantigens; Solid tumors; Surfaceome; T cell; Tumor antigens; Vaccine |
| 444 | Poster Presentation | MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination | Mathieu Gigoux, PhD; Roberta Zappasodi, PhD; Joseph J. Park; Stephane Pourpe; Arnab Ghosh, MD, PhD; Cansu Cimen Bozkus, PhD; Levi M. Mangarin, BS; David Redmond; Svena Verma, BS; Sara Schad, BS; William Duke; Max Jan; Matthew J. Leventhal; Vincent Ho; Gabriela S. Hobbs; Trine Alma Knudsen; Vibe Skov; Lasse Kjær; Thomas Stauffer Larsen; Dennis Lund Hansen; R. Coleman Lindsley; Hans Hasselbalch; Jacob H. Grauslund; Mads H. Andersen, PhD; Morten O. Holmström; Timothy A. Chan, MD, PhD; Raajit Rampal; Omar Abdel-Wahab, M.D.; Nina Bhardwaj, MD, PhD; Jedd D. Wolchok, MD, PhD; Ann Mullally, M.D.; Taha Merghoub, PhD; Mathieu Gigoux, PhD; | Combination Immunotherapies | Checkpoint blockade; Immune monitoring; Neoantigens; T cell; Tumor antigens; Tumor evasion; Vaccine |
| 445 | Poster Presentation | Blockade of the inhibitory collagen receptor LAIR-1 with NC410, a LAIR2-Fc fusion protein, enhances anti-tumor activity of the bifunctional fusion protein bintrafusp alfa | Lucas A. Horn, PhD; Linjie Tian, PhD; Dallas B. Flies, PhD; Linda N. Liu, PhD; Solomon Langermann, PhD; Jeffrey Schlom, PhD; Claudia M. Palena, PhD; | Combination Immunotherapies | Checkpoint blockade; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 446 | Oral Presentation | Immunopeptidome changes mediated by a novel ERAP1 inhibitor leads to tumor growth inhibition. | Peter I. Joyce, PhD; Lesley Young, PhD; Martin Quibell, PhD; Jason Shiers, PhD; Carmen Tong; Kristopher Clark, PhD; Edd James, PhD; Emma Reeves, PhD; Alihussein Remtulla, PhD; Henry Leonard; Camila de Almeida; Elisa Lori; Nicola Ternette, PhD; Fergus Poynton, PhD; Andrew Leishman; | Combination Immunotherapies | Checkpoint blockade; Neoantigens; Solid tumors; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 447 | Poster Presentation | VISTA targeting remodels the tumor microenvironment to overcome adaptive resistance | Janet L. Lines, Ph.D.; Evelien Schaafsma; Walburga Croteau; Mohamed ElTanbouly; Elizabeth Nowak; Nicole Smits; Cecilia A. Webber; Dina Rabadi; Jie Deng; Chao Cheng; Randolph Noelle; | Combination Immunotherapies | Gene expression; MDSC; Myeloid cells; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 448 | Poster Presentation | Discovery of clinical candidate IK-175, a selective orally active AHR antagonist | KAREN MCGOVERN, PhD; KAREN MCGOVERN, PhD; Alfredo C. Castro; Jill Cavanaugh; Marta Sanchez-Martin; Jeremy H. Tchaicha, PhD; Sakeena Syed; Hyejin Frosch; Prabitha Natarajan; Katie O'Callaghan; Ben Amidon, PhD; X. Michelle Zhang; Jeff Ecsedy; Mark Manfredi, PhD; | Combination Immunotherapies | Immune suppression; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 449 | Oral Presentation | Neoadjuvant cyclic dinucleotides combined with interleukin-2 and anti-PD-1 antibody limit lung metastasis of orthotopic breast tumors through prolonged NK cell activation | Lauren Milling, BS; Darrell J. Irvine, PhD; | Combination Immunotherapies | Checkpoint blockade; Cytokine; NK/NK T cell; Surgery |
| 450 | Poster Presentation | Combination of rhIL-7-hyFc and anti-PD-L1xCD3ε bispecific antibody enhances antitumor response in mice | Sujeong Park, graduate student; Ji-Hae Kim; Yeon-Woo Kang; Kun-Joo Lee; Dain Moon; Nara Tae; Yunji Park; Dae Hee Kim; Byung Ha Lee, PhD; Donghoon Choi, PhD; Se Hwan Yang, PhD; Seung-Woo Lee; | Combination Immunotherapies | Antibody; Bispecifics; Cytokine; Solid tumors; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs) |
| 451 | Poster Presentation | Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity | Annah S. Rolig, Ph. D; Daniel C. Rose, BS in biology; Saul Kivimae, PhD; Werner Rubas, PhD; William L. Redmond, Ph.D.; | Combination Immunotherapies | Cytokine; NK/NK T cell; Radiotherapy; TLR; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 452 | Poster Presentation | Combination treatment using KISIMATM protein-based cancer vaccine and systemic STING agonist results in profound modulation of tumor microenvironment and improved tumor control | Matteo Rossi, PhD; Elodie Belnoue; Susanna Carboni; Wilma Besson-Di Berardino; Erika Riva; Marie-Laure Santiago-Raber; Madiha Derouazi; | Combination Immunotherapies | Immune adjuvant; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| 453 | Poster Presentation | Novel combination immunotherapy for boosting and priming immune responses in pancreatic cancer: strong anti-tumour effects with interleukin-15 and CD40 agonist treatment | Jonas RM. Van Audenaerde, MSc; Elly Marcq; Bianca von Scheidt; Ashleigh S. Davey, PhD; Amanda J. Oliver; Jorrit De Waele; Delphine Quatannens; Jinthe Van Loenhout; Patrick Pauwels; Geert Roeyen; Filip Lardon; Clare Y. Slaney; Marc Peeters, MD, PhD; Michael H. Kershaw, PhD; Phillip K. Darcy; Evelien LJ. Smits; | Combination Immunotherapies | Antibody; Antigen presenting cells; Cytokine; Dendritic cell; NK/NKT cell; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| 454 | Poster Presentation | Oncolytic Parainfluenza Virus 5 Vector Enhances Natural Killer Cell Killing of Lung Tumor Cells in 2D and 3D spheroid cultures | Namita Varudkar, MS, PhD Candidate; Namita Varudkar, MS, PhD Candidate; Jeremiah L. Oyer; Alicja Copik, PhD; Griffith Parks, PhD; | Combination Immunotherapies | Adoptive immunotherapy; NK/NK T cell; Solid tumors; Targeted therapy |
| 455 | Oral Presentation | Impact of EphB4 and PD-1 treatment on immune infiltrate in advanced bladder cancer | Sarmad Sadeghi, MD; Tyler D. Hether; Jason Yeon; Richard Mangio; Jason W. Reeves; Yan Liang, MD PhD; Sarah E. Warren, PhD; Troy McEachron, MD; Parkash S. Gill, MD; | Combination Immunotherapies | Biomarkers; Checkpoint blockade; Clinical trial; Immune adjuvant; Immune tolerance; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 456 | Poster Presentation | Impact of angiotensin II pathway inhibition on tumor response to anti PD(L)1 based therapy | Julius Strauss, MD; Ravi A. Madan, MD; Marijo Bilusic, MD, PhD; Fatima Karzai; Scot Niglio; Jason M. Redman, MD; Houssein Abdul Sater, MD; Charalampos Floudas; Jung-Min Lee; Andrea B. Apolo, MD; Seth M. Steinberg; Jeffrey Schlom, PhD; James L. Gulley, MD, PhD; | Combination Immunotherapies | Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| 457 | Poster Presentation | Intratumoral interleukin-12 administered after cryoablation does not improve survival in multiple bilateral murine models | Maura R. Vrabel; Jake A. Schulman; David A. Zaharoff, PhD; | Combination Immunotherapies | Checkpoint blockade; Immune adjuvant; Solid tumors; Targeted therapy; Tumor antigens; Vaccine |
| 458 | Poster Presentation | Antitumor mechanisms of local radiation and combination immunotherapy in an immunologically cold model of neuroblastoma | Taylor Aiken, MD; Julie S. Voeller, MD; Amy K. Erbe, PhD; Alexander L. Rakhmilevich, MD, PhD; Paul M. Sondel, MD, PhD; | Combination Immunotherapies | NK/NK T cell; Pediatric tumors; Radiotherapy; Regulatory T cell (Treg cell); Tumor microenvironment; Vaccine |
| 459 | Poster Presentation | NK cells activation and recruitment to irradiated tumors is increased in the presence of IL-15. | Maud Charpentier, PhD; Karsten A. Pilones, MD, PhD; Elena Garcia-Martinez, MD, PhD; Sandra Demaria, MD; | Combination Immunotherapies | NK/NKT cell; Radiotherapy |
| 460 | Poster Presentation | The immuno-metabolic enzyme FASN prevents anti-tumor immune responses in irradiated glioblastoma | Mara De Martino, PhD; Camille Daviaud; Claire I. Vanpouille-Box, PhD; | Combination Immunotherapies | Dendritic cell; Immune suppression; Metabolism; Radiotherapy; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| 461 | Poster Presentation | Improving Specific Targeting of Tumors Through Bispecific SNIPER Antibodies | Amy K. Erbe, PhD; Daniel Gerhardt; Reinier Hernandez, PhD; Bonnie Hammer; Mildred A. Felder, BS; Mark Bercher; Jennifer Dennin; Christopher Massey; Sabrina VandenHeuvel; Arika S. Feils, BS; Mackenzie Heck; Jonathan Engle; Todd E. Barnhart; Jacquelyn A. Hank, PhD; Bryan Glaser, PhD; Roland Green, PhD; Paul M. Sondel, MD, PhD; | Combination Immunotherapies | Bispecifics; Cytokine; NK/NK T cell; Pediatric tumors; Radiotherapy |
| 462 | Poster Presentation | Single agent immunotherapy response in patients with head and neck squamous cell carcinoma with prior history of radiation therapy | Moises Harari-Turquie, MD; Shashank Cingam, MD; David Lee; Gregory Gan; Emrullah Yilmaz, MD, PhD; | Combination Immunotherapies | Chemotherapy; Epidemiology; Immune adjuvant; Metabolism; Radiotherapy; Solid tumors; Tumor microenvironment |
| 463 | Poster Presentation | Metastatic gastric cancer patient benefiting from combined radio-immunotherapy treatment displayed sustained anti-NY-ESO-1 specific T cells and expressed important immuno-modulatory markers | Maysaloun Merhi, PhD; Afsheen Raza; Varghese Inchakalody; Siveen Kodappully; Deepak Choubey; Fairooz Sahir; Sarra Mestiri; Shereena Hydrose; Niloofar Allahverdi; Munir D. Jalis; Allan Relecom; Lobna Al-Zaidan; Mohamed Sir Elkhatim Hamid; Mai Mostafa; Abdul Rehman Zar Gul; Shahab Uddin; Mohammed Ussama Al Homsi; Said Dermine; | Combination Immunotherapies | Biomarkers; Checkpoint blockade; Cytokine; Immune monitoring; Radiotherapy; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor antigens |
| 464 | Poster Presentation | Clonal replacement of tumor-infiltrating CD8+ T cells by induction and activation of tumor-residing Batf3-dependent dendritic cells | Takaaki Oba, MD,PhD; Mark Long; Tibor Keler, PhD; Henry Marsh, BS PhD; Hans Minderman; Scott I. Abrams, PhD; Song Liu; Fumito Ito; | Combination Immunotherapies | Costimulation; Dendritic cell; Radiotherapy |
| 465 | Oral Presentation | Radiotherapy and CTLA-4 blockade expand anti-tumor T cells differentiation states and cooperate with CD40 agonist to induce tumor rejection | Nils-Petter Rudqvist; Claire Lhuillier, PhD; Maud Charpentier, PhD; Erik Wennerberg, PhD; Sheila Spada, PhD; Caroline Sheridan; Xi Kathy Zhou; Tuo Zhang, PhD; Jennifer S. Sims, PhD; Alicia Alonso; Sandra Demaria, MD; | Combination Immunotherapies | Bioinformatics; Checkpoint blockade; Costimulation; Gene expression; Radiotherapy; T cell; Tumor infiltrating lymphocytes (TILs) |
| 467 | Poster Presentation | Anti-EGFR antibody added to ongoing anti-PD-1 antibody treatment for metastatic cutaneous squamous cell carcinoma of the face: two case reports | Omar Eton, MD, FACP; Emily Hsu, MD; Akshay V. Patel, DO; Omar Eton, MD, FACP; Richard Cartun, PhD; Jonathan S. Earle, MD; Laila O. Mnayer, PhD; Peter P. Yu, MD, FACP, FASCO; Jennifer Kotowitz, RN BSN; | Combination Immunotherapies | Biomarkers; Checkpoint blockade; Clinical study; Coinhibition; Solid tumors; Surgery; Targeted therapy; Tumor microenvironment |
| 468 | Poster Presentation | Enhancers and repressors of immunotherapy: translational perspectives on gene-mediated cytotoxic immunotherapy in glioblastoma | Sean E. Lawler, PhD; Marilin S. Koch, MD; Mikolay S. Zdioruk, phD; Estuardo Aguilar-Cordova; Laura K. Aguilar, MD, PhD; Brian W. Guzik; Ghazaleh Tabatabai; Michal Nowicki; E Antonio A. Chiocca; | Combination Immunotherapies | Solid tumors; T cell; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 469 | Poster Presentation | Cooperation between checkpoint inhibitors targeting the PD-1 / PD-L1 axis and ATRC-101, a novel clinical-stage candidate for the treatment of solid tissue malignancies | Amy Manning-Bog, PhD; Jeff DeFalco, PhD; Alexander Scholz, PhD; Iraz T. Aydin, PhD; Nikhil Vad, PhD; Cathrin Czupalla, Ph.D.; Felix Chu, MS; Mauricio Velasco-Delgado; Michael Harbell, M.S.; Judevin Lugar-Supagay; Yvonne Leung, Ph.D.; Shaun M. Lippow, Ph.D.; Anne Ye, PhD; Ish Dhawan, PhD; Gilson Baia, PhD; Dai-Chen Wu, PhD; Carl Millward, MD; Mark Whidden, PhD; Jonathan Benjamin, MD, PhD; John Vivian, PhD; Ngan Nguyen, BS PhD; William H. Robinson, MD PhD; Tito A. Serafini, PhD; Daniel Emerling, PhD; Norman M. Greenberg, PhD; | Combination Immunotherapies | Antibody; Checkpoint blockade; Solid tumors; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 470 | Oral Presentation | Targeting Pan-Tumor Associated Antigen B7H3 via Combination of Tri-specific Killer Engager and Off-the-shelf NK Cell Therapy Enhances Specificity and Function Against a Broad Range of Solid Tumors | Jeff S. Miller, MD; Nicholas A. Zorko, MD, PhD; Behiye Kodal; Zachary B. Davis, PhD; Alexander J. Lenvik; Todd R. Lenvik; Joshua S. Walker; Daniel A. Vallera; Svetlana Gaidarova, MS; Alejandro Garcia; Tom T. Lee, PhD; Ryan Bjordahl, PhD; Bahram Valamehr, PhD; Frank S. Cichocki, PhD; Martin S. Felices; | Combination Immunotherapies | Adoptive immunotherapy; Bispecifics; NK/NK T cell |
| 471 | Poster Presentation | Pancreatic cancer therapy based on combination of DNA vaccination and PI3Kgamma inhibition | Francesco Novelli, PhD; Claudia Curcio, PhD; Cecilia Roux; Laura Conti; Roberta Curto; Gianluca Mucciolo; Sara Bulfamante, MS; Silvia Brugiapaglia; Alessandro Scagliotti; Alessandra Ghigo; Paola Cappello, PhD MS; Emilio Hirsch; Francesco Novelli, PhD; | Combination Immunotherapies | Myeloid cells; Solid tumors; Targeted therapy; Tumor antigens; Tumor microenvironment; Vaccine |
| 472 | Oral Presentation | ImmunoPET-informed sequence for focused ultrasound-targeted mCD47 blockade controls glioma | Natasha D. Sheybani, PhD; Soumen Paul, PhD; Katelyenn S. McCauley; Victoria R. Breza; Stuart S. Berr, PhD; G. Wilson Miller, PhD; Kiel D. Neumann, PhD; Richard J. Price, PhD; | Combination Immunotherapies | Antibody; Checkpoint blockade; Immune adjuvant; Monocyte/Macrophage; Solid tumors; Targeted therapy |
| 473 | Poster Presentation | Mavrilimumab, a human monoclonal antibody targeting GM-CSFRα, inhibits polarization to myeloid-derived suppressor cells (MDSCs) that express PD-L1 and restores T-cell proliferation in vitro. | Luis A. Carvajal, PhD.; Luciana Gneo, PhD.; Carmela De Santo, PhD; Matt Perez, B.S; Tracy Garron, B.S; Francis Mussai, M.D; Annalisa D’Andrea, PhD.; | Combination Immunotherapies | Checkpoint blockade; Immune adjuvant; Immune suppression; Immune tolerance; MDSC; Monocyte/Macrophage; Solid tumors; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 474 | Poster Presentation | Multiple combinational strategies of immunotherapy for esophageal squamous cell carcinoma: one institutional experience in Taiwan since 2016 | Jo-Pai Chen, MD; Wei-Chen Lu, M. D.; Ruey-Long Hong, M.D. PhD; | Combination Immunotherapies | Checkpoint blockade; Chemotherapy; Clinical study; Solid tumors; Targeted therapy |
| 475 | Oral Presentation | Incidental finding of colorectal cancer in a COVID-19 patient, followed by deep profiling of SARS-CoV-2-associated immune landscape and tumour microenvironment | Chun Chau Lawrence Cheung, BA, MMedSc; Chun Chau Lawrence Cheung, BA, MMedSc; Xinru Lim; Denise Goh, BBiomedSc (Hons); Tracy Zhijun Tien; Jeffrey Chun Tatt Lim; Thuan Tong Tan; Shirin Kalimuddin; Jia Lin Ng; Jenny Guek-Hong Low; Joe P. Yeong, MD, PhD; Kiat Hon T. Lim; | COVID and Immunotherapy | COVID and Immunotherapy; Biomarkers; Chemokine; Cytokine; Immune contexture; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 476 | Poster Presentation | AK119, a humanized anti-CD73 monoclonal antibody, as Immunotherapy for COVID-19 | Tingting Zhong, MS; Zhaoliang Huang, BSc; Xinghua Pang, BSc; na chen, MD; Konyew Kwek, PhD; Chris Wynne, MB, ChB; Adam Konpa, MS; Xiaoping Jin, PhD; Yu Xia, PhD; Maxwell Zhongmin Wang, PhD; Baiyong Li, PhD; Yu Xia, PhD; | COVID and Immunotherapy | COVID and Immunotherapy; Antibody; B cell |
| 477 | Poster Presentation | Deep Learning to Drive COVID-19 Rapid Drug Repurposing | Sarah Kolitz, PhD; Jason Kim, PhD; Jenny Zhang, PhD; Yoonjeong Cha, PhD; Sailaja Battula, PhD; Rebecca Kusko, PhD; Rajaraman Krishnan, PhD; Benjamin J. Zeskind, PhD, MBA; Howard L. Kaufman, MD; | COVID and Immunotherapy | COVID and Immunotherapy; Bioinformatics; Systems biology |
| 478 | Poster Presentation | Translation of a therapeutic neoantigen vaccine workflow to SARS-CoV-2 vaccine development | Christof C. Smith, PhD; Christof C. Smith, PhD; Sarah Entwistle; Caryn Willis; Steven P. Vensko; Wolfgang Beck, AB; Jason Garness; Maria J. Sambade; Eric Routh; Kelly Olsen; Brandon Carpenter; Kaylee Gentry; Maria Fadri; Misha Fini; Amber Washington; Julia Kodysh, MSc; Timothy O'Donnell; Carsten Haber; Kirsten Heiss; Volker Stadler; Erik Garrison; Oliver C. Grant; Robert J. Woods; Mark Heise; Benjamin G. Vincent, MD; Alexander Rubinsteyn, PhD; | COVID and Immunotherapy | COVID and Immunotherapy; Antibody; B cell; Neoantigens; T cell; Vaccine |
| 479 | Poster Presentation | A lymph-node targeted amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2 | Martin Steinbuck, PhD; Peter C. DeMuth, PhD; Lochana Seenappa, MS; Christopher M. Haqq, MD, PhD; Aniela Jakubowski; Lisa K. McNeil, PhD; | COVID and Immunotherapy | COVID and Immunotherapy; Immune adjuvant; T cell; Vaccine |
| 480 | Oral Presentation | Preliminary evaluation of a novel coronavirus vaccine (CORVax) using electroporation of plasmid DNA encoding a stabilized prefusion SARS-CoV-2 spike protein alone or with transfection of plasmid IL-12 | Shawn M. Jensen, PhD; Christopher G. Twitty, PhD; Christopher C. Paustian, PhD; Madelein Laws; Glenna McDonnell, MS; Keith Wegmann; Tarsem L. Moudgil, MS; Michael E. Afentoulis, MSc; Mia Han; Kellie Malloy Foerter; David A. Canton, PhD; Jack Y. Lee; Bianca A. Nguyen; John Rodriguez; Kim Jaffe, PhD; Brian D. Piening, PhD; Carlo B. Bifulco, MD; Daniel J. O'Connor; Walter J. Urba, MD, PhD; Rom S. Leidner, MD; Traci L. Hilton, PhD; Hong-Ming Hu, PhD; Bernard A. Fox, PhD; | COVID and Immunotherapy | COVID and Immunotherapy; Antibody; B cell; Cytokine; Immune adjuvant; Immune monitoring; T cell; Vaccine |
| 481 | Poster Presentation | Impact of COVID-19 on Cancer Patients Receiving Immune Checkpoint Inhibitors | Kevin Tyan, BA; Ai-Tram N. Bui, BA; Anita Giobbie-Hurder, MS; Isaac A. Klein, MD, PhD; Michael P. Manos, BA; Leyre Zubiri, MD, PhD; Kerry L. Reynolds, MD; Shilpa Grover, MD, MPH; Gerald L. Weinhouse, MD; Patrick A. Ott, MD, PhD; Nicole R. LeBoeuf, MD, MPH; Osama E. Rahma, MD; | COVID and Immunotherapy | COVID and Immunotherapy; Checkpoint blockade; Immune toxicity |
| 482 | Poster Presentation | COVID-19 in patients with lung cancer receiving immunotherapy. A report from an spanish academic center. | David Viñal; Laura Gutierrez; Julia Villamayor; Oliver Higuera; Dario Sanchez Cabrero; Javier De Castro; | COVID and Immunotherapy | COVID and Immunotherapy; Clinical study; Solid tumors |
| 483 | Poster Presentation | Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis | Olivier OD. Demaria, PhD; Julien Carvelli, MD; Nassima Chouaki Benmansour, MD; Joanna Fares, PhD; Luciana Batista, PhD; Marie-Laure Thibult, PhD; Ariane Morel, PhD; Sabrina Carpentier, PhD; Romain Remark, PhD; Agnes Represa; Frederic Vely, PhD; Mikael Ebbo, MD; Nicolas Schleinitz, MD; Robert Zerbib, MSc; Yannis Morel, PhD; Eric Vivier, PhD; Olivier OD. Demaria, PhD; | COVID and Immunotherapy | COVID and Immunotherapy; Antibody; Biomarkers; Cytokine; Inflammation; MDSC; Monocyte/Macrophage; Myeloid cells |
| 491 | Poster Presentation | Developing Educational Materials about Immunotherapy for Patients and Their Caregivers | Maria B. Gonzalo; Claire Saxton, MBA; Kirstin Fearnley, MALS; Jenny Karubian, MA; Nick Power, BS; Alyssa Jaisle, PhD; | Education and Treatment Management | Immune adjuvant; Targeted therapy |
| 493 | Poster Presentation | Tired and Hungry: A potential role for CD47 in T cell exhaustion | Chien-Huan Weng, PhD; Levi M. Mangarin, BS; Cailian Liu, MD; Roberta Zappasodi, PhD; Pamela M. Holland, PhD; Jedd D. Wolchok, MD, PhD; Taha Merghoub, PhD; David Schroder, MD; | Immune Cell Biology | Adoptive immunotherapy; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 495 | Poster Presentation | Basal Cell Carcinoma demonstrates a T-cell exclusion immune phenotype in contrast to other anti-PD-1 therapy responsive cutaneous malignancies | Geoffrey T. Gibney, MD; Joanne Xiu; Gino K. In, MD, MPH; Steven J. O'Day, MD; Jose Lutzky, MD, FACP; Joseph J. Drabick, MD, FACP, FIDSA; Ari M. VanderWalde, MD, MPH, MBioeth; Kelsey Poorman; W. M. Korn; Michael B. Atkins, MD; | Immune Cell Biology | Angiogenesis; Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 500 | Poster Presentation | P2RX7 agonist treatment boosts the ability of IL-12-activated CD8+ T cells to infiltrate and control murine melanoma | Kelsey M. Wanhainen; Stephen C. Jameson; Henrique Borges Da Silva, PhD; | Immune Cell Biology | Adoptive immunotherapy; Immune adjuvant; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs) |
| 504 | Poster Presentation | Using multiplexed immunofluorescence to quantitatively analyze myeloid derived suppressor cells (MDSCs) in relation to tertiary lymphoid structures (TLS) in bladder cancer | Anna Juncker-Jensen, PhD; Gang Huang; Mate L. Nagy; Xin Lu; Anna Juncker-Jensen, PhD; Anna Juncker-Jensen, PhD; | Immune Cell Biology | Adoptive immunotherapy; B cell; Immune contexture; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 505 | Poster Presentation | Activation of NK T cells promote the inflammatory tumor microenvironment and control the growth of solid tumor | Sourav Paul, PhD; Amrita Mishra, MSc; Sushanta Chhatar; Girdhari Lal, PhD; Girdhari Lal, PhD; | Immune Cell Biology | Chemotherapy; Costimulation; Cytokine; Immune adjuvant; Inflammation; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 507 | Poster Presentation | High dimensional flow cytometry analysis in newly diagnosed acute myeloid leukemia predicts patients outcomes | Francesco Mazziotta, MD; Rupkatha Mukhopadhyay; Hanna A. Knaus; Anish Chowdhury; Amanda Blackford; Ivana Gojo, MD; Leo Luznik, MD; | Immune Cell Biology | Bioinformatics; Chemotherapy; Immune contexture; Immune monitoring; Leukemia/Lymphoma; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 510 | Poster Presentation | Helping the killers: innovative cancer immunotherapy harnessing quasi-universal tumor antigen-specific CD4 T cells | Margaux Saillard; Amelie Cachot; Georg Alexander Rockinger; Philippe Guillaume; Julien Schmidt, PhD; Alexandre Harari, PhD; Camilla Jandus, MD, PhD; Pedro J. Romero, MD; | Immune Cell Biology | Antigen presenting cells; T cell; Tumor antigens; Vaccine |
| 513 | Poster Presentation | CD26 enzymatic activity modulates efficient migration of adoptively transferred T cells to solid tumors | Megan M. Wyatt, MS; Michelle H. Nelson, PhD; Stefanie R. Bailey, PhD; Hannah M. Knochelmann, BS; Aubrey S. Smith, BS; Guillermo O. Rangel RIvera, B.S.; Amalia M. Rivera Reyes, BS; Chrystal M. Paulos, PhD; | Immune Cell Biology | Adoptive immunotherapy; Chemokine; Costimulation; Solid tumors; T cell |
| 515 | Oral Presentation | Metabolic reprogramming of antitumor CD8+ T cell immunity | Alison Jaccard, MS; Mathias Wenes, PhD; Gábor Gyülvészi; Ping-Chih Ho, PhD; Pedro J. Romero, MD; | Immune Cell Biology | Adoptive immunotherapy; Epigenetics; Immune monitoring; Metabolism; Post-translational modifications; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 516 | Poster Presentation | Caspase-8 regulated senescence as an immune checkpoint in T lymphocytes for adoptive cell therapy | Valérie Janelle, PhD; Mathieu Neault, PhD; Marie-Eve Lebel, PhD; Dave De Sousa, MSc; Salix Boulet, PhD; Ludovic Durrieu, PhD; Cedric Carli, PhD; Sebastien Lemieux, PhD; Nathalie Labrecque, PhD; Heather J. Melichar, PhD; Frederick A. Mallette, PhD; Jean-Sebastien Delisle, PhD, MD; | Immune Cell Biology | Adoptive immunotherapy; Bioinformatics; CAR T cells; Gene expression; Leukemia/Lymphoma; Metabolism; T cell; Targeted therapy |
| 534 | Poster Presentation | Better Immune Profiles on Elderly Colorectal Cancer Patients Correlated With 1 Year Diseases Free Survival (DFS) | Budhi Ida Bagus, MD; Metria Ida Bagus; Mastini Ida Ayu Kade; | Immune Cell Types | Chemotherapy; Immune monitoring; Solid tumors; Surgery |
| 542 | Poster Presentation | Expansion of cytotoxic NK Cells from PBMCs using individualized cytokine combination | Andreia Maia, PhD student; Joana R. Lerias, PhD; Markus J. Maeurer, MD, PhD, FRCP(London); Mireia Castillo-Martin, MD, PhD; Andreia Maia, PhD student; | Immune Cell Types | Adoptive immunotherapy; Cytokine; NK/NK T cell; Tumor evasion |
| 545 | Oral Presentation | TUMOR-SPECIFIC CYTOLYTIC CD4 T CELLS MEDIATE PROTECTIVE IMMUNITY AGAINST HUMAN CANCER | Amélie Cachot; Mariia Bilous; Yen-Cheng Liu; Xiaokang Li; Alexander Rockinger; Margaux Saillard; Tania Wyss; Philippe Guillaume; Julien Schmidt, PhD; Raphael Genolet; Maria Pia Protti; Walter Reith; Laurence De Leval; Kalliopi Ioannidou; George Coukos, MD, PhD; Alexandre Harari, PhD; Daniel E. Speiser, MD; Alexander Mathis; David Gfeller; Hatice Altug; Pedro J. Romero, MD; Camilla Jandus, MD, PhD; | Immune Cell Types | Adoptive immunotherapy; Solid tumors; T cell; T cell lineages; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 548 | Poster Presentation | CD8+ Tissue-resident memory T cells are tumour reactive and increase after immunotherapy in a case of metastatic mucosal melanoma | Angela Pizzolla, PhD; Simon P. Keam, PhD; Ismael Vergara; Franco Caramia; Minyu Wang; Nikolce Kocovski; ThuNgoc Nguyen; Sean Macdonald; Daniela Tantalo; Pasquale Petrone; Han Xian Aw Yeang; David E. Gyorki; Alison Weppler, MD; George Au-Yeung; Shahneen Sandhu, MBBS FRACP; Maurizio Perdicchio, PhD; Grant A. McArthur, MBBS (Hons), PhD, FRACP, FAHMS; Tony Papenfuss; Paul J. Neeson, PhD; | Immune Cell Types | Checkpoint blockade; Neoantigens; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 549 | Oral Presentation | Characterizing Double Positive T cells in the Tumor Microenvironment: a tale of promiscuous cell fates | Sara Schad, BS; Sara Schad, BS; Andrew Chow, MD, PhD; Heng Pan; Levi M. Mangarin, BS; Roberta Zappasodi, PhD; Mathieu Gigoux, PhD; David Redmond; Daniel Hirschhorn-Cymerman, PhD; Sadna Budhu, PhD; Hong Zhong, BS; Xia Yang; Olivier Elemento, PhD; Jedd D. Wolchok, MD, PhD; Taha Merghoub, PhD; | Immune Cell Types | Adoptive immunotherapy; CAR T cells; Gene expression; Regulatory T cell (Treg cell); Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 559 | Poster Presentation | Fostriecin potentiates genome instability and anti-tumor immunity in ovarian cancer | Remya Raja, PhD; Christopher Wu; Kristina A. Butler, M.D., MS; Marion Curtis, Ph.D.; | Immune-stimulants and immune modulators | Chemotherapy; Cytokine; Inflammation; Solid tumors; T cell |
| 565 | Poster Presentation | A novel long-acting interleukin-7 agonist, NT-I7, increases cytotoxic CD8+ T cells and enhances survival in mouse glioma models | Subhajit Ghosh, PhD; Ran Yan, PhD; Sukrutha Thotala; Arijita Jash, PhD; Anita Mahadevan, BS; Tong Hu, BS; Byung H. Lee, PhD; Se Hwan Yang, PhD; Dennis Hallahan, MD, PhD; Milan Chheda, MD; Dinesh Thotala, PhD; Jian L. Campian, MD, PhD; Jian L. Campian, MD, PhD; | Immune-stimulants and immune modulators | Cytokine; Radiotherapy; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 567 | Poster Presentation | MDK1319/MDK-701: A potent fully efficacious peptidyl agonist of IL-7Rαγc, designed with no reference to cytokine or receptor structure and unrelated to IL-7, fused to an Fc-domain for PK enhancement | William J. Dower, PhD; Alice V. Bakker, BA; Steven E. Cwirla; Prarthana Joshi, ME; Praechompoo Pongtornpipat, MS; Blake M. Williams, MS; Sandra M. Wang, BSc; Michael C. Needels, PhD; Ronald W. Barrett, PhD; | Immune-stimulants and immune modulators | COVID and Immunotherapy; CAR T cells; Cytokine; Immune adjuvant; T cell; T cell lineages; Vaccine |
| 570 | Poster Presentation | IL-15/IL-15Rα heterodimeric complex as cancer immunotherapy in murine breast cancer models | Siqi Guo; Ronald Smeltz B. Smeltz, PhD; Anthony Nanajian; Richard Heller; Siqi Guo; | Immune-stimulants and immune modulators | Cytokine; Solid tumors; T cell |
| 575 | Poster Presentation | Regression by hetIL-15 monotherapy in different mouse breast cancer models correlates with intratumoral infiltration of a novel population of dendritic cells | Sevasti Karaliota; Dimitris Stellas; Vasiliki Stravokefalou, MSc.; Bethany Nagy, BS; Cristina Bergamaschi, PhD; Barbara K. Felber, PhD; George N. Pavlakis, M.D., Ph.D.; | Immune-stimulants and immune modulators | Antigen presenting cells; Cytokine; Dendritic cell; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 576 | Poster Presentation | NL-201, a de novo IL-2 and IL-15 agonist, demonstrates enhanced in vivo antitumor activity in combination with multiple cancer immunotherapies | Carl Walkey, PhD; Ryan Swanson, BS; Umut Ulge, MD, PhD; Daniel Adriano Silva Manzano, PhD; Jonathan G. Drachman, MD; | Immune-stimulants and immune modulators | Antibody; Bispecifics; Checkpoint blockade; Costimulation; Cytokine; Inflammation; NK/NK T cell; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 577 | Poster Presentation | Engineered non-pathogenic synthetic biotic producing L-arginine synergize with PD-1-based cancer immunotherapy | Fernando P. Canale; Camilla Basso; Ning W. Li, PhD; Anna Sokolovska, PhD; Michela Perotti; Michael J. James, BS; Wenjie Jin; Jean-Philippe Theurillat; Daniel Leventhal; Kip A. West, PhD; Jose Lora; Federica Sallusto; Roger Geiger, PhD; | Immune-stimulants and immune modulators | Checkpoint blockade; Immune adjuvant; Immune suppression; Metabolism; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 580 | Poster Presentation | High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot | Simon P. Keam, PhD; Heloise Halse; ThuNgoc Nguyen; Minyu Wang; Nicolas Van Kooten Losio; Catherine Mitchell; Franco Caramia; David J. Byrne; Sue Haupt; Georgina Ryland; Phillip K. Darcy; Shahneen Sandhu, MBBS FRACP; Piers Blombery; Ygal Haupt; Scott G. Williams; Paul J. Neeson, PhD; | Immune-stimulants and immune modulators | Bioinformatics; Clinical study; Gene expression; Immune contexture; Immune suppression; Inflammation; Radiotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 581 | Poster Presentation | Effects of Acoustic Immune Priming with Low-Intensity Focused Ultrasound (LOFU) and Trabectedin on a Murine Model of Osteosarcoma | Shannon Keisling; | Immune-stimulants and immune modulators | Immune tolerance; Radiotherapy; Solid tumors; Tumor antigens |
| 582 | Poster Presentation | Modulation of TCR repertoire by radiotherapy-activated NBTXR3 nanoparticles | Audrey Darmon, BS; Ping Zhang, PhD; Sebastien Paris, PhD; | Immune-stimulants and immune modulators | Radiotherapy; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs) |
| 585 | Poster Presentation | Intralesional injection of rose bengal improves the efficacy of gemcitabine chemotherapy against pancreatic cancer. | Patrick Innamarato, B.S.; Shari A. Pilon-Thomas, PhD; Jennifer Morse, MS; Sarah Asby; Amy Mackay; Matthew Beatty, PhD; Jaime Blauvelt; Scott Kidd; John E. Mullinax, MD; | Immune-stimulants and immune modulators | Chemotherapy; Inflammation; Solid tumors; T cell |
| 590 | Poster Presentation | Pre-conditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy | Christianne Groeneveldt, MSc; Priscilla Kinderman; Diana J.M. van den Wollenberg; Ruben L. van den Oever; Jim Middelburg; Dana A.M. Mustafa; Rob C. Hoeben; Sjoerd H. van der Burg, PhD; Thorbald van Hall, PhD; Nadine Van Montfoort; | Immune-stimulants and immune modulators | Antibody; Immune adjuvant; Inflammation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Bispecifics |
| 598 | Oral Presentation | Reversal of epigenetic silencing of cGAS and STING in melanoma enhances the activity of tumor infiltrating lymphocytes | Rana Falahat, PhD; James Mulé, PhD; Anders E. Berglund, PhD; Patricio Perez- Villarroel; Ryan Putney, PhD; Shari A. Pilon-Thomas, PhD; Glen N. Barber, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Bioinformatics; Chemokine; Epigenetics; Immune adjuvant; Tumor antigens; Tumor evasion; Tumor infiltrating lymphocytes (TILs) |
| 599 | Poster Presentation | New checkpoints controlling function of cytotoxic lymphocytes infiltrating human carcinoma | Anna S. Herbstritt, MS; Elfriede Noessner, Prof. Dr.; Petra U. Prinz, Dr.; Mani D. Kadiyala, BS; Melissa Maxwell, MS; Dingxue Yan, PhD; James Cardia, PhD; Simon P. Fricker, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; NK/NK T cell; RNA; Solid tumors; T cell; Tumor evasion |
| 614 | Poster Presentation | Co-stimulation via PD1-41BB chimeric switch receptor enhances function of TCR-T cells in an immune-suppressive milieu and under chronic antigen stimulation | Melanie Salvermoser; Maria Gerget; Franziska Hasselmann; Elfriede Noessner, Prof. Dr.; Christian Ellinger, Dr. Rer. Nat.; Monika Braun; Dolores J. Schendel, PhD; Daniel Sommermeyer, PhD; Nadja Sailer, Dr. rer. nat.; | Immuno-conjugates and chimeric molecules | Adoptive immunotherapy; Checkpoint blockade; Costimulation; Solid tumors; T cell; Tumor microenvironment |
| 616 | Poster Presentation | A novel non-covalent linker peptide with nanomolar affinity for clinical IgG1 antibodies preserves antibody-antigen affinity and drug potency against PDL1+ melanoma when conjugated with DM1 | John T. Butterfield, BS; Shari L. Sutor, BS; Wendy K. Nevala, MS; Svetomir N. Markovic, MD, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Chemotherapy; Targeted therapy |
| 621 | Poster Presentation | A Tregs depleting, CD25-targeted antibody-drug conjugate synergizes with tumor-targeted radiotherapy and systemic interleukin-2 in pre-clinical models of solid cancers | Patrick H. van Berkel, Ph.D; Francesca Zammarchi, PhD; Francesca Zammarchi, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Radiotherapy; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 631 | Poster Presentation | Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platform | Dahea Lee; Donggeon Kim, DVM,PhD; Soomin Ryu; Byoung Chul Lee, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Bispecifics; Cytokine; Leukemia/Lymphoma; Targeted therapy; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 637 | Poster Presentation | Immune-related adverse events (irAEs) may indicate a favorable prognosis in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI) | Dylan J. Martini, BA; Sean T. Evans, BS; Subir Goyal, Ph.D; Yuan Liu, Ph.D; T. Anders Olsen, BA; Benjamin L. Magod, BS; Jacqueline T. Brown, MD; Lauren Yantorni, NP; Greta A. Russler, MSN, FNP-BC; Sarah Caulfield, PharmD, BCOP; Jamie M. Goldman, MD; Bassel Nazha, MD; Wayne B. Harris, MD; Viraj A. Master, MD Ph.D; Omer Kucuk, MD; Bradley C. Carthon, MD Ph.D; Mehmet A. Bilen, MD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Clinical study; Immune toxicity; Solid tumors |
| 638 | Poster Presentation | Plasma Proteome Analysis in Patients with Immune Checkpoint Inhibitors Related Arthritis and Pneumonitis | Noha Abdel-Wahab, MD, PhD; Adi Diab, MD; Hiroyuki Katayama, PhD; Sang Kim, MD, PhD; Samir M. Hanash, MD, PhD; Maria Suarez-Almazor, MD, PhD; | Immunotherapy Toxicities | Checkpoint blockade; Immune toxicity; Proteomics |
| 639 | Poster Presentation | Immune-Related Thyroid Dysfunction in Patients with Existing Thyroid Dysfunction | Francois Kaleta, MD; Heather Brody, MD; Praveen Namireddy, MD; | Immunotherapy Toxicities | Checkpoint blockade; Immune monitoring; Immune toxicity; Solid tumors |
| 640 | Poster Presentation | Characterizing severe acute kidney injury in patients treated with immune checkpoint inhibitors | Chung-Jiah Chen, MD; Lisa Kim, M.S.; Ashley Weaver; Sandip P. Patel, MD; | Immunotherapy Toxicities | Immune toxicity |
| 641 | Poster Presentation | Incidence and risk factors for stroke associated with immune checkpoint inhibitor therapy in cancer patients using real-world clinical data | Prantesh Jain, MD FACP; Jahir Gutierrez, PhD; Avirup Guha, MD; Chhavi Jain, PhD; Nirav Patil; Tingke Shen; Ilya Stanevich; Ankit Mangla, MD; Marcos De Lima, MD; Jill Barnholtz-Sloan, PhD; Afshin Dowlati, MD; | Immunotherapy Toxicities | Checkpoint blockade; Chemotherapy; Immune monitoring; Immune toxicity; Solid tumors; Targeted therapy |
| 642 | Poster Presentation | Retrospective Review of Pulmonary Pathology Associated with Chimeric Antigen Receptor T Cell Therapy | Jing Du, MD; David W. Woolston; Kimberly E. Costas, MD; Alexandre Hirayama, MD; Cameron J. Turtle, MBBS, PhD; Cecilia CS. Yeung, MD; | Immunotherapy Toxicities | CAR T cells; Clinical study; Granulocyte; Immune toxicity; Leukemia/Lymphoma; Monocyte/Macrophage |
| 643 | Poster Presentation | Autopsy Review of Chimeric-Antigen Receptor T Cell Therapy: A Single Institution Experience | KiBeom Kwon; David W. Woolston; Alexandre Hirayama, MD; Damian Green, MD; David G. Maloney, MD, PhD; Cameron J. Turtle, MBBS, PhD; Cecilia CS. Yeung, MD; | Immunotherapy Toxicities | B cell; Biomarkers; CAR T cells; Clinical study; Cytokine; Immune toxicity; Leukemia/Lymphoma; T cell |
| 644 | Poster Presentation | Ocular adverse events associated with Programmed Death-1 and Programmed Death Ligand-1 immunotherapy | LeAnne H. Young, BS; Shanda Finnigan, MPH, RN; Howard Streicher, MD; Helen Chen, MD; James Murray, PhD; H. Nida Sen, MD, MHSc; Elad Sharon, MD, MPH; | Immunotherapy Toxicities | Checkpoint blockade; Immune toxicity; Inflammation |
| 645 | Oral Presentation | Preclinical development of a novel colon-targeted therapeutic for the treatment of Immune Checkpoint Inhibitor (ICI)-colitis | Nazli Dizman, MD; Milton L. Greenberg, PhD; Andrew C. Newman, PhD; Jonathan Skupsky, MD, PhD; JoAnn Hsu, BS; Zeynep B. Zengin, MD; Nicholas Salgia, BS; Luis Meza, MD; Neal Chawla, MD; Sabrina Salgia; Jasnoor Kaur; Sumanta K. Pal, MD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Cytokine; Immune toxicity; Inflammation; Regulatory T cell (Treg cell); T cell |
| 646 | Poster Presentation | Evaluating a preclinical model of contact hypersensitivity for skin immune checkpoint toxicity | Barbara Ma, MD, MS; Abhinav Jaiswal, B.S.; K Sanjana P. Devi, PhD; Qingrong Huang, PhD; Joy Hsu, B.A.; Yong Liu, PhD; Niroshana Anandasabapathy, MD, PhD, MS; | Immunotherapy Toxicities | Checkpoint blockade; Immune toxicity; Inflammation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| 647 | Poster Presentation | Evaluation of efficacy and toxicity of CD137 immunotherapy with urelumab-mIgG1 chimeric antibody in CD137 HuGEMM™ | Hongjuan Zhang, PhD; Daniel X. He; Mingkun Zhang; Xinhe Feng; Annie X. An; Cunxiang Ju; Henry Q. Li; Davy X. Ouyang, PhD; | Immunotherapy Toxicities | Antibody; Immune toxicity; T cell |
| 648 | Poster Presentation | Cytokine changes during immune-related adverse events and steroid treatment in melanoma patients receiving immune checkpoint inhibitors | Kevin Tyan, BA; Joanna Baginska, PhD; Martha Brainard; Anita Giobbie-Hurder, MS; Mariano Severgnini, MSc; Michael P. Manos, BA; Rizwan Haq, MD, PhD; Elizabeth I. Buchbinder, MD; Patrick A. Ott, MD, PhD; F. Stephen Hodi, Jr., MD; Osama E. Rahma, MD; | Immunotherapy Toxicities | Biomarkers; Checkpoint blockade; Chemokine; Cytokine; Immune toxicity; Inflammation |
| 649 | Poster Presentation | Incidence of thromboembolism (TE) in patients with melanoma receiving immune checkpoint inhibitor (ICI) therapy and its adverse impact on survival | Tamara A. Sussman, MD; Joanna Roopkumar, MBBS, MPH; Hong Li, MS; Keith R. McCrae, MD; Pauline Funchain, MD; Alok A. Khorana, MD; | Immunotherapy Toxicities | Checkpoint blockade; Immune toxicity; Inflammation; Solid tumors |
| 651 | Poster Presentation | NEUROLOGICAL ADVERSE EVENTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS: OUR EXPERIENCE IN A TERTIARY CARE CENTER | Pablo Alvarez-Ballesteros; Javier Buisan-Catevilla; Alvaro Beltrán-Corbellini; Iñigo Corral-Corral; Javier Pozas-Perez; Victor Albarran-Fernandez; Lucia Sanz-Gomez; Jorge Esteban-Villarrubia; Javier Torres-Jimenez; Jesús Chamorro-Perez; Diana Rosero-Rodriguez; María San Román-Gil; Ainara Soria-Rivas; | Immunotherapy Toxicities | Clinical study; Immune toxicity |
| 652 | Poster Presentation | Early Outcomes of an APP Acute Checkpoint Inhibitor (CPI) Care Clinic | Lisa Kottschade, NP, MS, RN; Casey Fazer; Anna Schwecke; | Immunotherapy Toxicities | Checkpoint blockade; Immune toxicity |
| 653 | Oral Presentation | Dasatinib as a rapid pharmacological ON/OFF switch for T cell bispecific antibody-induced T cell activation and cytokine release | Gabrielle Leclercq, M. Sc. Eng.; Helene Haegel, PhD; Anneliese Schneider, PhD; Estelle Marrer Berger, PhD; Antje Walz, PhD; Christophe Boetsch, PhD; Vesna Pulko, PhD; Cristiano Ferlini, MD; Christian Klein, Dr rer nat; | Immunotherapy Toxicities | Antibody; Bispecifics; Cytokine; Immune suppression; Immune toxicity; Inflammation; T cell; Targeted therapy |
| 654 | Poster Presentation | Real world incidence of grade III and higher adverse effects, emergency room utilization and hospital admissions during treatment with commonly used PD-1/PDL-1 targeting immune check point inhibitors. | Nerea Lopetegui Lia, M.D.; Syed Imran Jafri; Khalid Shalaby; Dimitrios Drekolias; James Vredenburgh, M.D.; Nerea Lopetegui Lia, M.D.; | Immunotherapy Toxicities | Checkpoint blockade; Immune monitoring; Immune toxicity; Targeted therapy |
| 655 | Poster Presentation | Concordance Between Healthcare Providers and Expert Consensus Recommendations in the Management, Monitoring, and Mitigation of Adverse Events Associated with CAR T-Cell Therapy: An Updated Analysis | Matthew J. Frigault, MD, MSc; Megan Cartwright, PhD; Krista Marcello, BA; Timothy A. Quill, PhD; Daniel J. DeAngelo, MD, PhD; Ilene A. Galinsky, NP; Shilpa Paul, PharmD, BCOP; Jae H. Park, MD; Matthew J. Frigault, MD, MSc; | Immunotherapy Toxicities | CAR T cells; Cytokine; Immune toxicity; Leukemia/Lymphoma |
| 656 | Poster Presentation | Time to diagnostic clarity for suspected checkpoint-inhibitor pneumonitis in patients with lung cancer | Eric Olson, MD; Andrew Faucheux, MD; JiaHao Liang, MD; Janardhana Ponnatapura, MD; Jeffrey Lantz, DO; Nathan Roberts, MD; Andy Dothard, MD; Thomas W. Lycan, Jr., DO; Eric Olson, MD; | Immunotherapy Toxicities | Checkpoint blockade; Immune toxicity; Solid tumors |
| 657 | Poster Presentation | Interleukin-6 Receptor Blockade for Management of Immune Checkpoint Inhibitor Related Adverse Events in Patients with Melanoma | Chantal Saberian, MD; Faisal Fa'ak; Jean H. Tayar, MD; Maryam Buni, MD; Sang Kim, MD, PhD; Huifang Lu, MD, PhD; Maria Suarez-Almazor, MD, PhD; Stephen Gruschkus, PhD; May Daher, MD; Kaysia Ludford; Daniel Johnson, MD; Noha Abdel-Wahab, MD, PhD; Adi Diab, MD; | Immunotherapy Toxicities | Autoimmunity; Cytokine; Immune toxicity; Inflammation |
| 658 | Poster Presentation | Toxicities of single agent and combination immune checkpoint inhibitors in patients with pre-existing autoimmune diseases. | Sabina Sandigursky; Safa Houssein; Xerxes Pundole, MD, PhD; Elizaveta Efuni; Samuel Cytryn; Maryam Buni, MD; Anna C. Pavlick, MD, MBA; Michelle Krogsgaard, PhD; Chantal Saberian, MD; Mehmet Altan, MD; Maria Suarez-Almazor, MD, PhD; Jeffrey S. Weber, MD, PhD; Adi Diab, MD; Noha Abdel-Wahab, MD, PhD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Immune toxicity |
| 659 | Poster Presentation | Blocking Cytokine IL-1 with Anakinra for the Prevention of Cytokine Release Syndrome in COVID-19 | Erik R. Soule; Jason R. Williams, MD; Matthias Piesche; | Immunotherapy Toxicities | Clinical study; Cytokine; Immune toxicity; Targeted therapy |
| 660 | Poster Presentation | Developing generalizable deep learning models for tumor segmentation in pathology images to enable the identification of predictive biomarkers for immunotherapies | Qinle Ba, PhD; Qinle Ba, PhD; Peng Yang; Jennifer Yearley, PhD; | Machine Learning, Artificial Intelligence and Computational Modeling | Biomarkers; Tumor microenvironment; Tumor stroma |
| 664 | Poster Presentation | Applying Advanced Data Analysis to Immunotherapy Drug Discovery for Uveal Melanoma | Sarah Kolitz, PhD; Yoonjeong Cha, PhD; Sailaja Battula, PhD; Rebecca Kusko, PhD; Benjamin J. Zeskind, PhD, MBA; Howard L. Kaufman, MD; | Machine Learning, Artificial Intelligence and Computational Modeling | Gene expression; Solid tumors; Systems biology; Targeted therapy |
| 670 | Poster Presentation | Develop a Multiplex Immunofluorescence Panel to Identification of distinct complex immune landscapes in pleural effusion liquids from patients with metastatic lung adenocarcinoma | Caddie Laberiano, MD; Luisa Solis, MD; Sinchita Roy Chowdhuri; Edwin R. Parra, MD, PhD; Caddie Laberiano, MD; | Microbiome and other environmental factors | Antibody; Biomarkers; Immune contexture; Tumor microenvironment |
| 671 | Poster Presentation | Update of a systematic review and meta-analysis studying the association between antibiotic use and clinical outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors | Pierre-Alain Bandinelli, MSc; Julie Cervesi; Clément Le Bescop; Renaud Buffet; Jean De Gunzburg; Gérard Zalcman; Pierre-Alain Bandinelli; | Microbiome and other environmental factors | Autoimmunity; Checkpoint blockade; Microbiome; Solid tumors |
| 672 | Oral Presentation | Identification of microbial-derived HLA-bound peptides in melanoma | Adi Nagler, MSc; Shelly Kalaora; Deborah Gitta Rosenberg; Michal Alon; Eilon Barnea; Ronen Levy; Kevin Vervier; Sophie Trabish; Tali Dadosh; Smadar Zaidman; Leore Geller; Polina Greenberg; Neerupma Bhardwaj; Alexandre Reuben; Reetakshi Arora; Michal Lotem; Arie Admon; Yishai Levin; Trevor Lawley; David Adams; Naama Geva-Zatorsky; Jennifer A. Wargo, MD, MMSc; Ravid Straussman; Yardena Samuels; | Microbiome and other environmental factors | Antigen presenting cells; Bioinformatics; Checkpoint blockade; Microbiome; Neoantigens; Proteomics; T cell; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Vaccine |
| 673 | Poster Presentation | Precision microbiome mapping identifies a microbiome signature predictive of Immune Checkpoint Inhibitor response across multiple research study cohorts | Matthew J. Robinson, PhD; Kevin Vervier; Simon R. Harris; David Adams; Doreen Milne; Catherine Booth; Emily Barker; Christine Parkinson; David Bruce; Sarah Welesh; Pippa Corrie, PhD, BMBCh, FRCP; Trevor D. Lawley; | Microbiome and other environmental factors | Bioinformatics; Biomarkers; Checkpoint blockade; Microbiome |
| 674 | Poster Presentation | Late antibiotic administration during durvalumab treatment may be associated with clinical benefit | Siddharth Sheth, DO MPH; Christopher A. Morehouse, MD; Elizabeth A. Dozier; Chen Gao; Paul Warrener; Vancheswaran Gopalakrishnan, PhD, MPH, BDS; Scott Hammond, PhD; Taylor Cohen; Bret Sellman; | Microbiome and other environmental factors | Checkpoint blockade; Microbiome; Solid tumors |
| 675 | Poster Presentation | Oxygen concentration alters Natural Killer cell phenotype and function in the solid tumor microenvironment | Upasana Sunil Arvindam, MSc; Phillipa Kennedy; Brianna Ettestad; Peter Hinderlie; Gwen Phung; James Lim; Jeff S. Miller, MD; Martin S. Felices; | Microbiome and other environmental factors | Adoptive immunotherapy; Immune suppression; Metabolism; NK/NK T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 676 | Poster Presentation | PD-L1 is induced by the periodontal pathogen Porphyromonas gingivalis and can be blocked by small molecule gingipain inhibitors, including atuzaginstat | Shirin Arastu-Kapur; Mai Nguyen; Sean Broce; Joseph P. Vacca; Kirk Ehmsen; Florian Ermini; Ursula L. Haditsch; Aurora Martinez-Horta; Debasish Raha; Leonardo Rodriguez; Casey Lynch; Stephen S. Dominy; Leslie J. Holsinger; | Microbiome and other environmental factors | Checkpoint blockade; Coinhibition; Immune suppression; Inflammation; Microbiome; Monocyte/Macrophage; Solid tumors; Targeted therapy; Tumor evasion; Tumor microenvironment |
| 677 | Poster Presentation | Evaluation of anti-PD1 efficacy in germ-free and antibiotic-treated SPF mice bearing MC38 tumors | Ying Jin; Xue Liang; Frieda Z. Zhang; Guangmao Mu; Wei Zhou; Annie X. An; Marvin Y. Ouyang; Cai Li; Andy Liaw; Henry Q. Li; Davy X. Ouyang, PhD; | Microbiome and other environmental factors | Checkpoint blockade; Microbiome |
| 678 | Poster Presentation | Addition of a single bacteria facilitates anti-tumor immunity and long-term survival in colorectal cancer. | Abigail E. Overacre-Delgoffe, PhD; Anthony R. Cillo, PhD; Hannah J. Bumgarner, BS; Ansen Burr; Justin Tometich; Amrita Bhattacharjee; Tullia C. Bruno, PhD; Dario A. Vignali, PhD; Timothy W. Hand; | Microbiome and other environmental factors | Dendritic cell; Microbiome; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 679 | Poster Presentation | High fiber diet modifies gut microbiome, propionate production, intratumor immune response and is associated with outcome in patients with lung cancer treated with immune checkpoint inhibitors | Corentin Richard, PhD; Myriam Benlaifaoui; Omar El Ouarzadi; Khoudia Diop; Antoine Desilets; Julie Malo; Wiam Belkaid; Andréanne Leblanc; Julien Lamontagne; Meriem Messaoudene; Arielle Elkrief; Bertrand Routy; | Microbiome and other environmental factors | Bioinformatics; Checkpoint blockade; Gene expression; Microbiome; Tumor microenvironment |
| 680 | Poster Presentation | Automated Ion Torrent based solution enables accurate gut microbiome quantification of bacterial species relevant to research in cancer and its response to immunotherapy | Shrutii Sarda, PhD; David Merrill, PhD; Heesun Shin; Anna McGeachy, PhD; Birgit Drews; Wing Lee; Rajesh K. Gottimukkala, MS; Janice K. Au-Young, PhD; Fiona Hyland; Shrutii Sarda, PhD; | Microbiome and other environmental factors | Autoimmunity; Bioinformatics; Microbiome |
| 681 | Poster Presentation | Single pipeline re-analysis revises microbiome associations with anti-tumor response to checkpoint inhibitors | Fyza Y. Shaikh, MD, PhD; James R. White, PhD; Joell J. Gills, PhD; Taiki Hakozaki; Richard Corentin; Bertrand Routy; Yusuke Okuma; Mykhaylo Usyk; Abhishek Pandey; Jeffrey S. Weber, MD, PhD; Jiyoung Ahn; Jarushka Naidoo, MB BCH MHS; Evan J. Lipson, MD; Drew M. Pardoll, MD, PhD; Cynthia Sears; | Microbiome and other environmental factors | Bioinformatics; Biomarkers; Checkpoint blockade; Microbiome; Solid tumors |
| 682 | Poster Presentation | Antibody-mediated Blockade of Interleukin-10 Receptor-alpha Promotes the Activation of Immune Cells from in vitro Dissociated Tumor Samples | Alexey Berezhnoy, PhD, DVM; Kalpana Shah, BS; Daorong Liu; Peter Lung, BS, HT (ASCP); Vatana Long; Kurt Stahl, BS; Douglas Smith, PhD; Francine Z. Chen, MD; Hua Li, MS; Jonathan Li, PhD; Ralph F. Alderson, PhD; Valentina Ciccarone, PhD; James K. Tamura, PhD; Ezio Bonvini, MD; Gundo Diedrich, PhD; Paul A. Moore, PhD; | Novel Single-Agent Immunotherapies | Antigen presenting cells; Checkpoint blockade; Immune suppression; Immune tolerance; Monocyte/Macrophage; Myeloid cells; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 683 | Poster Presentation | A novel mechanism of Neuropilin-1 inhibition results in improved tumor growth inhibition in vivo | Daniel Blom; Shalini Sethumadhavan; Chengfeng Merriman; Katherine Molloy; alexandria Fink; Shan Lou; andrew rogantino; Ameya Apte; Mandana abbassi; Tiffany Liao; Hongyue Dai; aaron fulgham; Jonathan Hurov; Pearl Huang; | Novel Single-Agent Immunotherapies | Angiogenesis; Antibody; MDSC; Monocyte/Macrophage; Regulatory T cell (Treg cell); Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 684 | Poster Presentation | A low affinity bivalent mesothelin-binding MATCH4 multispecific T cell engager increases cytotoxic selectivity for high mesothelin expressing cells | Bithi Chatterjee, PhD; Alexandre Simonin, PhD; Daniel Snell, PhD; Tea Gunde, PhD; Christian Hess, PhD; Matthias Brock, PhD; Stefan Warmuth, PhD; Christopher Weinert, PhD; Niels Kirk; Dania Diem; Naomi Flückiger; Robin Heiz; Benjamin Küttner; Dana Mahler; Diego Morenzoni; Sandro Wagen; Julia Zeberer; David Urech, PhD; | Novel Single-Agent Immunotherapies | Antibody; Bispecifics; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| 685 | Poster Presentation | A Highly Selective and Potent HPK1 Inhibitor Enhances Immune Cell Activation and Induces Robust Tumor Growth Inhibition in a Murine Syngeneic Tumor Model | David Ciccone, PhD; Vad Lazari; Ian Linney; Michael Briggs; Samantha Carreiro; Joshua McElwee; Ian Waddell; Chris Hill; Christine Loh; Peter Tummino; Alan Collis; Neelu Kaila; | Novel Single-Agent Immunotherapies | Antigen presenting cells; B cell; Checkpoint blockade; Cytokine; Dendritic cell; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs) |
| 686 | Poster Presentation | Preclinical characterization of a novel therapeutic antibody targeting LILRB2 | Maria Jose Costa, PhD; Ryan Stafford, PhD; Zhiqiang Ku, PhD; Jing-Tyan Ma; Krista McCutcheon; Xiaoye Liu, PhD; Heyu Chen, PhD; Kyu Hong; Tao Huang, PhD; Ningyan Zhang, PhD; Zhiqiang An, PhD; Cheng Cheng Zhang, PhD; X. Charlene Liao, PhD; An Song, PhD; | Novel Single-Agent Immunotherapies | Antibody; Antigen presenting cells; Checkpoint blockade; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor evasion; Tumor microenvironment |
| 687 | Poster Presentation | Enhancement of anti-tumor immunity by ICT01: a novel g9d2 T cell-activating antibody targeting Butyrophilin-3A (BTN3A) | Aude de Gassart, PhD; Patrick Brune; Suong LE; Sophie Agaugue; Emmanuel Valentin, PhD; Remy Castellano; Jennifer Sims; Alem Truneh; Daniel Olive, M.D., Ph.D.; Rene Hoet; | Novel Single-Agent Immunotherapies | Antibody; T cell; T cell lineages |
| 688 | Poster Presentation | In vivo expansion of gamma delta T cells by a CD19-targeted butyrophilin heterodimer leads to elimination of peripheral B cells | Suresh De Silva, Ph.D.; George J. Fromm, Jr., Ph.D.; Louis E. Gonzalez, Ph.D.; Arpita Patel, BSc; Kyung J. Yoon; Zachery Opheim; Robert Farmer; Dean Chamberlain, Ph.D.; Taylor H. Schreiber, MD, PhD; | Novel Single-Agent Immunotherapies | B cell; Bispecifics; T cell |
| 689 | Poster Presentation | ATRC-101 Drives Potent Single-Agent Activity in Mouse Syngeneic Tumor Models via a Novel Cellular Mechanism of Action | Yvonne Leung, Ph.D.; Nikhil Vad, PhD; Anne Ye, PhD; Daniel R. Santos, MS; Wei Cao; Cathrin Czupalla, Ph.D.; John Vivian, PhD; Carlene Williams; Judevin Sapugay, BS; Michael Harbell, M.S.; Shaun M. Lippow, Ph.D.; Chantia Carroll, BS; Lance Kates, BS; Benjamin Haugen, BS; Gary Bolton, BS; Mark Armanini, BS; Iraz T. Aydin, PhD; Mark Whidden, PhD; Mauricio Velasco-Delgado, MS; Felix Chu, MS; Erin Wechsler, PhD; Ngan A. Nguyen, PhD; William H. Robinson, MD PhD; Tito A. Serafini, PhD; Daniel Emerling, PhD; Norman M. Greenberg, PhD; Amy Manning-Bog, PhD; Alexander Scholz, PhD; | Novel Single-Agent Immunotherapies | Chemokine; Cytokine; Dendritic cell; Myeloid cells; RNA; T cell; T cell lineages; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 690 | Poster Presentation | CD122-selective IL-2 complexes treat ovarian carcinomas, induce Treg fragility and promote T cell stem cells | Yilun Deng, MD, PhD; Justin M. Drerup; Xinyue Zhang; Ryan M. Reyes, BS; Jenny A. Mendez; Aravind Kancharla, MS; Myrna G. Garcia, BS; Haiyan Bai; Alvaro S. Padron, PhD; Harshita B. Gupta, PhD; Tyler J. Curiel, MD, MPH; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Cytokine; Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs) |
| 691 | Poster Presentation | MDK-271: A dual function molecule consisting of empirically-designed peptidyl agonists of IL-2/15Rβγc and IL-7Rαγc, unrelated to IL-2, IL-15, or IL-7, incorporated into a bispecific Fc fusion protein | William J. Dower, PhD; Steven E. Cwirla; Alice V. Bakker, BA; Praechompoo Pongtornpipat, MS; Blake M. Williams, MS; Prarthana Joshi, ME; Sandra M. Wang, BSc; Michael C. Needels, PhD; Ronald W. Barrett, PhD; | Novel Single-Agent Immunotherapies | Bispecifics; Cytokine; NK/NK T cell; Regulatory T cell (Treg cell); T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 692 | Poster Presentation | AMV564, a clinically active T cell engager, induces a target-dependent adaptive immune response | Sterling C. Eckard, PhD; Aurelien Sarde; Li Mei; Curtis Ruegg, PhD; Patrick Chun, MD; Victoria Smith, PhD; | Novel Single-Agent Immunotherapies | Clinical trial; Immune suppression; MDSC; Myeloid cells; Solid tumors; T cell; Targeted therapy |
| 693 | Poster Presentation | APX601, a Novel TNFR2 Antagonist Antibody for Cancer Immunotherapy | Erin L. Filbert, PhD; Sushma Krishnan, MSc in Biology; Ryan Alvarado; George Huang; Francis R. Bahjat; Xiaodong Yang, MD, PhD; | Novel Single-Agent Immunotherapies | Antibody; Immune suppression; MDSC; Myeloid cells; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 694 | Poster Presentation | NC410 is a Novel Immunomedicine for the Treatment of Solid Tumors | Linjie Tian, PhD; M. Ines Pascoal Ramos, PhD; Emma de Ruiter; Ana Paucarmayta; Eline Elshof; Stefan Willems, MD, PhD; Chang Song, PhD; Zachary Cusumano, PhD; Jason Bosiacki; Linda N. Liu, PhD; Solomon Langermann, PhD; Linde Meyaard, PhD; Dallas B. Flies, PhD; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Solid tumors; T cell; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 695 | Poster Presentation | Oral delivery of a microbial extracellular vesicle induces potent anti-tumor immunity in mice | Loise Francisco-Anderson, PhD; Mary Abdou, BS; Michael Goldberg, PhD; Erin Troy, PhD; Alicia Ballok, PhD; Fabian Romano Chernac, PhD; Maria Sizova, PhD; Krutika Invally, PhD; Shubhra Kashyap, MS; Audrey McBride, BS; Jessica Tsang, BS; Shannon Argueta, PhD; Kristie Barth, PhD; Valeria Kravitz, MS; Holly Ponichtera, PhD; Tyler Rommel, MS; Kevin Huynh, MS; Tanmoy Ganguly, PhD; Mark Bodmer, PhD; | Novel Single-Agent Immunotherapies | Antigen presenting cells; Extracellular vesicles/exosomes; TLR; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 696 | Poster Presentation | Brentuximab vedotin, a CD30-directed antibody-drug conjugate, selectively depletes activated Tregs in vitro and in vivo | Bryan M. Grogan, MS; Reice D. James, BS; Michelle Ulrich, BS; Shyra J. Gardai, PhD; Ryan Heiser, PhD; | Novel Single-Agent Immunotherapies | Antibody; Biomarkers; Immune suppression; Leukemia/Lymphoma; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor microenvironment |
| 697 | Poster Presentation | Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors | Michael Hedvat, PhD; Veronica Zeng, PhD; Juan Diaz, PhD; Christine Bonzon, PhD; Kendra N. Avery, PhD; Rumana Rashid, PhD; Irene Leung, PhD; Norm Bartlow, PhD; Charles Bakhit; Matthew Dragovich, PhD; Liz Bogart, PhD; Umesh Muchhal, PhD; John R. Desjarlais, PhD; Gregory L. Moore, PhD; | Novel Single-Agent Immunotherapies | Antibody; Bispecifics; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 698 | Poster Presentation | Targeting HLA-G-mediated immunosuppression with a first-in-class antagonist antibody | Douglas Hodges; Christina M. Kochel, PhD; Michael Totagrande; Jeffrey Jones; Megan Welch; Bradley N. Spatola, PhD; Shelby Joe; John A. Corbin, PhD; Vanessa B. Soros, PhD; Courtney Beers, PhD; Achim K. Moesta, PhD; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Immune suppression; Immune tolerance; Solid tumors; Tumor evasion; Tumor microenvironment |
| 699 | Poster Presentation | A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models | Ye Liu, Ph.D; Beibei Jiang; Tong Zhang; Zuobai Wang; Yingcai Feng; Haiying Li; Wenfeng Gong; Xing Wang; Yajuan Gao; Xiaosui Zhou; Bo Zhang; Yuan Hong; Jing Wang; Zilin Wang; Hongjia Hou; Hanzi Sun; Xiaomin Song, PhD; Kang Li; Xuesong Liu; | Novel Single-Agent Immunotherapies | Antibody; Costimulation; T cell |
| 700 | Poster Presentation | EphA2/CD137 Bicycle tumor-targeted immune cell agonists (TICAsTM) induce tumor regressions, immunogenic memory, and reprogramming of the tumor immune microenvironment | Kristen E. Hurov, PhD; Johanna lahdenranta, PhD; Gemma Mudd, .; Punit Upadhyaya, PhD; Elizabeth M. Repash, MSc; Jun Ma, MSc; Julia Kristensson, .; Marianna Kleyman; Jessica Kublin; Liuhong Chen; Eric Haines, PhD; Sailaja Battula; Kevin McDonnell, PhD; Philip E. Brandish; Nicholas Keen, PhD; | Novel Single-Agent Immunotherapies | Bispecifics; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 701 | Poster Presentation | Nanoparticulate monobenzone (MBEH) as a potential drug candidate for melanoma | Dinesh Jaishankar, PhD; Steven Henning; Anqi Zhang, PhD; Basar Bilgicer, PhD; SonBinh Nhuyen, PhD; I. Caroline Le Poole, PhD; | Novel Single-Agent Immunotherapies | Neoantigens; Solid tumors; T cell |
| 702 | Poster Presentation | Dual blockade of the PD-1 checkpoint pathway and the adenosinergic negative feedback signaling pathway with a PD-1/CD73 bispecific antibody for cancer immune therapy | Tingting Zhong, MS; Zhaoliang Huang, BSc; Xinghua Pang, BSc; na chen, MD; Xiaoping Jin, PhD; Yu Xia, PhD; Zhongmin Maxwell Wang, PhD; Baiyong Li, PhD; Yu Xia, PhD; | Novel Single-Agent Immunotherapies | Antibody; Bispecifics; Checkpoint blockade; Immune monitoring; Immune suppression |
| 703 | Poster Presentation | Engineered exosomes with altered cellular tropism achieve targeted STING agonist delivery and single-agent tumor control in vivo | Monique Kauke, PhD; Nikki Ross, PhD; Dalia Burzyn; Shelly Martin; Ke Xu; Nuruddeen Lewis; Charan Leng; Su Chul Jang, PhD; Christine McCoy; Stephanie Yu; Kevin Dooley; Sriram Sathyanarayanan, PhD; Jonathan Finn; | Novel Single-Agent Immunotherapies | Antibody; Antigen presenting cells; Dendritic cell; Extracellular vesicles/exosomes; Monocyte/Macrophage; Myeloid cells; Proteomics; Solid tumors |
| 704 | Poster Presentation | Preclinical mechanism of action and pharmacodynamic biomarker studies of DuoBody®-CD3x5T4 in vitro and in vivo in solid cancer models | Kristel Kemper, PhD; Ellis Gielen; Mischa Houtkamp, PhD; Peter Boross; Saskia Burm, PhD; Stefanie A. De Poot; Patrick Engelberts; Bart E. de Goeij; David Satijn, PhD; Kate Sasser, PhD; Esther Breij, PhD; | Novel Single-Agent Immunotherapies | Antibody; Biomarkers; Bispecifics; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| 705 | Poster Presentation | Anti-tumor activity of CB-668, a potent, selective and orally bioavailable small-molecule inhibitor of the immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1) | Andrew MacKinnon, PhD; Deepthi Bhupathi; Jason Chen; Tony Huang; Weiqun Li, PhD; Yong Ma; Natalija Sotirovska, MS; Susanne Steggerda, PhD; Winter Zhang; Francesco Parlati, PhD; | Novel Single-Agent Immunotherapies | Immune suppression; Metabolism; Solid tumors; T cell; Tumor microenvironment |
| 706 | Poster Presentation | BT7480, a fully synthetic tumor-targeted immune cell agonist (TICA™) induces tumor localized CD137 agonism and modulation of tumor immune microenvironment | Punit Upadhyaya, PhD; Kristen E. Hurov, PhD; Jessica Kublin; Jun Ma, MSc; Elizabeth M. Repash, MSc; Marianna Kleyman; Julia Kristensson, .; Drasti Kanakia; Fanglei You; Liuhong Chen; Eric Haines, PhD; Sailaja Battula; Kevin McDonnell, PhD; Philip E. Brandish; Johanna lahdenranta, PhD; Nicholas Keen, PhD; | Novel Single-Agent Immunotherapies | Bispecifics; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 707 | Poster Presentation | Discovery of a novel EP2 and EP4 dual antagonist | Yeri Lee; Hyun Jin Kim; Donggeon Kim, DVM,PhD; Joo Youn Lee; Chang Soo Yun; Hyuk Lee; Young Sook Shin; Soo Bong Han; Sang Kyun Lim; | Novel Single-Agent Immunotherapies | Coinhibition; Dendritic cell; Immune suppression; Inflammation; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; Tumor microenvironment |
| 708 | Poster Presentation | Application of a novel mSENS drug delivery technology for mRNA therapeutics | Sojin Lee, Dr.; Joon Young Park; Goo-Young Kim, Ph.D.; Sang Woo Jo; Minhyuk Yun; Hye Yeong Nam; Helen Cho; | Novel Single-Agent Immunotherapies | RNA; Solid tumors; T cell; Tumor antigens; Vaccine |
| 709 | Poster Presentation | Exosome surface display of IL-12 results in tumor-retained pharmacology with superior potency and limited systemic exposure | Nuruddeen Lewis, PhD; Katherine Kirwin; Sonya Haupt; Gauri Mahimkar; Tong Zi; Ke Xu; Kevin Dooley; Su Chul Jang, PhD; Bryan Choi; Andrew Grube; Christine McCoy; Jorge Sanchez-Salazar; Michael Doherty; Scott Estes; Kyriakos Economides; Douglas E. Williams; Sriram Sathyanaryanan, PhD; | Novel Single-Agent Immunotherapies | Cytokine; Extracellular vesicles/exosomes; Immune adjuvant; NK/NK T cell; T cell |
| 710 | Poster Presentation | Development of IL-33 as a novel immunotherapy of cancer | Joshua Zhong; Runzi Sun; Binfeng Lu, PhD; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Cytokine; NK/NK T cell; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 711 | Poster Presentation | HBM1022, a Novel Anti-CCR8 Antibody Depletes Tumor-infiltrating Regulatory T cells via Enhanced ADCC Activity, Mediates Potent Anti-Tumor Activity with Keytruda | Shuang Lu, MS; Shaoping Hu; Xin Gan; Yongqiang Wang; Chuchu Zhao; Yi Ding; Jinqiu He; Qing Du; Xiaocheng Lv; Beibei Qin; Yun He; Lei Niu; Yuntao Wu; Fei Chen; Yuandong Wang; Yunxing Yang; Yang Cao; Musheng Bao; Jason Noon; Wenhao Yu; Juan Liu; Joe Zhao, PhD; Yiping Rong; Shuang Lu, MS; | Novel Single-Agent Immunotherapies | Antibody; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 712 | Poster Presentation | SBT6290, a systemically administered Nectin-4-directed TLR8 ImmunoTAC (TM) therapeutic, is a potent human myeloid cell agonist for the treatment of Nectin-4-expressing tumors | Heather Metz, PhD; Ty Brender; Brenda Stevens; Damion Winship; Jamie Brevik; Michael Comeau; Monica Childs; Jenny R. Chang; Li-Qun Fan; Hengyu Xu; Jonathan Grey; Jeffrey Adamo; Ben Setter; Ray Carrillo; Sean W. Smith; Phil Tan; Robert E. DuBose; Yvette Latchman, PhD; Peter Baum; Valerie Odegard, PhD; | Novel Single-Agent Immunotherapies | Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; TLR; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 713 | Poster Presentation | Antibody-based approach of MT1-MMP metalloprotease inhibition results in decreased invasive properties of pancreatic cancer cells | Nikita A. Mitkin, PhD; Alisa M. Gorbacheva; Alina S. Ustiugova; Aksinya N. Uvarova; Kirill V. Korneev; Vsevolod V. Pavshintsev, PhD; Nikita A. Mitkin, PhD; | Novel Single-Agent Immunotherapies | Antibody; B cell; Immune adjuvant; Inflammation; Tumor microenvironment |
| 714 | Poster Presentation | PD1 x TGFβR2 bispecifics selectively block TGFβR2 on PD1-positive T cells, promote T cell activation, and elicit an anti-tumor response in solid tumors | Gregory L. Moore, PhD; Suzanne Schubbert, PhD; Christine Bonzon, PhD; Kendra N. Avery, PhD; Rumana Rashid, PhD; Erik Pong, BS; Lukasz J. Ochyl, PhD; Alex Nisthal, PhD; Seung Chu, PhD; James Ernst, PhD; John R. Desjarlais, PhD; | Novel Single-Agent Immunotherapies | Antibody; Bispecifics; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| 715 | Poster Presentation | FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, induces LAG-3 shedding resulting in receptor downregulation by T cells via a novel mechanism of action | Michelle Morrow, PhD; Mustapha Faroudi, PhD; Krishnendu Chakraborty, PhD; Wenjia Liao, BSc; Julia Winnewisser, PhD; Claire Seal, PhD; Daniel Gliddon, PhD; Neil Brewis, PhD, DSc; | Novel Single-Agent Immunotherapies | Antibody; Bispecifics; Checkpoint blockade; Coinhibition; T cell |
| 716 | Poster Presentation | CELL-BASED VIROTHERAPY FOR TARGETING CANCERS | Duong H. Nguyen; Alberto Gomez; Forrest Neuharth; Ashley Alamillo; Thomas Herrmann; Barbara Härtl; Laura Schneider; Ivelina Minev; Boris Minev, MD; Dobrin Draganov, PhD; Antonio F. Santidrian; | Novel Single-Agent Immunotherapies | Solid tumors; Stem cell/cancer-initiating cell; Tumor infiltrating lymphocytes (TILs); Vaccine |
| 717 | Poster Presentation | AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy | Katharina Lueckerath, Dr.; Julie M. Bailis, PhD; Kyle Current, BA; Mark E. Salvati, PhD; Caius Radu, MD; Johannes Czernin, MD; | Novel Single-Agent Immunotherapies | Bispecifics; Clinical trial; Solid tumors; T cell; Tumor antigens |
| 718 | Poster Presentation | AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells | Cong Li, PhD; Madeline Fort, PhD; Lingming Liang, MS; Gregory L. Moore, PhD; Matthew J. Bernett, PhD; Umesh Muchhal, PhD; Tao Osgood, BS; Rodolfo Yabut, BA; Sarav Kaliyaperumal, MPH, PhD; John Harrold, PhD; Jude Canon, PhD; Anna Rogojina, PhD; Raushan Kurmasheva, PhD; John R. Desjarlais, PhD; Peter Houghton, PhD; Olivier Nolan-Stevaux, PhD; | Novel Single-Agent Immunotherapies | Antibody; Bispecifics; Chemotherapy; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| 719 | Poster Presentation | CD122-directed interleukin-2 complexes and αPD-L1 differentially require innate and adaptive immunity to treat local and metastatic bladder cancer | Ryan M. Reyes, BS; Yilun Deng, MD, PhD; Deyi Zhang, PhD; Niannian Ji, PhD; Neelam Mukherjee, PhD; Karen Wheeler, MD PhD; Harshita B. Gupta, PhD; Aravind Kancharla, MS; Myrna G. Garcia, BS; Anand VR. Kornepati, BS; Robert S. Svatek, MD MSCI; Tyler J. Curiel, MD, MPH; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Cytokine; NK/NKT cell; T cell; Tumor microenvironment |
| 720 | Poster Presentation | Targeting MARCO and IL-37R on anti-inflammatory macrophages in lung cancer blocks regulatory T cells and shift balance to support cytotoxic lymphocyte function | Linnéa La Fleur; Johan Botling; Fei He; Catarina Pelicano; Giorgia Palano; Artur Mezheyeuski; Patrick Micke; Jeffrey V. Ravetch, MD, PhD; Mikael Karlsson; Dhifaf Sarhan, PhD; | Novel Single-Agent Immunotherapies | Immune suppression; Myeloid cells; Solid tumors; Targeted therapy; Tumor microenvironment |
| 721 | Poster Presentation | AT1412, a patient-derived CD9 antibody in preclinical development promoting tumor immune infiltration and inducing tumor rejection | Remko Schotte, PhD; Julien Villaudy, PhD; Martijn Kedde, PhD; Wouter Pos, PhD; Daniel Go; Christien Fatmawati; Gemma Moiset, PhD; Etsuko Yasuda; Madalina Cercel; Esmay Frankin; Susan van Hal; Pauline M. van Helden, PhD; Els Verdegaal, PhD; Sjoerd H. van der Burg, PhD; Hergen Spits, PhD; Hans van Eenennaam, PhD; | Novel Single-Agent Immunotherapies | Antibody; B cell; Extracellular vesicles/exosomes; Monocyte/Macrophage; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 722 | Poster Presentation | Inhibition of Integrin avß8-Mediated TGF-ß Activation with C6D4 Provides Improved Potency and Selectivity vs General TGF-ß Inhibitors for Cancer Immunotherapy | Robert Seed, PhD; Stephen Nishimura, MD; Robert Seed, PhD; | Novel Single-Agent Immunotherapies | Antibody; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 723 | Poster Presentation | Lymph node-targeted AMP-vaccine enables tumor-directed mKRAS-specific immune responses with potent polyfunctional and cytolytic activity | Martin Steinbuck, PhD; Peter C. DeMuth, PhD; Lochana Seenappa, MS; | Novel Single-Agent Immunotherapies | Immune adjuvant; T cell; Vaccine |
| 724 | Poster Presentation | STAT3 inhibition in acute myeloid leukemia cells allows for TLR9-driven differentiation to immunogenic monocytic cells and induction of T-cell mediated immune responses | Yu-Lin Su, PhD; Marcin Kortylewski, PhD; Priyanka Duttagupta, PhD; | Novel Single-Agent Immunotherapies | Antigen presenting cells; Bispecifics; Immune suppression; Leukemia/Lymphoma; MDSC; Monocyte/Macrophage; Myeloid cells; RNA; Targeted therapy; TLR |
| 725 | Poster Presentation | Pre-clinical development of TNFR2 ligand-blocking BI-1808 for cancer immunotherapy | Linda Mårtensson, PhD; Mathilda Kovacek; Petra Holmkvist, PhD; Monika Semmrich, PhD; Carolin Svensson; Therese Blidberg; Carl Roos, PhD; Andres McAllister, MD, PhD; Mimoza Demiri, PhD; Marie Borggren, PhD; Ingrid Karlsson, PhD; Björn Frendeus, PhD; Ingrid Teige, PhD; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 726 | Poster Presentation | SRF114 is a fully human, CCR8 selective IgG1 antibody that induces destruction of tumor Tregs through ADCC | Andrew C. Lake, PhD; Michael C. Warren, MS; Sonia G. Das, PhD; Christopher C. Wells, BS; Maria Scrivens, BA; Ernest S. Smith, PhD; Vito J. Palombella, PhD; Bijan Etemad-Gilbertson, PhD; Pamela M. Holland, PhD; Austin Dulak, PhD; | Novel Single-Agent Immunotherapies | Antibody; Regulatory T cell (Treg cell); T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs) |
| 727 | Poster Presentation | Increased serum levels of EBI3 are associated with poor outcome in hepatocellular carcinoma patients and SRF388, a first-in-class IL-27 blocking antibody, inhibits the growth of murine liver tumors | Matthew P. Rausch, PhD; Devapregasan Moodley, PhD; Marisa O. Peluso, MS; Secil Koseoglu, PhD; Jing Hua, MD, MS; Gege Tan, MA; Ricard Masia, MD PhD; Benjamin H. Lee, MD PhD; Isabelle Cousineau, PhD; Simon Turcotte, MD MSc; John Stagg, PhD; Vito J. Palombella, PhD; Pamela M. Holland, PhD; Jonathan A. Hill, PhD; | Novel Single-Agent Immunotherapies | Antibody; Cytokine; Immune suppression; Myeloid cells; Tumor evasion |
| 728 | Poster Presentation | Antibiotics and response to immunotherapy: Real-world experience | Yasar Ahmed, MD, FRCP; Paula Calvert; Yasar Ahmed, MD, FRCP; | Other | Microbiome; Solid tumors |
| 729 | Poster Presentation | The impact of immune and targeted therapies for Melanoma in Asian populations: A National Cancer Database analysis 2004-2016 | Lifen Cao, MD PhD; Lifen Cao, MD PhD; Kavin Sugumar, MD; Ankit Mangla, MD; Megan E. Miller, MD; Luke D. Rothermel, MD MPH; | Other | Epidemiology |
| 730 | Poster Presentation | Histotripsy focused ultrasound ablation induces immunological cell death in treated and distant untreated tumors | Anutosh Ganguly, Ph.D; Ashley A. Pepple, MS; Reliza McGinnis; Ryan Hubbard; Amy E. Felsted, MD; Tejaswi Worlikar; Hannah Garavaglia; Joe Dib; Joe Guy; Michal Olszewski; Zhen Xu; Clifford S. Cho, MD, FACS; | Other | Inflammation; Solid tumors; Surgery; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 731 | Poster Presentation | Costs of care for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): a real-world claims analysis | Jonathan Kish; Jonathan Kish; Dhruv Chopra; Djibril Liassou; Solomon J. Lubinga, PhD; John Hartman; Bruce Feinberg; | Regulatory - Financial - and Access Considerations | Checkpoint blockade; Chemotherapy |
| 733 | Poster Presentation | Integrative molecular profiling of high-grade primary prostate cancer identifies patients with a biomarker profile that favors the combination of standard of care (SOC) therapy with immunotherapy | Evisa Gjini, PhD; Jimena Trillo-tinoco; Andrew Browne; Ryan Powles; Tai Wang; Christine Tauras; Ana Lako; Ruben Ferrer-Luna; Zoe Bleicher; timothy consedine; Chensheng Zhou; Evan Kelemen; anne lewin; Catherine King; sumit bhattacharya; harris bell-temin; ashok dongre; David Nelson; Christos Hatzis, PhD; Kenzie Macisaac; Fadi Towfic; Benjamin Chen, MD, PhD; Michaela Bowden, PhD; Evisa Gjini, PhD; | Tumor and Stromal Cell Biology | Biomarkers; Gene expression; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 734 | Poster Presentation | A novel NQO1 specific anti-tumor agent, SBSC-S3001, selectively regresses the growth of tumors with high NQO1 expression. | Minhyuk Yun; Goo-Young Kim, Ph.D.; Sang Woo Jo; Changhoon In; Gyu-Young Moon; In Seok Ko; Eun Ju Lee; Yong Rae Hong; Whee Seong Lee; Helen Cho; | Tumor and Stromal Cell Biology | Chemotherapy; Gene expression; Immune monitoring; Metabolism |
| 737 | Poster Presentation | A novel humanized murine model to identify neoantigen-specific T cells in pediatric acute megakaryoblastic leukemia. | Elizabeth A. Garfinkle, BS; Anthony E. Zamora, PhD; Jeremy C. Crawford, PhD; Paul G. Thomas, PhD; Tanja A. Gruber, MD, PhD; | Tumor and Stromal Cell Biology | Adoptive immunotherapy; Bioinformatics; Cytokine; Leukemia/Lymphoma; Neoantigens; T cell; Tumor infiltrating lymphocytes (TILs) |
| 739 | Poster Presentation | Development of Patient-Derived Models of Esophageal Cancer for GUCY2C-Directed Immunotherapeutic Testing | Megan Weindorfer, BS; Amanda N. Lisby, MS; Alicja Zalewski, MD; Trevor R. Baybutt, BA; Robert Carlson, BS; Madison Crutcher, MD; David Loren, MD; Ernest Rosato, MD; Nathaniel Evans III, MD; Scott A. Waldman, MD, PhD; Adam E. Snook, PhD; | Tumor and Stromal Cell Biology | Adoptive immunotherapy; CAR T cells; Carcinogenesis; Targeted therapy |
| 742 | Poster Presentation | Phosphopeptides are Increased in the MHC-I Immunopeptidome of Irradiated Human Breast Cancer Cells | Samantha J. Van Nest, PhD, MS; Tomer M. Yaron; Martin G. Klatt; Noah Dephoure; Gad Getz, PhD; Laura Santambrogio; Olivier Elemento, PhD; David A. Scheinberg; Sandra Demaria, MD; Lewis C. Cantley; | Tumor and Stromal Cell Biology | Proteomics; Radiotherapy; Tumor antigens; Post-translational modifications |
| 743 | Poster Presentation | High levels of stromal tumor infiltrating lymphocytes, CD3, CD8 cells & Immunoscore® are associated with pathological CR and time to progression in TNBC patients undergoing neo-adjuvant chemotherapy. | Bernardo L. Rapoport, MD, MMed; Jérôme Galon; Simon Nayler; Aurelie Fugon; Isabelle Boquet; Marine Martel; Mlecnik B; Teresa Smit; Carol Ann Benn; Farhana Moosa; Liezl Heyman; Ronald Anderson, Prof; | Tumor and Stromal Cell Biology | Biomarkers; Chemotherapy; Immune monitoring; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 754 | Poster Presentation | Dysregulation of soluble immune checkpoint proteins in newly - diagnosed early breast cancer patients. | Bernardo L. Rapoport, MD, MMed; Helen Steel; Simon Nayler; Teresa Smit; Liezl Heyman; Annette Theron; Nomsa Hlatswayo; Luyanda Kwofie; Carol Ann Benn; Lidia jooste; Ronald Anderson, Prof; | Tumor and Stromal Cell Biology | Biomarkers; Chemokine; Chemotherapy; Costimulation; Cytokine; Immune suppression; Solid tumors; Tumor microenvironment |
| 757 | Poster Presentation | Intratumoral delivery CD40 agonist antibody via novel nanofluidic drug-eluting seed reduced tumor burden of murine pancreatic ductal adenocarcinoma | Hsuan-Chen Liu, PhD; Dixita I. Viswanath; Robin Vander Pol; Corrine Chua; Alessandro Grattoni, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Radiotherapy; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 764 | Poster Presentation | Expansion with IL-15 increases cytotoxicity of Vγ9Vδ2 T cells and is associated with higher levels of cytotoxic molecules and T-bet | Pia Aehnlich, M.Sc.; Per Thor Straten, PhD; Ana Micaela M. Carnaz Simoes, MSc; Signe K. Skadborg, MSc; Gitte H. Olofsson, BA, MSc; | Cellular Therapies | Adoptive immunotherapy; Cytokine; T cell |
| 765 | Poster Presentation | Contextual secretion of nanoscale interleukin (IL)-12 by CAR T cells for the treatment of cancer | Zhifen Yang, Dr.; Maggie Bobbins, Dr.; Hana Choi; Ofir Stefanson; Jin Yang, Dr.; Khristina Magallanes; Bing C. Wang, PhD; Lei Stanley Qi, Dr.; Francesco M. Marincola, MD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Costimulation; Immune contexture; Immune suppression; Monocyte/Macrophage; Solid tumors; T cell; Tumor microenvironment; Tumor stroma |
| 766 | Poster Presentation | Novel bioluminescent bioassays for the discovery and development of T cell redirecting Cancer Therapies | Vanessa Ott, PhD; Julia Gilden, Ph.D.; Jamison J. Grailer, PhD; Michael Slater; Pete Stecha, BS; Jim Hartnett, BS; Dan Lazar; Frank Fan, PhD; Mei Cong, PhD; Zhijie Jey Cheng; | Cellular Therapies | Bispecifics; Adoptive immunotherapy; Antibody; CAR T cells; NK/NK T cell; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 767 | Poster Presentation | Interferon gamma reduces CAR-T exhaustion and toxicity without compromising therapeutic efficacy in hematologic malignancies | Stefanie R. Bailey; Sonika Vatsa; Amanda Bouffard; Rebecca Larson; Irene Scarfo; Michael Kann; Andrea Schmidts; Marcela V. Maus, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; B cell; CAR T cells; Chemokine; Cytokine; Immune toxicity; Inflammation; Leukemia/Lymphoma; Monocyte/Macrophage; T cell |
| 770 | Poster Presentation | Analysis of gut microbiome in patients receiving adoptive T-cell therapy (ACT) across different solid tumour types | Arantzazu Barquin Garcia, MD; Sergio Ruiz; Paloma Navarro; Juan Francisco Rodriguez-Moreno; Elena Sevillano, MD; Monica Yague; Sandra Amarilla; Jesus Garcia-Donas; | Cellular Therapies | Adoptive immunotherapy; Microbiome; Solid tumors; Tumor infiltrating lymphocytes (TILs) |
| 771 | Poster Presentation | Characterization of tumor infiltrating immune cells from adult soft tissue sarcomas | Jacky H. Chen, HBSc; Jay S. Wunder, MD, MSc, FRCSC; Nalan Gokgoz, PhD; Irene L. Andrulis, PhD; | Cellular Therapies | Adoptive immunotherapy; Coinhibition; Costimulation; Cytokine; Regulatory T cell (Treg cell); Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 772 | Poster Presentation | A potent and off-the-shelf oNK cell therapy product targets HER2+ cancer cells and resists suppressive tumor microenvironment | Hao-Kang Li, Ph.D; Ching-Wen Hsiao; Sen-Han Yang; Hsiu-Ping Yang; Tai-Sheng Wu; Zih-Fei Cheng; Chia-Yun Lee; Yan-Liang Lin; Yan-Da Lai; Sai-Wen Tang; Janet Pan; Wei-Lun Lo; Shih-Chia Hsiao; | Cellular Therapies | Adoptive immunotherapy; Antibody; NK/NK T cell; Solid tumors; Targeted therapy; Tumor antigens; Tumor microenvironment |
| 774 | Poster Presentation | Antibiotic Administration Prior to Immunotherapy Leads to Poor Overall Survival Across Multiple Malignancies | Eric J. Vick, MD, PhD; Inas Abuali, MD; Sarah Ludvigsen, DO; Andrew Kelleher, MD; Nathanael D. Moore, MD; Nicholas Arias; Shuchi Gulati, MD, FACP; Trisha M. Wise-Draper, MD, PhD; | Checkpoint Blockade Therapy | Surfaceome; Bioinformatics; Checkpoint blockade; Clinical study |
| 775 | Poster Presentation | Rare case reports on thymic carcinoma patients treated with pembrolizumab | Evelyn Paszkan; Erna Ganofszky; Zsolt Megyesfalvi; Aron Ghimessy; Balazs Dome; Laszlo Agocs; Erika Toth; Ferenc Renyi-Vamos; Gabor Rubovszky; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Chemotherapy; Immune tolerance; Solid tumors |
| 776 | Poster Presentation | A role for immune checkpoint blockade to enhance T cell-mediated responses in combination with chemotherapy in oesophageal adenocarcinoma | Maria D. Davern, PhD; Joanne Lysaght; Andrew D. Sheppard; Stephen G. Maher; Noel E. Donlon, MRCS; John V. Reynolds, FRCS; Fiona O. Connell; Conall Hayes; Ross King; Anshul Bhardwaj; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Chemotherapy; Coinhibition; Costimulation; Immune tolerance; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 780 | Poster Presentation | Quantitative Cell-Based Bioassays to Advance Immunotherapy Programs Targeting Immune Checkpoint Receptors | Jamison J. Grailer, PhD; Julia Gilden, Ph.D.; Pete Stecha, BS; Denise Garvin, BS; Jun Wang; Michael Beck, MS; Jim Hartnett, BS; Gopal B. Krishnan; Frank Fan, PhD; Mei Cong, PhD; Zhi-jie J. Cheng, PhD; | Checkpoint Blockade Therapy | Adoptive immunotherapy; Antibody; Antigen presenting cells; Checkpoint blockade; T cell; Targeted therapy; Vaccine |
| 781 | Poster Presentation | Validation of the Combinatorial Effect of Blinatumomab and Nivolumab in Cancer Therapy | Tienan Wang, PhD; Qing Lin; Jie Zhang; | Checkpoint Blockade Therapy | Bispecifics; Adoptive immunotherapy; Antibody; Checkpoint blockade; Clinical trial; T cell; Tumor antigens |
| 782 | Poster Presentation | ALDH1A inhibition as adjuvant to ovarian cancer immunotherapy | Bingsi Gao; Mainpal Rana, PhD; Dongli Yang, PhD; Edward Grimley; Stacy McGonigal; Ronald P. Buckanovich, MD.PhD; Anda M. Vlad, MD, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune adjuvant; Monocyte/Macrophage; Regulatory T cell (Treg cell); T cell |
| 785 | Poster Presentation | Estrogen-deprivation promotes Th1 polarization of tumor-associated T cells in a mouse model of high grade serous ovarian cancer | Daniel M. Falcon, PhD; Marina D. Miller, MD; Chelsea D. Goff; Ichiko Kinjyo, MD PhD; Sarah F. Adams, MD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Chemotherapy; Coinhibition; Immune suppression; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 786 | Poster Presentation | Distinct efficacy and immunological responses to aPD-1, aPD-L1 and aPD-L2 immunotherapy in B16 melanoma in aged versus young hosts includes T-cell stem cell effects and PD-L2 expression differences | Myrna G. Garcia, BS; Alvaro S. Padron; Yilun Deng, MD, PhD; Aravind Kancharla, MS; Ryan M. Reyes, BS; Harshita B. Gupta, PhD; Tyler J. Curiel, MD, MPH; | Checkpoint Blockade Therapy | Checkpoint blockade; Cytokine; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 796 | Poster Presentation | A phase I/II trial combining Avelumab and Trabectedin for advanced liposarcoma and leiomyosarcoma | Michael J. Wagner, M.D.; Qianchuan He; Yuzheng Zhang; Lee Cranmer; Elizabeth T. Loggers; Sabrina McDonnell; Shannon Maxwell; Seth M. Pollack, MD; | Completed Clinical Trials | Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Monocyte/Macrophage; T cell |
| 801 | Poster Presentation | PRIME™ IL-15 (RPTR-147): Preliminary clinical results and biomarker analysis from a first-in-human Phase 1 study of IL-15 loaded peripherally-derived autologous T cell therapy in solid tumor patients | Erika P. Hamilton, MD; Sarah Nikiforow; Philip D. Bardwell, PhD; Christine M. McInnis, PhD; Jeffrey Zhang; George R. Blumenschein, Jr., MD; Mihaela Cristea, MD; Keren Osman; Anthony F. Shields, MD PhD; Marlyane Motta; Sanela Bilic; Oliver Schoenborn-Kellenberger; James A. Rakestraw; Shawn P. Carey, PhD; Elena Geretti, PhD; Karsten Sauer; Tim Harris, PhD, D.Sc; Tap Maniar, MD; Becker Hewes, MD; Thomas Andresen, PhD; Jonathan B. Fitzgerald, PhD; Harriet Kluger, MD; | In-Progress Clinical Trials | Adoptive immunotherapy; Biomarkers; Clinical study; Clinical trial; Cytokine; Solid tumors; T cell; Tumor antigens |
| 804 | Poster Presentation | A Phase II study of the anti-programmed cell death-1 (PD-1) antibody Penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy | Xiaozhong Chen; Wei Wang; Qingfeng Zou; Jingao Li; Chaosu Hu, MD; Chaosu Hu, MD; Qin Lin; Xiaodong Zhu; Yi Jiang; Yan Sun; Liangfang Shen; Lin Wang; Guorong Zou; Xiaoyan Lin; Ying Wang; Shaojun Lin; Minying Li; Rui Ao; Ruilian Xu; Haifeng Lin; Rensheng Wang; Jiacheng Yang; Weifeng Song; Max Wang; Baiyong Li, PhD; Yu Xia, PhD; | In-Progress Clinical Trials | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune toxicity; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| 805 | Poster Presentation | Safety and emerging evidence of immune modulation of the live biotherapeutic MRx0518 in the neoadjuvant setting for patients awaiting surgical removal of solid tumours | Mark Lythgoe, MBBS, MRPharmS; Justin Stebbing; Emily Pickford; Axel Glasmacher; Marsilio Adriani, PhD; Gayle L. Fyvie; Adam Frampton; Alex Stevenson; Jonathan Krell, PhD, MRCP, MBChB, BSc; | In-Progress Clinical Trials | Clinical study; Clinical trial; Microbiome; Solid tumors; Tumor infiltrating lymphocytes (TILs); TLR |
| 807 | Poster Presentation | A multicenter open-label phase I/lb study of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors | Aurelien Marabelle, MD, PhD; Stephane Champiat; Elena Garralda, MD; Alberto Hernando; Filip Janku, MD, PhD; Anjali Raina; Richard Sachse; David Bechard; Inna Krasnopolskaya; Stefano Ferrara; Patricia LoRusso, DO; | In-Progress Clinical Trials | Cytokine; NK/NK T cell; T cell lineages |
| 814 | Poster Presentation | MCLA-145 (CD137xPD-L1): a potent CD137 agonist and immune checkpoint inhibitor that that does not show signs of peripheral toxicity. | Kees Bol, PhD; Wilfred Marissen, PhD; Jeroen Elaissais-Schaap, PhD; Paul J. Tacken, PhD; Steef Engels; Liang-chuan Wang, PhD; Arpita Mondal; Mark Throsby, PhD; Alan Roberts, PhD; Patrick Mayes, PhD; Cecile Geuijen, PhD; | Combination Immunotherapies | Bispecifics; Antibody; Checkpoint blockade; Costimulation; Immune suppression; Immune toxicity; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 816 | Poster Presentation | Evaluating the potential of harnessing anti-leukemia T cells for the treatment of T cell Acute Lymphoblastic Leukemias (T-ALL) | Todd A. Triplett, PhD; Sarah E. Church, PhD; Tyler D. Hether; Joshua F. Rios; Srividya Kottapalli; Nisha Holay, B.S.; | Combination Immunotherapies | Checkpoint blockade; Coinhibition; Cytokine; Immune contexture; Leukemia/Lymphoma; Pediatric tumors; T cell; T cell lineages; Tumor microenvironment; Tumor stroma |
| 817 | Poster Presentation | DT095895, a selective EP4 receptor antagonist with monotherapy efficacy in syngeneic mouse model(s) and best-in-class properties | Anne-Laure Blayo; Laurène Deshons; Alexia Dumont; Christel Franchet; Célia Halter; Ludovic Herbin; Gaël Hommet; Stanislas Mayer; Alban Bessede; Imane Nafia; Marjorie Sidhoum; Xavier Leroy; Stéphan Schann; | Combination Immunotherapies | Biomarkers; Checkpoint blockade; Immune suppression; Solid tumors; Tumor microenvironment |
| 818 | Poster Presentation | Synergistic cancer immunotherapy using tumor tissue-derived exosomes and artificially produced bacterial outer membrane vesicles | Kyong-su Park, PhD; Jan Lötvall; Kristina Svennerholm; Rossella Crescitelli; Cecilia Lässer; Inta Gribonika; | Combination Immunotherapies | Extracellular vesicles/exosomes; Cytokine; Dendritic cell; Inflammation; Neoantigens; T cell; Tumor antigens; Vaccine |
| 819 | Poster Presentation | Targeting vasoactive intestinal peptide receptor signaling: A novel approach to enhance anti-tumor response in pancreatic ductal adenocarcinoma | Sruthi Ravindranathan, PhD, MS; Passang Tenzin; Sanjay Chandrasekaran, MD; Brandon Ware; Mohammad Y. Zaidi, MD, MS; Shuhua Wang, MD; Rohan K. Dhamsania, BS; Jingru Zhu; Susan N. Thomas, PhD, BS; Anish Majumdar,; Gregory B. Lesinski, PhD; Bassel El-rayes, MD; Edmund K. Waller, MD, PhD; | Combination Immunotherapies | Solid tumors |
| 820 | Poster Presentation | MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells | Paul J. Tacken, PhD; Liang-chuan Wang, PhD; Rinse Klooster; Pieter Fokko Van Loo, PhD; Jing Zhou, MD, PhD; Arpita Mondal; Yao-Bin Liu; Arjen Kramer; Thomas Condamine, PhD; Alla Volgina; Linda Hendriks; Hans van der Maaden; Eric Rovers; Steef Engels; Floris Fransen; Renate den Blanken-Smit; Vanessa Zondag-van der Zande; Abdul Basmeleh; Willem Bartelink; Ashwini Kulkarni; Wilfred Marissen, PhD; Cheng-Yen Huang; Leslie Hall; Shane Harvey; Chrysi Kanellopoulou, PhD; Shaun Stewart; Horacio Nastri; Lex Bakker, PhD; Ton Logtenberg; Simon Plyte; Patrick Mayes, PhD; Mark Throsby, PhD; Cecile Geuijen, PhD; | Combination Immunotherapies | Bispecifics; Antibody; Checkpoint blockade; Coinhibition; Costimulation; Immune adjuvant; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 821 | Poster Presentation | Class specific HDAC inhibition differentially affects the function of specific T cell subsets | Nisha Holay, B.S.; Uma Giri, Ph.D.; Carla Van Den Berg, Pharm.D.; Gail Eckhardt, MD; Todd A. Triplett, PhD; | Combination Immunotherapies | Post-translational modifications; Epigenetics; Cytokine; T cell; T cell lineages |
| 822 | Poster Presentation | Local radiotherapy synergizes with tumor-specific TCR redirected T cells in the rejection of prostate cancer | Marco Catucci; Veronica Basso; Chiara Lucrezia Deantoni; Simone Baroni; Antonello Spinelli; Massimo Freschi; Cesare Cozzarini; Claudio Fiorino; Nadia Di Muzio; Silvia C. Formenti, MD; Sandra Demaria, MD; Anna Mondino; | Combination Immunotherapies | Adoptive immunotherapy; Radiotherapy; Solid tumors |
| 823 | Poster Presentation | CD4 T cells are essential for an anti-tumor effect in a B78 murine melanoma tumor model | Arika S. Feils, BS; Mackenzie Heck; Anna Hoefges, MS; Peter M. Carlson, BS; Luke Zangl; Ravi Patel, MD, PhD; Dmitriy Kravtsov; Jacquelyn A. Hank, PhD; Zachary S. Morris, MD, PhD; Alexander L. Rakhmilevich, MD, PhD; Paul M. Sondel, MD, PhD; Amy K. Erbe, PhD; | Combination Immunotherapies | Radiotherapy; T cell; T cell lineages; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 824 | Poster Presentation | Modulation of TLR3 protein in response to radiation in squamous cell lung carcinoma | Jeru M. Manuel, PhD; Ebru Tas, B.Sc; Cleopatra Rutihinda, B.Sc; Ayman J. Oweida, PhD; | Combination Immunotherapies | Gene expression; Radiotherapy; TLR; Tumor microenvironment |
| 825 | Oral Presentation | Deep immune profiling of SARS-CoV-2 associated immune microenvironment in cancer tissues from recovered COVID-19 patients | Denise Goh, BBiomedSc (Hons); Chun Chau Lawrence Cheung, BA, MMedSc; Xinru Lim; Tracy Zhijun Tien; Jeffrey Chun Tatt Lim; Sanjna Nilesh Nerurkar; Loong Shihleone; Peng Chung Cheow; Chung Yip Chan; Ye Xin Koh; Thuan Tong Tan; Shirin Kalimuddin; Wai Meng David Tai; Jia Lin Ng; Jenny Guek-Hong Low; Joe Poh Sheng Yeong; Tony Kiat Hon Lim; | COVID and Immunotherapy | COVID and Immunotherapy; Biomarkers; Chemokine; Cytokine; Immune contexture; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 826 | Poster Presentation | Risk of COVID-19 infection among patients receiving immune checkpoint inhibitor therapy: A tertiary care hospital system collaboration with the Massachusetts Department of Health | William Murphy, AB; Vartan Pahalyants, BA; Nicholas Theodosakis, MD; Leyre Zubiri, MD, PhD; Monina Klevens, DDS; Evelyn Lilly, MD; Kerry L. Reynolds, MD; Yevgeniy R. Semenov, MD, MA; | COVID and Immunotherapy | COVID and Immunotherapy; Epidemiology |
| 830 | Poster Presentation | Targeting cellular senescence to increase CAR-T cell fitness | Rashmi Bankoti; Hazal Pektas Akbal; Maddalena Adorno; Benedetta N. Di Robilant; | Immune Cell Biology | Epigenetics; Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Immune adjuvant; Leukemia/Lymphoma; Stem cell/cancer-initiating cell; Solid tumors |
| 831 | Poster Presentation | E3 ubiquitin ligase Cbl-b deficient CD8+ T cells overcome Treg cell-mediated suppression through IFN-γ and induce robust anti-tumor immunity | SeongJun Han, MSc; Zhe Qi Liu; Douglas Chung; Michael St. Paul; Carlos Garcia-Batres; Azin Sayad; Alisha R. Elford; Matthew J. Gold; Natasha Grimshaw; Pamela S. Ohashi, PhD; | Immune Cell Biology | Adoptive immunotherapy; Cytokine; Immune suppression; Immune tolerance; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor microenvironment |
| 836 | Poster Presentation | Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy | Laura A. Ridgley, PhD; Angus G. Dalgleish, MD, PhD; Mark Bodman-smith; | Immune Cell Types | Checkpoint blockade; T cell; Vaccine |
| 837 | Poster Presentation | Interleukin-10 drives the development of T regulatory type 1 (Tr1) cells and is a target for immunotherapy | Yanchun Ma, MD student; Vera Bauer, Doctoral candidate; Tanja Riedel; Thomas Hofer; Martin Roecken; Ralph Mocikat; | Immune Cell Types | Cytokine; Immune suppression; Leukemia/Lymphoma; T cell; T cell lineages; Tumor microenvironment |
| 844 | Poster Presentation | Immunomodulatory Activity of Epigenetic Drugs Combinations in Mesothelioma: Laying the Ground for New Immunotherapeutic Strategies | Sara Cannito, Health biology; Ornella Cutaia; Carolina Fazio; Maria Fortunata Lofiego; Francesca Piazzini; Laura Solmonese; LUANA CALABRÒ; Michele Maio, MD; Alessia Covre, PhD; | Immune-stimulants and immune modulators | RNA; Post-translational modifications; Epigenetics; Biomarkers; Gene expression; Tumor antigens; Tumor microenvironment |
| 846 | Poster Presentation | Neospora caninum - an Immunotherapeutic Protozoan Against Solid Cancers | Louis Lantier, PhD; Agathe Poupee-Beauge, PhD; Céline DUCOURNAU; Anne Di Tommaso, PhD; Stéphanie Germon, PhD; Nathalie Moiré, PhD; Gordon Lee, MBChB; Antoine Touze, PhD; Isabelle Dimier-Poisson, PhD; | Immune-stimulants and immune modulators | Antibody; Cytokine; Immune adjuvant; Immune suppression; Neoantigens; Solid tumors; Tumor antigens; Tumor microenvironment; Tumor stroma; Vaccine |
| 848 | Poster Presentation | Prime-boost vaccination for the treatment of triple negative breast cancer | Seyedeh-Raheleh Niavarani; Christine Lawson, PhD; Lee-Hwa Tai, PhD; | Immune-stimulants and immune modulators | Biomarkers; Checkpoint blockade; Chemotherapy; Immune adjuvant; Surgery; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); TLR; Vaccine |
| 853 | Poster Presentation | Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients. | Mohamed Eltahir, MD; Erika A. Fletcher, MSc; Linn Dynesius; Justina Jarblad; Martin Lord; Ida R. Olsson; Mikaela Zekarias; Xiaojie Yu; Mark Cragg; Caroline Hammarstom; Kerstin Hamberg Levedahl; Martin Höglund; Gustav J. Ullenhag, PhD, MD; Mattias Mattsson; Sara M. Mangsbo, PhD MSc; | Immunotherapy Toxicities | Antibody; Cytokine; NK/NK T cell |
| 854 | Poster Presentation | Prediction of severe immune-related adverse events in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the United States | Mark Kalinich, PhD; William Murphy, AB; Shannon Wongvibulsin, PhD; Vartan Pahalyants, BA; Kun-Hsing Yu, MD, PhD; Feicheng Wang, PhD; Leyre Zubiri, MD, PhD; Vivek Naranbhai, MBChB, PhD, DPhil; Alexander Gusev; Shawn G. Kwatra, MD; Kerry L. Reynolds, MD; Yevgeniy R. Semenov, MD, MA; | Immunotherapy Toxicities | Immune toxicity |
| 855 | Poster Presentation | Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses | Thomas K. Le; Subuhi Kaul, MD; Shannon Wongvibulsin, PhD; Laura Cappelli, MD; Jarushka Naidoo, MB BCH MHS; Yevgeniy R. Semenov, MD, MA; Shawn G. Kwatra, MD; | Immunotherapy Toxicities | Checkpoint blockade; Clinical study; Epidemiology; Immune toxicity |
| 856 | Poster Presentation | Preliminary review of Diabetes Mellitus incidence in patients treated with immune checkpoint inhibitors (ICI) therapy – Roswell Park Comprehensive Cancer Center (RPCCC) experience | Zhen Zhang, PharmD, BCPS; Grazyna Riebandt, PharmD, BCOP; Rajeev Sharma, MD, FACE; Jordan Scott, BS; Lamya Hamad, RPh, MPH; Laurie Plewinski, BS; | Immunotherapy Toxicities | Antibody; Autoimmunity; Checkpoint blockade; Immune toxicity; Solid tumors |
| 857 | Poster Presentation | LAMP1 targeting of the large T antigen of Merkel cell polyomavirus elicits potent CD4+ T cell responses and prevents tumor growth | Claire Buchta Rosean, PhD; Pratima Sinha, PhD; David M. Koelle, MD; Paul Nghiem, MD, PhD; Teri Heiland, PhD; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| 858 | Poster Presentation | A bispecific antibody targeting CD40 and EpCAM induces superior anti-tumor effects compared to the combination of the monospecific antibodies | Peter Ellmark, PhD; Karin Hägerbrand; Mattias levin; Laura Von Schantz, -; Adnan Deronic, PhD; Laura Varas; Anna Säll; Karin Barchan; Doreen Werchau, BS; Lill Ljug; Mia Thageson; Anna Rosen, MSc; Christina Sakellariou; Malin Lindstedt, PhD; | Novel Single-Agent Immunotherapies | Extracellular vesicles/exosomes; Antibody; Dendritic cell; Neoantigens; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| 859 | Poster Presentation | Inhibition of the kinase activity of Hematopoietic Progenitor Kinase 1 enhances anti-PD-1-induced reinvigoration of human tumor-infiltrating CD8+ T cells | Yongjoon Lee; Seung Hyuck Jeon; A Yeong Park; Suyeon Jo; Jinhwa Lee; Su-Hyung Park; Jamie Jae Eun Kim, PhD; Eui-Cheol Shin; | Novel Single-Agent Immunotherapies | Checkpoint blockade; T cell; Tumor infiltrating lymphocytes (TILs) |
| 860 | Poster Presentation | Targeting immunosuppressive macrophages overcomes PARP-inhibitor resistance in BRCA1-associated triple-negative breast cancer | Anita K. Mehta, PhD; Emily Cheney; Christina Hartl; Constantia Pantelidou; Madison Oliwa; Jessica Castrillon; Jia-Ren Lin; Katie E. Hurst; Mateus de Oliveira Taveira; Nathan Johnson; William Oldham; Marian Kalocsay; Matthew Berberich; Sarah Boswell; Aditi Kothari; Shawn Johnson, BS; Deborah Dillon; Mikel Lipschitz; Scott J. Rodig, MD, PhD; Sandro Santagata; Judy Garber; Nadine M. Tung, MD; José Yélamos; Jessica E. Thaxton, PhD, MS; Elizabeth A. Mittendorf, MD, PhD; Peter K. Sorger; Geoffrey I. Shapiro, MD, PhD; Jennifer L. Guerriero, PhD; | Novel Single-Agent Immunotherapies | Antibody; Immune suppression; Monocyte/Macrophage; Myeloid cells; Metabolism; Tumor microenvironment |
| 861 | Poster Presentation | Development of FPA157, an anti-CCR8 depleting antibody engineered to preferentially eliminate tumor-infiltrating T regulatory cells | Andrew Rankin, PhD; Edwina Naik, PhD; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| 862 | Poster Presentation | Targeting PSGL-1, a novel macrophage checkpoint, repolarizes suppressive macrophages, induces an inflammatory tumor microenvironment, and suppresses tumor growth | Phuong A. Nguyen, PhD; Ryan Phennicie; Kevin Kauffman, PhD; Dominika Nowakowska, PhD; Mohammad Zafari; Veronica Komoroski; Steve Sazinsky, PhD; Joe Wahle, PhD; Denise Manfra, PhD; Shantashri Vaidya, PhD; Michael A. Brehm, PhD; Igor Feldman, PhD; Tatiana Novobrantseva, PhD; | Novel Single-Agent Immunotherapies | Antigen presenting cells; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Tumor stroma |
| 863 | Poster Presentation | Identification and characterization of an immunodominant SARS-CoV-2-specific CD8 T cell response | Anastasia Gangaev; Pia Kvistborg, PhD; | Other | T cell; Vaccine |
| 872 | Poster Presentation | Neoadjuvant chemoradiotherapy enhances T cell infiltration in pancreatic ductal adenocarcinoma but high percentage of regulatory T cells associates with poor survival | Benjamin T. Fullerton, BA; Robyn D. Gartrell, MD; Thomas Enzler, MD PhD; Pan S. Kim, MD; Ladan Fazlollahi, MD, MPH; Andrew X. Chen, BS; Subha Perni, MD; Stuart P. Weisberg, MD, PhD; Emanuelle M. Rizk; Eun Jeong Oh; Xinzheng Guo; Codruta Chiuzan, PhD; Raul Rabadán, PhD; Donna Farber, PhD; Helen E. Remotti, MD; David P. Horowitz, MD; Yvonne M. Saenger, MD; | Tumor and Stromal Cell Biology | Chemotherapy; Radiotherapy; Regulatory T cell (Treg cell); T cell; Tumor microenvironment |
